

01-10-00

A



DOCKET NO. : ISIS-4313

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Stanley T. Crooke

Serial No.: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Filing Date: Herewith

Examiner: Not Yet Assigned

For: OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA

EXPRESS MAIL LABEL NO: EL219292663US
DATE OF DEPOSIT: January 7, 2000

Box Patent Application
 Provisional Design

Assistant Commissioner for Patents
Washington DC 20231

Sir:

PATENT APPLICATION TRANSMITTAL LETTER

Transmitted herewith for filing, please find

A Utility Patent Application under 37 C.F.R. 1.53(b).

It is a continuing application, as follows:

continuation divisional continuation-in-part of prior application number
Serial No. 08/870,608, filed June 6, 1997 which is a Continuation-in-part of Serial
No. 08/659,440 filed June 6, 1996.

A Provisional Patent Application under 37 C.F.R. 1.53(c).
 A Design Patent Application (submitted in duplicate).

Including the following:

- Provisional Application Cover Sheet.
- New or Revised Specification, including pages ____ to ____ containing:
 - Specification
 - Claims
 - Abstract
 - Substitute Specification, including Claims and Abstract.
- The present application is a continuation application of Application No. _____ filed _____. The present application includes the Specification of the parent application which has been revised in accordance with the amendments filed in the parent application. Since none of those amendments incorporate new matter into the parent application, the present revised Specification also does not include new matter.
- The present application is a continuation application of Application No. _____ filed _____, which in turn is a continuation-in-part of Application No. _____ filed _____. The present application includes the Specification of the parent application which has been revised in accordance with the amendments filed in the parent application. Although the amendments in the parent C-I-P application may have incorporated new matter, since those are the only revisions included in the present application, the present application includes no new matter in relation to the parent application.
- A copy of earlier application Serial No.08/870,608 filed June 6, 1997, including Specification, Claims and Abstract (pages 1 - 126), to which no new matter has been added TOGETHER WITH a copy of the executed oath or declaration for such earlier application and all drawings and appendices. Such earlier application is hereby incorporated into the present application by reference.
- Please enter the following amendment to the Specification under the Cross-Reference to Related Applications section (or create such a section) : "This Application:
 - is a continuation of is a divisional of claims benefit of U.S. provisional Serial No. 08/870,608, filed June 6, 1997.

- Signed Statement attached deleting inventor(s) named in the prior application.
- A Preliminary Amendment.
- _____ Sheets of Formal Informal Drawings.
- Petition to Accept Photographic Drawings.
- Petition Fee
- An Executed Unexecuted Declaration or Oath and Power of Attorney.
- An Associate Power of Attorney.
- An Executed Copy of Executed Assignment of the Invention to _____
 - A Recordation Form Cover Sheet.
 - Recordation Fee - \$40.00.
- The prior application is assigned of record to ISIS Pharmaceuticals, Inc.
- Priority is claimed under 35 U.S.C. § 119 of Patent Application No. _____ filed _____ in _____ (country).
 - A Certified Copy of each of the above applications for which priority is claimed:
 - is enclosed.
 - has been filed in prior application Serial No. _____ filed _____.
- An Executed or Copy of Executed Earlier Statement Claiming Small Entity Status under 37 C.F.R. 1.9 and 1.27
 - is enclosed.
 - has been filed in prior application Serial No. 08/870,608 filed June 6, 1997, said status is still proper and desired in present case.
- Diskette Containing DNA/Amino Acid Sequence Information.

- Statement to Support Submission of DNA/Amino Acid Sequence Information.
- The computer readable form in this application, is identical with that filed in Application Serial Number SN 08/870,608, filed June 6, 1997. In accordance with 37 CFR 1.821(e), please use the first-filed, last-filed or only computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is included in the originally-filed specification of the instant application, included in a separately filed preliminary amendment for incorporation into the specification.
- Information Disclosure Statement.
 - Attached Form 1449.
 - Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
- A copy of Petition for Extension of Time as filed in the prior case.
- Appended Material as follows: _____
- Return Receipt Postcard (should be specifically itemized).
- Other as follows: _____

FEE CALCULATION:

Cancel in this application original claims 1-42; 47-67; 83-88 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

	SMALL ENTITY		NOT SMALL ENTITY	
	RATE	FEE	RATE	FEE
PROVISIONAL APPLICATION	\$75.00	\$	\$150.00	\$
DESIGN APPLICATION	\$155.00	\$	\$310.00	\$
UTILITY APPLICATIONS BASE FEE	\$345.00	\$345.00	\$690.00	\$
UTILITY APPLICATION; ALL CLAIMS CALCULATED AFTER ENTRY OF ALL AMENDMENTS				
	No. Filed	No. Extra		
TOTAL CLAIMS	24- 20 =	4	\$9 each	\$46.00
INDEP. CLAIMS	6- 3 =	3	\$39 each	\$117.00
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM			\$130	\$0
ADDITIONAL FILING FEE			\$0	\$
TOTAL FILING FEE DUE			\$554.00	\$

A Check is enclosed in the amount of \$ 554.00.

The Commissioner is authorized to charge payment of the following fees and to refund any overpayment associated with this communication or during the pendency of this application to deposit account 23-3050. This sheet is provided in duplicate.

The foregoing amount due.

Any additional filing fees required, including fees for the presentation of extra claims under 37 C.F.R. 1.16.

Any additional patent application processing fees under 37 C.F.R. 1.17 or 1.20(d).

The issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance.

The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or

any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to deposit account 23-3050. This sheet is provided in duplicate.

SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the United States Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: *7 JANUARY 2000*

Paul K. Legaard

Paul K. Legaard
Registration No. 38,534

Woodcock Washburn Kurtz
Mackiewicz & Norris LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 1997 WWKMN

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Stanley T. Crooke

Serial No.: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Filed: January 7, 2000

Examiner: Not Yet Assigned

**For: OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING
RNA**

BOX SEQUENCE

Assistant Commissioner
for Patents
Washington, D.C. 20231

Dear Sir:

PRELIMINARY AMENDMENT

This Preliminary Amendment is filed along with the application enclosed herewith, which is a divisional application of Serial No. 08/870,608 filed June 6, 1997. Applicant respectfully requests that the application be amended as indicated below.


In the Specification:

Please delete pages 105-107 of the application containing the Sequence Listing and insert substitute pages 105-107 enclosed herewith, which contains the amended Sequence Listing.

REMARKS

Substitute pages 105-107 are provided to comply with the Sequence Rules set forth in 37 CFR § 1.821-1.825. In addition, the paper copy of the Sequence Listing included herein is identical to the last-filed computer readable form (CRF) filed in the parent application. Accordingly, no new matter has been added.

Respectfully submitted,



Paul K. Legaard
Registration No. 38,534

Date: **January 7, 2000**

WOODCOCK WASHBURN KURTZ
MACKIEWICZ & NORRIS LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
(215) 568-3100
(215) 568-3439 facsimile

OLIGORIBONUCLEOTIDES AND RIBONUCLEASES
FOR CLEAVING RNA

CROSS REFERENCED TO RELATED APPLICATIONS

This application is a continuation in part of U.S.
5 Serial Number 08/659,440 filed June 6, 1996.

FIELD OF THE INVENTION

This invention is directed to the synthesis and use of oligomeric compounds, including oligoribonucleotides and oligoribonucleosides, useful for strand cleavage of target RNA 10 strands. Included in the invention are oligoribonucleotides having modified sugars, bases or phosphate backbones and oligoribonucleosides having standard sugars and bases or modified sugars and bases linked together via non-phosphate backbones. Further included in the invention are chimeric 15 oligoribonucleotides and oligoribonucleosides having mixed backbones, either phosphate or non-phosphate. Also included in the invention are mammalian ribonucleases, i.e., enzymes that degrade RNA. Such a ribonuclease is referred to herein as a dsRNase, wherein "ds" indicates the RNase's specificity 20 for certain double-stranded RNA substrates. The oligoribonucleotides, oligoribonucleosides, ribonucleases and ribonuclease substrates of the invention are useful for therapeutics, diagnostics and as research reagents.

BACKGROUND OF THE INVENTION

Oligonucleotides are known to hybridize to single-stranded DNA or RNA molecules. Hybridization is the sequence-specific base pair hydrogen bonding of nucleobases of the 5 oligonucleotides to nucleobases of target DNA or RNA. Such nucleobase pairs are said to be complementary to one another.

The complementarity of oligonucleotides has been used for inhibition of a number of cellular targets. Such complementary oligonucleotides are commonly described as being 10 antisense oligonucleotides. Various reviews describing the results of these studies have been published including *Progress In Antisense Oligonucleotide Therapeutics*, Crooke, S.T. and Bennett, C.F., *Annu. Rev. Pharmacol. Toxicol.*, 1996, 36, 107-129. These oligonucleotides have proven to be very powerful 15 research tools and diagnostic agents. Further, certain oligonucleotides that have been shown to be efficacious are currently in human clinical trials.

To date most oligonucleotides studied have been oligodeoxynucleotides. Antisense oligodeoxynucleotides are 20 believed to cause a reduction in target RNA levels principally through the action of RNase H, an endonuclease that cleaves the RNA strand of DNA:RNA duplexes. This enzyme, thought to play a role in DNA replication, has been shown to be capable of cleaving the RNA component of the DNA:RNA duplexes in cell free 25 systems as well as in *Xenopus* oocytes. RNase H is very sensitive to structural alterations in antisense oligonucleotides. This sensitivity is such that prior attempts to increase the potency of oligonucleotides by increasing affinity, stability, lipophilicity and other characteristics 30 by chemical modifications of the oligonucleotide have often resulted in oligonucleotides that are no longer substrates for RNase H. In addition, RNase H activity is quite variable. Thus a given disease state may not be a candidate for antisense 35 therapy only because the target tissue has insufficient RNase H activity. Therefore it is clear that effective terminating mechanisms in addition to RNase H are of great value to the development of therapeutic and other agents.

Several publications describe the interaction of RNase H and oligonucleotides. A recently publication is: Crooke, et. al., *Biochem. J.*, 1995, 312, 599-608. Other earlier papers are: (1) Dagle et al., *Nucleic Acids Research*, 1990, 18, 4751; (2) Dagle et al., *Antisense Research And Development*, 1991, 1, 11; (3) Eder et al., *J. Biol. Chem.*, 1991, 266, 6472; and (4) Dagle et al., *Nucleic Acids Research*, 1991, 19, 1805. According to these publications, DNA oligonucleotides having both unmodified phosphodiester internucleoside linkages and modified phosphorothioate internucleoside linkages are substrates for cellular RNase H. Since they are substrates, they activate the cleavage of target RNA by RNase H. However, these authors further noted that in *Xenopus* embryos, both phosphodiester linkages and phosphorothioate linkages are also subject to exonuclease degradation. Nuclease degradation is detrimental since it rapidly depletes the oligonucleotide.

As described in references (1), (2) and (4), to stabilize oligonucleotides against nuclease degradation while still providing for RNase H activation, 2'-deoxy oligonucleotides having a short section of phosphodiester linked nucleosides positioned between sections of phosphoramidate, alkyl phosphonate or phosphotriester linkages were constructed. While the phosphoramidate-containing oligonucleotides were stabilized against exonucleases, in reference (4) the authors noted that each phosphoramidate linkage resulted in a loss of 1.6°C in the measured T_m value of the phosphoramidate-containing oligonucleotides. Such a decrease in the T_m value is indicative of a decrease in hybridization between the oligonucleotide and its target strand.

Other authors have commented on the effect such a loss of hybridization between an oligonucleotide and its target strand can have. Saison-Behmoaras et al. (*EMBO Journal*, 1991, 10, 1111) observed that even though an oligonucleotide could be a substrate for RNase H, cleavage efficiency by RNase H was low because of weak hybridization to the mRNA. The authors

also noted that the inclusion of an acridine substitution at the 3' end of the oligonucleotide protected the oligonucleotide from exonucleases.

U.S. Patent 5,013,830, issued May 7, 1991, discloses 5 mixed oligomers comprising an RNA oligomer, or a derivative thereof, conjugated to a DNA oligomer via a phosphodiester linkage. The RNA oligomers also bear 2'-O-alkyl substituents. However, being phosphodiesters, the oligomers are susceptible to nuclease cleavage.

10 European Patent application 339,842, published November 2, 1989, discloses 2"-O-substituted phosphorothioate oligonucleotides, including 2'-O-methylribonucleotide phosphorothioate derivatives. The above-mentioned application also discloses 2'-O-methyl phosphodiester oligonucleotides 15 which lack nuclease resistance.

U.S. Patent 5,149,797, issued September 22, 1992, discloses mixed phosphate backbone oligonucleotides which include an internal portion of deoxynucleotides linked by phosphodiester linkages, and flanked on each side by a portion 20 of modified DNA or RNA sequences. The flanking sequences include methyl phosphonate, phosphoromorpholidate, phosphoropiperazidate or phosphoramidate linkages.

U.S. Patent 5,256,775, issued October 26, 1993, describes mixed oligonucleotides that incorporate 25 phosphoramidate linkages and phosphorothioate or phosphorodithioate linkages.

U.S. Patent 5,403,711, issued April 4, 1995, describes RNA:DNA probes targeted to DNA. The probes are labeled and are used in a system that includes RNase H. The 30 RNase H enzyme cleaves those probes that bind to DNA targets. The probes can include modified phosphate groups. Mentioned are phosphotriester, hydrogen phosphonates, alkyl or aryl phosphonates, alkyl or aryl phosphoramidates, phosphorothioates or phosphoroselenates.

35 In contrast to the pharmacological inhibition of gene expression via the RNase H enzyme, it is becoming clear that organisms from bacteria to humans use endogenous antisense RNA

transcripts to alter the stability of some target mRNAs and regulate gene expression, see Nellen, W., and Lichtenstein, C., *Curr.Opin.Cell.Biol.*, 1993, 18, 419-424 and Nellen, W., et al, *Biochem. Soc.Trans.* 1992, 20, 750-754. Perhaps one of the best 5 examples comes from certain bacteria where an antisense RNA regulates the expression of *mok* mRNA, which is required for the translation of the cytotoxic *hok* protein. Thus as the antisense level drops, *mok* mRNA levels and consequently *hok* protein levels rise and the cells die, see Gerdes, K. et al., 10 *J.Mol.Biol.*, 1992, 226, 637-649. Other systems regulated by such mechanisms in bacteria include the RNA I-RNA II hybrid of the *ColE1* plasmid, see Haeuptle, M.T., Frank, R., and Dobberstein, B., *Nucleic Acids Res.* 1986, 14, 1427, Knecht, D., *Cell Motil.Cytoskel.*, 1989, 14, 92-102; and Maniak, M., and 15 Nellen, W., *Nucleic Acids Res.*, 1990, 18, 5375-5380; OOP-cII RNA regulation in bacteriophage Lambda, see Krinke, L., and Wulff, D.L. (1990) *Genes Dev.*, 1990, 4, 2223-2233; and the *copA-copT* hybrids in *E.coli*. See Blomberg, P., Wagner, E.G., and Nordstrom, K., *EMBO J.*, 1990, 9, 2331-2340. In *E.coli* the 20 RNA:RNA duplexes formed have been shown to be substrates for regulated degradation by the endoribonuclease RNase III. Duplex dependent degradation has also been observed in the archaebacterium, *Halobacterium salinarium*, where the antisense transcript reduces expression of the early (T1) transcript of 25 the phage gene *phiH*, see Stolt, P., and Zillig, W., *Mol. Microbiol.*, 1993, 7, 875-882. In several eukaryotic organisms endogenous antisense transcripts have also been observed. These include p53, see Khochbin and Lawrence, *EMBO*, 1989, 8, 30 4107-4114; basic fibroblast growth factor, see Volk et al, *EMBO*, 1989, 8, 69, 2983-2988; N-myc, see Krystal, G.W., Armstrong, B.C., and Battey, J.F., *Mol. Cell. Biol.*, 1990, 10, 4180-4191; eIF-2 α , see Noguchi et al., *J. Biol. Chem.*, 1994, 269, 29161-29167. The conservation of endogenously expressed 35 antisense transcripts across evolutionary lines suggests that their biological roles and molecular mechanisms of action may be similar.

In bacteria, RNase III is the double stranded

endoribonuclease (dsRNase) activity responsible for the degradation of some antisense:sense RNA duplexes. RNase III carries out site-specific cleavage of dsRNA-containing structures, see Saito, H. and Richardson, C.C., *Cell*, 1981, 27, 5 533-540. The RNase III also plays an important role in mRNA processing and in the processing of rRNA precursors into 16S, 23S and 5S ribosomal RNAs, see Dunn, J.J. and Studier, F.W. *J. Mol. Biol.*, 1975, 99, 487. In eukaryotes, a yeast gene (RNT1) has recently been cloned that codes for a protein that has 10 homology to E.coli RNase III and shows dsRNase activity in ribosomal RNA processing, see Elela, S.A., Igel, H. and Ares, M. *Cell*, 1996, 85, 115-124. Avian cells treated with interferon produce and secrete a soluble nuclease capable of degrading dsRNA, see Meegan, J. and Marcus, P.I., *Science*, 15 1989, 244, 1089-1091. However such a secreted dsRNA activity is not a likely candidate to be involved in cytoplasmic degradation of antisense:sense RNA duplexes. Despite these findings almost nothing is known about human or mammalian dsRNase activities. While it has been recognized that 20 regulation (via any mechanism) of a target RNA strand would be useful, to date only two mechanisms for eliciting such an effect are known. These are hybridization arrest and use of an oligodeoxynucleotide to effect RNase H cleavage of the RNA target. Accordingly, there remains a continuing long-felt need 25 for methods and compounds for regulation of target RNA. Such regulation of target RNA would be useful for therapeutic purposes both in vivo and ex vivo and, as well as, for diagnostic reagents and as research reagents including reagents for the study of both cellular and *in vitro* events.

30 **SUMMARY OF THE INVENTION**

In accordance with this invention there are provided oligomeric compounds formed from a linear sequence of linked ribonucleoside subunits that are specifically hybridizable to a preselected RNA target. The oligomeric compounds have at 35 least a first segment and a second segment. The first segment incorporates at least one ribonucleoside subunit that is

modified to improve at least one of its pharmacokinetic properties, its binding characteristics to target RNA or to modify its charge. The second segment includes at least four consecutive ribofuranosyl nucleoside subunits. The subunits 5 of the oligomeric compounds are connected together in a linear sequence by internucleoside linkages that are stabilized from degradation as compared to phosphodiester linkages.

In certain preferred embodiments of the invention, the compounds will include a third segment having properties 10 corresponding to the properties of the first segment. It is preferred to position the second segment between the first and third segments such that they form a continuous, linear sequences of linked nucleoside units. In preferred compounds the number of such linked nucleoside subunits will range from 15 about eight to about fifty with a more preferred range being from about twelve to about thirty linked nucleoside subunits.

Modification of pharmacokinetic properties includes any one or more of the modification of binding, absorption, distribution or clearance properties of the compound. 20 Modification of binding characteristics includes modification of the affinity or specificity of said compound to its target RNA. Modification of the charge of said compound includes modifying the net charge of the compound as compared to an unmodified compound. Normally modification of charge will 25 decrease the overall net negative charge of a phosphorus linked oligomeric compound to provide the compound with less negative charge, a neutral charge or a net positive charge.

Further in accordance with this invention, there are provided oligomeric compounds formed from linear sequences of 30 linked ribonucleoside subunits that are specifically hybridizable to a preselected RNA target. The oligomeric compounds have at least a first segment and a second segment. The first segment incorporates at least one ribonucleoside subunit that is functionalized to provide greater affinity to 35 the target RNA. The second segment includes at least four ribofuranosyl nucleoside subunits. The subunits of the oligomeric compounds are connected together in a linear

sequence by internucleoside linkages that are modified to stabilize the linkages from degradation as compared to phosphodiester linkages.

In certain preferred oligomeric compounds of the invention, the first or first and third segments of oligomeric compounds are formed of nucleoside subunits that include 2'-substituent groups thereon. In preferred embodiments, the 2'-substituent group includes fluoro, C₁-C₂₀ alkoxy, C₁-C₆ aminoalkoxy, allyloxy, imidazolylalkoxy and polyethylene glycol. Preferred alkoxy substituents include methoxy, ethoxy and propoxy. A preferred aminoalkoxy substituent is aminopropoxy. A preferred imidazolylalkoxy substituent is imidazolylpropoxy. A preferred polyethylene glycol substituent is -O-ethyl-O-methyl, i.e., methoxyethoxy or -O-CH₂-CH₂-O-CH₃.

In further preferred oligomeric compounds of the invention, the oligomeric compounds are formed of nucleoside subunits that are modified by including certain selected nucleobases thereon. In preferred embodiments, the selected nucleobases include 2,6-diaminopurine, N₂-alkylpurines, N₂-aminoalkylpurines, 7-deaza-7-substituted purines, 5-substituted pyrimidines, and 2-substituted pyrimidines.

Other preferred oligomeric compounds of the invention include oligoribonucleotides having nucleoside subunits connected by phosphorus linkages including phosphorothioate, 3'-(or -5')deoxy-3'-(or -5') thio-phosphorothioate, phosphorodithioate, phosphoroselenates, 3'-(or -5')deoxy phosphinates, borano phosphates, 3'-(or -5')deoxy-3'-(or 5')-amino phosphoramidates, hydrogen phosphonates, borano phosphate esters, phosphoramidates, alkyl or aryl phosphonates and phosphotriester linkages. A selected group of oligoribonucleotide linkages for use in linking the nucleosides of the second segment include phosphorothioate, phosphinates and phosphoramidates, all of which are charged species.

Further preferred oligomeric compounds of the invention may also include oligoribonucleosides having nucleoside subunits connected by carbonate, carbamate, silyl, sulfur, sulfonate, sulfonamide, formacetal, thioformacetal,

oxime, methyleneimino, methylenemethylimino, methylenehydrazo, methylenedimethylhydrazo and methyleneoxymethylimino linkages.

Further preferred oligomeric compounds of the invention include having nucleoside subunits connected by 5 alternating phosphorus and non-phosphorous linkages. Such non-phosphorous linkages include carbonate, carbamate, silyl, sulfur, sulfonate, sulfonamide, formacetal, thioformacetal, oxime, methyleneimino, methylenemethylimino, methylenehydrazo, methylenedimethylhydrazo and methyleneoxymethylimino linkages 10 while the phosphorous linkages include phosphodiester, phosphorothioate, 3'-(or -5')deoxy-3'-(or -5')thio-phosphoro-thioate, phosphorodithioate, phosphoroselenates, 3'-(or -5')deoxy phosphinates, borano phosphates, 3'-(or -5')deoxy-3'-(or 5')-amino phosphoramidates, hydrogen phosphonates, borano 15 phosphate esters, phosphoramidates, alkyl or aryl phosphonates and phosphotriester linkages.

Further preferred oligomeric compounds of the invention include oligoribonucleotides, oligoribonucleosides or mixtures of oligoribonucleotides and oligoribonucleosides 20 having a plurality of linked nucleoside subunits that are linked in a sequences that is complementary strand of target RNA and wherein the sequence of the compound is divided into a first subsequence or segment and a second subsequence or segment. The first subsequence comprises linked nucleoside 25 subunits bearing 2'-O-substituted-pentofuranosyl sugar moieties and the second subsequence comprises linked nucleoside subunits bearing 2'-hydroxyl-pentofuranosyl sugar moieties. Preferably, said second subsequence has from four to twelve or more nucleoside subunits, and more preferably, has five to about 30 nine nucleoside subunits. In further preferred embodiments there exists a third subsequence, the nucleoside subunits of which are selected from those which are selectable for the first subsequence. It is preferred that the second subsequence be positioned between the first and the third subsequences. 35 Such oligomeric compounds of the invention are also referred to as "chimeras," "chimeric" or "gapped" oligoribonucleotides or oligoribonucleosides.

In further preferred oligomeric compounds of the invention, nucleoside subunits bearing substituents that are modified to improve at least one of: pharmacokinetic binding, absorption, distribution or clearance properties of 5 the compound: affinity or specificity of said compound to said target RNA: or modification of the charge of said compound, compared to an unmodified compound; are located at one or both of the 3' or the 5' termini of the oligomeric compounds. In certain preferred compounds there are from one to about eight 10 nucleoside subunits that are substituted with such substituent groups.

The nucleoside subunits are joined together in a linear sequence to form the oligomeric compounds of the invention. Each nucleoside subunit includes a base fragment 15 and a sugar fragment. The base fragment comprises a heterocyclic base, alternately hereinafter referred to as a nucleobase. The bases or nucleobases are covalently bonded to the sugar fragment. The sugar fragments may include a 2'-substituted sugar moiety, a 2'-hydroxyl sugar moiety or a sugar 20 surrogate moiety.

Preferred nucleobases of the invention include purines and pyrimidines such as adenine, guanine, cytosine, uridine, and thymine, as well as other synthetic and natural nucleobases such as xanthine, hypoxanthine, 2-aminoadenine, 6-25 methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, amino, thiol, thioalkyl, hydroxyl and other 30 8-substituted adenines and guanines, 5-trifluoromethyl and other 5-substituted uracils and cytosines, and 7-methylguanine. Further purines and pyrimidines include those disclosed in United States Patents Nos. 3,687,808, 5,484,908, 5,459,255, 5,457,191 and 5,614,617 (corresponding to United States patent 35 application serial number 07/971,978), and those disclosed in the *Concise Encyclopedia Of Polymer Science And Engineering*, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, 1990,

and those disclosed by Englisch et al., *Angewandte Chemie, International Edition*, 1991, 30, 613.

Preferred sugar fragments are pentoribofuranosyl sugar moieties, i.e., the "natural" sugar moiety of messenger 5 ribonucleic acids. Other sugar-like or sugar surrogate compounds suitable for use in the oligoribonucleotides or oligoribonucleosides of the invention include cyclobutyl nucleoside surrogates as described in U.S. Patent 5,359,044, pyrrolidine nucleoside surrogates as described in U.S. Patent 10 5,519,134, morpholino nucleoside surrogates as described in U.S. Patents 5,142,047 and 5,235,033, and in related patent disclosures, and PNA (peptide nucleic acid) nucleoside surrogates.

In further preferred embodiments of the invention 15 there are provided synthetic oligomeric compounds that are specifically hybridizable with a preselected RNA target and where the compounds include a first segment including at least one surrogate nucleoside subunit and a second segment comprising at least four ribofuranosyl nucleoside subunits 20 located in a consecutive sequence and having 2'-hydroxyl moieties thereon. Further the nucleoside subunits of the oligomeric compound are connected by internucleoside linkages that are stable to degradation as compared to phosphodiester bonds.

25 In other preferred embodiments of the invention, there are provided synthetic oligomeric compounds that are specifically hybridizable with a preselected RNA target and that include a first segment having at least one ribofuranosyl nucleoside subunit that is not a DNA or RNA "major" building 30 block nucleoside and a second segment that includes at least four consecutive ribofuranosyl nucleoside subunits having 2'-hydroxyl moieties thereon. The nucleoside subunits of the compounds are connected by internucleoside linkages which are modified to stabilize the linkages from degradation as compared 35 to phosphodiester linkages. Nucleoside subunits that are not DNA or RNA major building block nucleosides as that term is used in connection with this invention, are members of the

group consisting of adenosine, 2'-deoxyadenosine, guanosine, 2'-deoxyguanosine, cytidine, 2'-deoxycytidine, uridine and 2'-deoxythymidine. As such, this group excludes "minor" nucleosides that may be found in tRNA or in other nucleic acids.

The invention also provides methods of for specifically cleaving preselected RNA. These methods include contacting the RNA with a compound that includes at least twelve ribofuranosyl nucleosides subunits joined in a sequence which is specifically hybridizable with the preselected RNA. The nucleoside subunits are joined by internucleoside bonds that are stable to degradation as compared to phosphodiester bonds. The compound has at least one segment that includes at least one modified nucleoside subunit, which modified nucleoside subunit is modified to improve at least one of pharmacokinetic binding, absorption, distribution or clearance properties of the compound; affinity or specificity of the compound to target RNA; or modification of the charge of the compound, compared to an unmodified compound. The compound additionally includes a further segment having at least four ribonucleoside subunits.

The invention also provides methods for treating an organism having a disease characterized by the undesired production of a protein. These methods include contacting the organism with an oligomeric compound of the invention having a sequence of nucleoside subunits capable of specifically hybridizing with a complementary strand of ribonucleic acid with at least one of the nucleoside subunits being functionalized to modify one or more properties of the oligomeric compounds compared to native RNA. The compound further includes a plurality of the nucleoside subunits having 2'-hydroxyl-pentofuranosyl sugar moieties.

Further in accordance with the present invention, there are provided compositions including a pharmaceutically effective amount of an oligomeric compound having a sequence of nucleoside subunits capable of specifically hybridizing with

a complementary strand of RNA and wherein at least one of the nucleoside subunits is modified to improve at least one of pharmacokinetic binding, absorption, distribution or clearance properties of the compound; affinity or specificity of said 5 compound to said target RNA; or modification of the charge of said compound, compared to an unmodified compound. In such compounds, a plurality of the nucleoside subunits have 2'-hydroxyl-pentofuranosyl sugar moieties. The compositions further include a pharmaceutically acceptable diluent or 10 carrier.

The present invention also provides mammalian ribonucleases, isolatable from human T24 cells, other cell lines, and rat tissues, that degrade RNA in an oligoribonucleotide:RNA duplex. Such a ribonuclease is 15 referred to herein as a dsRNase, wherein "ds" indicates the RNase's specificity for certain double-stranded RNA substrates. Useful substrates for such dsRNases are also herein provided, as well as affinity matrices comprising such substrates.

Methods are also provided for *in vitro* modification 20 of a sequence-specific target RNA including contacting a test solution containing a dsRNase enzyme, *i.e.*, a double stranded RNase enzyme, and said target RNA with an oligomeric compound. The oligomeric compound has a sequence of nucleoside subunits capable of specifically hybridizing to a complementary strand 25 of the nucleic acid, where at least one of the nucleoside subunits is functionalized to increase the binding affinity or binding specificity of the oligoribonucleotide to the complementary strand of nucleic acid, and where a plurality of the nucleoside subunits have 2'-hydroxyl-pentofuranosyl sugar 30 moieties.

There are also provided methods of concurrently enhancing hybridization and/or dsRNase enzyme activation in an organism that includes contacting the organism with an oligomeric compound having a sequence of nucleoside subunits 35 capable of specifically hybridizing to a complementary strand of target RNA. At least one of the nucleoside subunits is modified to improve at least one of pharmacokinetic binding,

absorption, distribution or clearance properties of the compound; affinity or specificity of said compound to said target RNA; or modification of the charge of said compound, compared to an unmodified compound. Again, a plurality of the 5 nucleoside subunits have 2'-hydroxy-pentofuranosyl sugar moieties.

The invention further provides diagnostic methods for detecting the presence or absence of abnormal RNA molecules, or abnormal or inappropriate expression of normal RNA molecules 10 in organisms or cells. The invention further provides research reagents for modulating enzyme activity including dsRNase activity in *in vitro* solutions.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 schematically depicts certain illustrative 15 chimeric oligomeric compounds of the invention wherein open squares represent 2'-methoxy modified ribonucleotides, filled circles represent 2'-hydroxyl ribonucleotides and phosphorothioate linkages are utilized through the compounds shown in the figure.

Figures 2 depicts Ha-ras mRNA levels in cells treated 20 with full 2'-methoxy or chimeric RNA gapmer oligonucleotides. Northern blot analyses for Ha-ras mRNA levels in T24 cells treated with the indicated doses of full 2'-methoxy oligonucleotide (panel 2A) or 3 gap oligoribonucleotide (panel 25 2C) for 24 hrs. are shown. The upper band is the signal for Ha-ras, this signal was normalized to that obtained for G3PDH (lower band), relative Ha-ras levels were determined and are presented graphically (panels 2C-2D). Neither oligonucleotide treatment reduced Ha-ras mRNA levels.

Figure 3 shows Northern blot analyses of T24 cell 30 treated as in Figure 2 except with chimeric RNA gapmer oligonucleotides containing either a 5, 7 or 9 ribonucleotide gap or a full ribonucleotide molecule (left panels 3A, 3B, 3C and 3D, respectively); cells were also treated with a control 35 oligoribonucleotide that contains four mismatched base pairs

to the Ha-ras mRNA sequence (left panel 3E). Ha-ras signals were normalized to that of G3PDH and relative Ha-ras levels are shown graphically (right panels).

In Figure 4, the effect of T24 cytosolic extracts and 5 RNase H on duplexes *in vitro* are shown. A 17 base pair duplex consisting of the Ha-ras targeted 9 RNA gapmer oligonucleotide annealed to a ³²P-labeled RNA complement was incubated with 3 ug of T24 cytosolic protein fraction for the indicated times at 37°C, the reaction was stopped and products were resolved on 10 a denaturing polyacrylamide gel. Digestion products (arrows) indicate that cleavage of the duplex is restricted to the RNA:RNA region (see schematic of duplex, far right).

Figure 5 shows the same 9 RNA gapmer oligonucleotide:RNA duplex as in Figure 4, incubated with or 15 without *E. coli* RNase H (- and +, respectively). The lack of digestion products indicates that this duplex is not a substrate for RNase H. Duplexes consisting of ³²P-labeled RNA annealed to either a full oligodeoxynucleotide (middle panel) or 9 DNA gapmer oligonucleotide (left panel) are substrates for 20 cleavage by RNase H and thus generate digestion products as expected (arrows).

Figure 6 depicts SDS-polyacrylamide gel electrophoretic analysis of the concentrated rat liver active fractions after size exclusion chromatography. MW, molecular 25 weight markers in kilodaltons (kD). Fraction 3 (lane 4), having an apparent molecular weight in the range of about 35 to about 100 kD, with much of the material having an apparent molecular weight in the range 50 to about 80 kD, had the greatest amount of dsRNase activity.

30 Figure 7 shows analysis of products of digestion of dsRNase substrates by native polyacrylamide gel electrophoresis. Antisense and sense oligonucleotides were preannealed and incubated with cellular extracts and purified dsRNases as described herein. Lane 1, untreated "sense" strand 35 RNA; lane 2, "sense" strand RNA treated with 0.02 units RNase V1; remaining lanes: dsRNase substrates treated with 0.02 (lane 3) and 0.002 (lane 4) units of RNase V1, with unpurified

nuclear extract for 0 minutes (lane 5) or 240 minutes (lane 6), with unpurified nuclear extract for 240 minutes without Mg⁺⁺ (lane 7), with unpurified cytosolic extract for 240 minutes (lane 8), with ion exchange purified cytosolic extract for 240 minutes in the presence (lane 9) or absence (lane 10) of Mg⁺⁺, and with ion exchange/gel filtration purified cytosolic extract for 240 minutes in the presence (lane 9) or absence (lane 10) of Mg⁺⁺.

Figure 8 shows analysis of products of digestion of dsRNase substrates by denaturing polyacrylamide gel electrophoresis. Lane 1, "sense" strand RNA treated with 5 x 10⁻³ units of RNase A; lane 2, "sense" strand RNA treated with 0.02 units RNase V1; lanes 3-9: dsRNase products treated with 0.02 (lane 3) and 0.002 (lane 4) units of RNase V1, with unpurified nuclear extract for 0 minutes (lane 5) or 240 minutes (lane 6), with unpurified cytosolic extract for 240 minutes (lane 7), with ion exchange purified cytosolic extract for 240 minutes (lane 8), and with ion exchange/gel filtration purified cytosolic extract for 240 minutes (lane 9). Lane 10, base hydrolysis ladder.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

While not wishing to be bound by theory, it is now believed that by the use of certain chemically modified oligomeric compounds, one can exploit certain enzymatic activities in eukaryotic cells, including human cells, resulting from the unexpected interaction of these compounds with a target RNA strand to form double-stranded RNA like structures that are cleaved by certain enzymes. Heretofore, such activity has not recognized nor exploited in eukaryotic systems. It has now been found that the oligomeric compounds of the invention have certain RNA like features that allow them to form a double stranded structure with a targeted RNA region and this double stranded structure is subsequently degraded by eukaryotic dsRNases, *i.e.* double-stranded RNase enzymes, in a cell or test solution. Using T24 human bladder carcinoma cells as an illustrative eukaryotic cellular system, it has been

demonstrated that this activity is present at comparable levels in both the nuclear and cytoplasmic fractions.

In certain illustrative procedures provided herein to illustrate this invention, in common with some other known 5 nuclease activities, it has been found that this activity leaves 5' phosphate and 3' hydroxyl groups after cleavage of the RNA substrate. This generation of 5' phosphate, 3' hydroxyl termini is a feature in common with several other nucleases that recognize double-stranded nucleic acid 10 molecules, including RNase HI and II that cleave the RNA component of a DNA:RNA duplex in E.coli., RNase III which catalyses the hydrolysis of high molecular weight double stranded RNA and mediates degradation of sense-antisense duplexes, and RNase VI.

15 Many components of mRNA degradation systems have been conserved between prokaryotes and eukaryotes. It has now been found that like prokaryotic organisms, in which RNase III carries out the degradation of sense-antisense hybrids to regulate expression of some genes, human cells have conserved 20 an activity capable of performing a similar role. In addition to other uses including therapeutic and diagnostic uses, by virtue of this activity the compounds of this invention can be used as research reagents to assist in understanding how human cells use endogenously expressed antisense transcripts to 25 modulate gene expression.

The vast majority of antisense oligonucleotides used experimentally or currently being tested in the clinic in humans are modified oligodeoxynucleotides. It has been demonstrated that the heteroduplex formed between such 30 oligodeoxynucleotide antisense compounds and their target RNA is recognized by an intracellular nuclease, RNase H, that cleaves only the RNA strand of this duplex. Although RNase H mediated degradation of target RNA has proven a useful mechanism, it has certain limitations. RNase H is highly 35 sensitive to structural modifications made to the antisense oligonucleotides and thus most of the modifications designed to improve the therapeutic properties such as increased

affinity, increased nuclease resistance and greater cellular permeability have resulted in oligonucleotides that do not support cleavage by RNase H. Another limitation to RNase H as a terminating mechanism of antisense action is the fact that 5 the oligonucleotides must be DNA 'like', and in being DNA 'like', such oligonucleotides have inherently low affinity to their target RNA. Strategies designed to circumvent this low affinity include the design of "gapmer" oligonucleotides that are composed of a stretch of high affinity chemically modified 10 oligonucleotides on the 5' and 3' ends (the wings) with a stretch of unmodified deoxyoligonucleotides in the center (the gap). DNA gapmers, *i.e.*, oligodeoxynucleotides gapmers, have significantly higher affinities for their target than oligodeoxynucleotides, however, depending on the size of the 15 DNA gap, RNase H activity has been shown to be compromised.

In using RNase H as a termination mechanism via RNA degradation, the cellular localization and tissue distribution of RNase H must also be considered. RNase H activity is primarily localized to the nucleus although it has been 20 detected in the cytoplasm at lower levels. Most of a given mRNA is found in the cytoplasm of cells, therefore the ideal activity to be exploited as a terminating mechanism would be one with high levels in both the nucleus and the cytoplasm. RNase H activity also is highly variable from cell line to cell 25 line or between tissues, thus a given disease state may not be a good candidate for RNA degradation only because the target tissue has insufficient RNase H activity. It is clear that alternative terminating mechanisms for degrading target RNA are highly desirable.

30 Among other uses, the activity that has now been recognized can now be exploited as an alternative terminating mechanism to RNase H for antisense therapeutics. It has been found that in using RNA-like oligonucleotides that have high affinity for their target and thus higher potency than DNA-like 35 oligonucleotides, activity can be expressed in human cells. The presence of the activity in both the cytoplasm and the nucleus allows the compounds of the invention to be used to inhibit

many RNA processing events from nuclear pre-mRNA splicing and transport to degradation of mature transcript in the cytoplasm.

To illustrate this invention and to compare it to other known antisense mechanisms, e.g. RNase H, the dsRNase activity induced by the compounds of the invention has been examined by targeting it to codon 12 of *Ha-ras*. As described in U.S. Patent 5,297,248, corresponding to serial number 08/297,248, and its related application International Publication Number WO 92/22651, published December 23, 1992, both commonly assigned with this application, the entire contents of which are herein incorporated by reference, the *ras* oncogenes are members of a gene family that encode related proteins that are localized to the inner face of the plasma membrane and have been shown to be highly conserved at the amino acid level, to bind GTP with high affinity and specificity, and to possess GTPase activity. Although the cellular function of *ras* gene products is unknown, their biochemical properties, along with their significant sequence homology with a class of signal-transducing proteins, known as GTP binding proteins, or G proteins, suggest that *ras* gene products play a fundamental role in basic cellular regulatory functions related to the transduction of extracellular signals across plasma membranes.

Three *ras* genes, designated *H-ras*, *K-ras*, and *N-ras*, have been identified in the mammalian genome. Mammalian *ras* genes acquire transformation-inducing properties by single point mutations within their coding sequences. Mutations in naturally occurring *ras* oncogenes have been localized to codons 12, 13, and 61. The most commonly detected activating *ras* mutation found in human tumors is in codon 12 of the *H-ras* gene in which a base change from GGC to GTC results in a glycine-to-valine substitution in the GTPase regulatory domain of the *ras* protein product. This single amino acid change is thought to abolish normal control of *ras* protein function, thereby converting a normally regulated cell protein to one that is continuously active. It is believed that such deregulation of normal *ras* protein function is responsible for the

transformation from normal to malignant growth.

While for illustrative purposes, the compounds of the invention are targeted to *ras* RNA, it is of course recognized that a host of other RNAs also are suitable as the target RNA. 5 Thus the compounds of the invention can be used to modulate the expression of any suitable target RNA that is naturally present in cells or any target RNA *in vitro*.

The *ras* target site utilized for illustrative purposes is one the most RNase H sensitive oligonucleotide 10 sites that has been identified in the literature. The selective inhibition of mutated genes such as the *ras* oncogene necessitates hybridization of a regulatory compound in the coding region of the mRNA. This requires either a high 15 affinity interaction between such a compound and *ras* mRNA to prevent displacement of the compound by the polysome, or rapid degradation of the target mRNA by a given terminating mechanism. Again while not wishing to be bound by theory, the RNA like compounds of the invention, have both inherently high affinity and are able to take advantage of the cellular dsRNase 20 activity.

In accordance with the objects of this invention, novel oligomeric compounds that bind to a target RNA strand and that are substrates for dsRNase enzymes are provided. The oligomeric compounds of the invention include oligoribonucleotides, oligoribonucleosides and other oligomeric compounds having a linear sequence of linked ribonucleoside subunits incorporated therein. Such other oligomeric compounds will include chimeric structures formed between PNA (peptide nucleic acid) segments and linked ribonucleosides. Thus for the 25 purposes of this specification, the term "oligomeric compound" is meant to be inclusive of the terms oligoribonucleotides and oligoribonucleosides, either used singly or in combination, as well as other oligomeric compounds including chimeric compounds formed between PNA segments (and other surrogate nucleoside 30 components) and linked ribonucleoside segments. As used in 35 this specification and the claims attached hereto, in one sense the term oligomeric compound is used to represent

oligoribonucleotides, in a further sense to represent oligoribonucleosides, in even a further sense to represent mixtures of oligoribonucleotides and oligoribonucleosides and in other instances to indicated further chimeric compounds such 5 as the above identified PNA chimeric compounds.

The oligoribonucleotides and oligoribonucleosides of the invention are assembled from a plurality of nucleoside subunits. In certain preferred oligoribonucleotide or oligoribonucleosides of the invention at least one of the 10 nucleoside subunits bear a substituent group that increases the binding affinity of the oligoribonucleotide or oligoribonucleoside for a complementary strand of nucleic acid. Additionally, at least some of the nucleoside subunits comprise 2'-hydroxyl-pentofuranosyl sugar moieties.

15 For cellular use, for an oligonucleotide to be particularly useful, the oligonucleotide must be reasonably stable to nucleases in order to survive in cells for a time period sufficient for it to interact with target nucleic acids of the cells. Therefore, in certain embodiments of the 20 invention, specific nucleoside subunits or internucleoside linkages are functionalized or selected to increase the nuclease resistance of the oligoribonucleotide or oligoribonucleoside. However, for non-cellular uses, such as use of oligomeric compounds of the invention as research 25 reagents and as diagnostic agents, such nuclease stability may not be necessary.

In determining the extent of binding affinity of a first nucleic acid to a complementary nucleic acid, the relative ability of the first nucleic acid to bind to the 30 complementary nucleic acid may be compared by determining the melting temperature of a particular hybridization complex. The melting temperature (T_m), a characteristic physical property of double stranded nucleotides, denotes the temperature (in degrees centigrade) at which 50% helical 35 (hybridized) versus coil (unhybridized) forms are present. T_m is measured by using the UV spectrum to determine the formation and breakdown (melting) of the hybridization complex. Base

1234567890

stacking which occurs during hybridization is accompanied by a reduction in UV absorption (hypochromicity). Consequently, a reduction in UV absorption indicates a higher T_m . The higher the T_m , the greater the strength of the bonds between the 5 strands.

It has been found in the present invention that the binding affinity of oligoribonucleotides and oligoribonucleosides of the present invention can be increased by incorporating substituent groups in the nucleoside subunits of 10 these compounds. Preferred substituent groups are 2' substituent groups, i.e. substituent groups located at the 2' position of the pentofuranosyl sugar moieties of the nucleoside subunits of the compounds of the present invention. Presently preferred substituent groups include fluoro, alkoxy, amino-15 alkoxy, allyloxy, imidazolylalkoxy and polyethylene glycol. Alkoxy and aminoalkoxy groups generally include lower alkyl groups, particularly C₁-C₉ alkyl. Polyethylene glycols are of the structure (O-CH₂-CH₂)_n-O-alkyl. A particularly preferred substituent group is a polyethylene glycol substituent of the 20 formula $(-O-CH_2-CH_2)_n-O$ -alkyl, wherein n=1 and alkyl=CH₃. This modification has been shown to increase both affinity of a oligonucleotide for its target and nuclease resistance of an oligonucleotide.

A further particularly useful 2'-substituent group 25 for increasing the binding affinity is the 2'-fluoro group. In a published study (*Synthesis and Biophysical Studies of 2'-dRIBO-F Modified Oligonucleotides*, Conference On Nucleic Acid Therapeutics, Clearwater, FL, January 13, 1991) an increase in binding affinity of 1.6°C per substituted nucleoside subunit 30 was reported for a 15-mer phosphodiester oligonucleotide having 2'-fluoro substituent groups on five of the nucleoside subunits of the oligonucleotide. When 11 of the nucleoside subunits of the oligonucleotide bore 2'-fluoro substituent groups, the binding affinity increased to 1.8°C per substituted nucleoside 35 subunit. In this study, the 15-mer phosphodiester oligonucleotide was derivatized to the corresponding phosphorothioate analog. When the 15-mer phosphodiester

oligonucleotide was compared to its phosphorothioate analog, the phosphorothioate analog had a binding affinity of only about 66% of that of the 15-mer phosphodiester oligonucleotide. Stated otherwise, binding affinity was lost in derivatizing the 5 oligonucleotide to its phosphorothioate analog. However, when 2'-fluoro substituents were located on 11 of the nucleosides subunits of the 15-mer phosphorothioate oligonucleotide, the binding affinity of the 2'-substituent groups more than overcame the decrease noted by derivatizing the 15-mer 10 oligonucleotide to its phosphorothioate analog. In this compound, i.e. the 15-mer phosphorothioate oligonucleotide having 11 nucleoside subunits substituted with 2'-fluoro substituent groups, the binding affinity was increased to 2.5°C per substituent group.

15 For use in preparing the nucleoside structural subunits of the compounds of the invention, suitable nucleobases for incorporation in these nucleoside subunits include purines and pyrimidines such as adenine, guanine, cytosine, uridine, and thymine, as well as other synthetic and 20 natural nucleobases such as xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil 25 (pseudouracil), 4-thiouracil, 8-halo, amino, thiol, thioalkyl, hydroxyl and other 8-substituted adenines and guanines, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine. Further purines and pyrimidines include those disclosed in United States Patent No. 3,687,808, those 30 disclosed in the *Concise Encyclopedia Of Polymer Science And Engineering*, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, 1990, and those disclosed by Englisch et al., *Angewandte Chemie, International Edition*, 1991, 30, 613. Certain of these nucleobases are particularly useful for 35 increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines,

including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. Other modified pyrimidine and purine bases are also expected to increase the binding affinity of oligomeric compounds to a complementary strand of nucleic acid.

5 Preferred oligoribonucleotides and oligoribonucleosides in accordance with this invention preferably comprise from about 5 to about 50 nucleoside subunits. In the context of this invention it is understood that this encompasses non-naturally occurring oligomers as hereinbefore described, having
10 5 to 50 nucleoside subunits. It is more preferred that the oligoribonucleotides and oligoribonucleosides of the present invention comprise from about 15 to about 25 nucleoside subunits. As will be appreciated, a "nucleoside subunit" is a nucleobase and sugar or sugar surrogate combination suitably
15 bound to adjacent subunits through phosphorus linkages in oligoribonucleotides and through non-phosphorus linkages in oligoribonucleosides. In this context, the term "nucleoside subunit" is used interchangeably with the term "nucleoside unit" or "nucleoside."

20 The oligoribonucleotides of the invention have their nucleoside subunits connected by phosphorus linkages including phosphodiester, phosphorothioate, 3'-(or -5')deoxy-3'-(or -5')thio-phosphorothioate, phosphorodithioate, phosphoro-selenates, 3'-(or -5')deoxy phosphinates, borano phosphates,
25 3'-(or -5')deoxy-3'-(or 5')amino phosphoramidates, hydrogen phosphonates, borano phosphate esters, phosphoramidates, alkyl or aryl phosphonates and phosphotriester phosphorus linkages. Whereas the oligoribonucleosides of the invention have their nucleoside subunits connected by carbonate, carbamate, silyl,
30 sulfur, sulfonate, sulfonamide, formacetal, thioformacetyl, oxime, methyleneimino, methylenemethylimino, methylenehydrazo, methylenedimethylhydrazo and methyleneoxymethylimino linkages.

In order to elicit a dsRNase response within the total overall sequence length of the oligomeric compounds of
35 the invention there will be a segment or subsequence of greater than three, but preferably, four, five or more consecutively

linked 2'-hydroxyl-pentofuranosyl-containing nucleoside subunits. It is presently preferred to incorporate the 2'-hydroxyl-pentofuranosyl-containing nucleoside subsequence in the oligomeric compound such that further subsequences or 5 segments of oligomeric compound are located on either side of the 2'-hydroxyl-pentofuranosyl-containing nucleoside subsequence. In such a construction, the 2'-hydroxyl-pentofuranosyl containing nucleoside subsequence is also referred to as the "central" or "gap" region or segment and the 10 other nucleoside subsequences or segments are referred to as "flanking" or "wing" regions or segments. Thus the "gap" region is flanked on either side by "wings." Other constructions are also possible, including locating the 2'-hydroxylpentofuranosyl containing nucleoside subsequence at 15 either the 3' or the 5' terminus of the oligomeric compound of the invention. These other constructions can be considered as "open" gapped structures, *i.e.*, the gap region is open on the end (either 3' or 5' end) of the oligomeric compound.

The oligoribonucleotides and oligoribonucleosides 20 used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis, see for example "Oligonucleotide synthesis, a practical approach", Ed. M.J. Gait, IRL Press, 1984; "Oligonucleotides and Analogues, A Practical Approach", Ed. F. 25 Eckstein, IRL Press, 1991 (especially Chapter 1, Modern machine-aided methods of oligodeoxyribonucleotide synthesis, Chapter 2, Oligoribonucleotide synthesis, Chapter 3, 2'-O-Methyloligonucleotides: synthesis and applications, Chapter 4, Phosphorothioate oligonucleotides, Chapter 5, Synthesis of 30 oligonucleotide phosphorodithioates, Chapter 6, Synthesis of oligo-2'-deoxyribonucleoside methylphosphonates, and Chapter 7, Oligodeoxynucleotides containing modified bases. Other particularly useful synthetic procedures, reagents, blocking groups and reaction conditions are described in Martin, P., 35 *Helv. Chim. Acta*, 1995, 78, 486-504; Beaucage, S.L. and Iyer, R.P., *Tetrahedron*, 1992, 48, 2223-2311 and Beaucage, S.L. and Iyer, R.P., *Tetrahedron*, 1993, 49, 6123-6194, or references

referred to therein.

Equipment for oligonucleotide and oligonucleoside synthesis is sold by several vendors including Applied Biosystems. Various amidite reagents are also commercially available, including 2'-O-methyl amidites and 2'-O-hydroxyl amidites. Any other means for such synthesis may also be employed. The actual synthesis of the oligonucleotides is well within the talents of those skilled in the art. It is also well known to use similar techniques to prepare other oligonucleotides such as the phosphorothioates and alkylated derivatives. It is also well known to use similar techniques and commercially available modified amidites and controlled-pore glass (CPG) products such as biotin, fluorescein, acridine or psoralen-modified amidites and/or CPG (available from Glen Research, Sterling VA) to synthesize fluorescently labeled, biotinylated or other conjugated oligonucleotides.

In a further embodiment, the present invention is drawn to a mammalian ribonuclease isolatable from human T24 cells, and other cell lines, that degrades RNA in an antisense oligoribonucleotide:RNA duplex. The ribonuclease is referred to herein as a dsRNase, wherein "ds" indicates the RNase's specificity for double-stranded RNA substrates. Antisense oligodeoxynucleotides containing 2'-methoxy modified sugar moieties bind to their cellular mRNA targets with high affinity but the resulting ["DNA-like"]:[RNA] duplexes are not substrates for nucleolytic degradation in T24 cells. As detailed in the Examples, 2'-methoxy phosphorothioate antisense oligonucleotides targeting codon 12 of Ha-Ras mRNA were modified by substituting 2'-methoxy nucleotides with a stretch of ribonucleotides in the center of the oligonucleotide to form 2'-methoxy/ribo/2'-methoxy chimeric or "gapmer" oligonucleotides, with the phosphorothioate linkage maintained throughout the molecules. These "RNA-like" gapmer oligonucleotides bind to their cellular mRNA target with an affinity comparable to that of the full 2'-methoxy oligodeoxynucleotide, but, unlike the ["DNA-like"]:[RNA] duplexes, the resultant ["RNA-like"]:[RNA] duplexes are

substrates for nucleolytic degradation in T24 cells. Degradation of the [antisense "RNA-like" gapmer oligonucleotide]:[Ha-Ras mRNA] duplex is dependent on the number of ribonucleotides incorporated into the antisense 5 molecule. A 17 base pair 9 RNA gapmer oligonucleotide:RNA duplex is not a substrate for RNase H cleavage, but is a substrate for cleavage by an the dsRNase of the invention in T24 cellular lysates. Furthermore, the cleavage sites seen with T24 cellular lysates are localized to the RNA:RNA portion 10 of the duplex and are not seen in the 2'-methoxy:RNA portion of the duplex. Cleavage of the duplex by the dsRNase of the invention produces 5'-phosphate and 3'-hydroxyl termini.

Compounds of the invention can be utilized as diagnostics, therapeutics and as research reagents and kits. 15 They can be utilized in pharmaceutical compositions by adding an effective amount of a compound of the invention to a suitable pharmaceutically acceptable diluent or carrier. They further can be used for treating organisms having a disease characterized by the undesired production of a protein. The 20 organism can be contacted with a compound of the invention having a sequence that is capable of specifically hybridizing with a strand of target nucleic acid that codes for the undesirable protein.

The formulation of therapeutic compositions and their 25 subsequent administration is believed to be within the skill of those in the art. In general, for therapeutics, a patient in need of such therapy is administered a compound in accordance with the invention, commonly in a pharmaceutically acceptable carrier, in doses ranging from 0.01 μ g to 100 g per 30 kg of body weight depending on the age of the patient and the severity of the disease state being treated. Further, the treatment regimen may last for a period of time which will vary depending upon the nature of the particular disease, its 35 severity and the overall condition of the patient, and may extend from once daily to once every 20 years. Following treatment, the patient is monitored for changes in his/her condition and for alleviation of the symptoms of the disease

state. The dosage of the compound may either be increased in the event the patient does not respond significantly to current dosage levels, or the dose may be decreased if an alleviation of the symptoms of the disease state is observed, or if the 5 disease state has been ablated.

In some cases it may be more effective to treat a patient with a compound of the invention in conjunction with other traditional therapeutic modalities. For example, a patient being treated for a viral disease may be administered 10 a compound of the invention in conjunction with a known antiviral agent, or a patient with atherosclerosis may be treated with a compound of the invention following angioplasty to prevent reocclusion of the treated arteries.

Following successful treatment, it may be desirable 15 to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the compound of the invention is administered in maintenance doses, ranging from 0.01 μ g to 100 g per kg of body weight, once or more daily, to once every 20 years.

20 The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic, vaginal, rectal, intranasal, 25 transdermal), oral or parenteral. Parenteral administration includes intravenous drip, subcutaneous, intraperitoneal or intramuscular injection, or intrathecal or intraventricular administration.

Formulations for topical administration may include 30 transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

35 Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring

agents, diluents, emulsifiers, dispersing aids or binders may be desirable.

Compositions for intrathecal or intraventricular administration may include sterile aqueous solutions which may 5 also contain buffers, diluents and other suitable additives.

Formulations for parenteral administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives.

Dosing is dependent on severity and responsiveness 10 of the disease condition to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. 15 Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual compounds, and can generally be estimated based on EC₅₀s found to be effective in *in vitro* and *in vivo* animal models. In general, 20 dosage is from 0.01 µg to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years.

Such treatment can be practiced in a variety of organisms ranging from unicellular prokaryotic and eukaryotic 25 organisms to multicellular eukaryotic organisms. Any organism that utilizes DNA-RNA transcription or RNA-protein translation as a fundamental part of its hereditary, metabolic or cellular machinery is susceptible to such diagnostic, therapeutic and/or prophylactic treatment. Seemingly diverse organisms such as 30 bacteria, yeast, protozoa, algae, plant and higher animal forms, including warm-blooded animals, can be treated in this manner. Further, since each of the cells of multicellular eukaryotes also includes both DNA-RNA transcription and RNA- 35 protein translation as an integral part of their cellular activity, such therapeutics and/or diagnostics can also be practiced on such cellular populations. Furthermore, many of the organelles, e.g. mitochondria and chloroplasts, of

eukaryotic cells also include transcription and translation mechanisms. As such, single cells, cellular populations or organelles also can be included within the definition of organisms that are capable of being treated with the 5 therapeutic or diagnostic compounds of the invention. As used herein, therapeutics is meant to include eradication of a disease state, killing of an organism, e.g. bacterial, protozoan or other infection, or control of aberrant or undesirable cellular growth or expression.

10 In the context of this invention, "target RNA" shall mean any RNA that can hybridize with a complementary nucleic acid like compound. Further in the context of this invention, "hybridization" shall mean hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, 15 between complementary nucleobases. "Complementary" as used herein, refers to the capacity for precise pairing between two nucleobases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. "Complementary" and "specifically 20 hybridizable," as used herein, refer to precise pairing or sequence complementarity between a first and a second nucleic acid-like oligomers containing nucleoside subunits. For example, if a nucleobase at a certain position of the first nucleic acid is capable of hydrogen bonding with a nucleobase 25 at the same position of the second nucleic acid, then the first nucleic acid and the second nucleic acid are considered to be complementary to each other at that position. The first and second nucleic acids are complementary to each other when a sufficient number of corresponding positions in each molecule 30 are occupied by nucleobases which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity such that stable and specific binding occurs between a compound of the invention and a target RNA molecule. 35 It is understood that an oligomeric compound of the invention need not be 100% complementary to its target RNA sequence to be specifically hybridizable. An oligomeric compound is

specifically hybridizable when binding of the oligomeric compound to the target RNA molecule interferes with the normal function of the target RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-
5 specific binding of the oligomeric compound to non-target sequences under conditions in which specific binding is desired, *i.e.* under physiological conditions in the case of *in vivo* assays or therapeutic treatment, or in the case of *in vitro* assays, under conditions in which the assays are
10 performed.

The following examples and procedures illustrate the present invention and are not intended to limit the same. In illustrating the invention, Example 1 identifies certain commercial nucleoside amidites and other additional nucleoside
15 amidites that are useful for the preparation of certain illustrative oligoribonucleotide or oligoribonucleoside compounds of the invention. Examples 2 through 5 illustrate the preparation of further nucleoside amidites use in preparing other illustrative oligoribonucleotide or oligoribonucleoside
20 compounds of the invention. Example 6 illustrates the preparation of oligoribonucleotide compounds of the invention. Example 7 illustrates the preparation of oligoribonucleoside compounds of the invention. Examples 8 through 16 illustrate the preparation of chimeric oligomeric compounds of the
25 invention including certain "gapmers," *i.e.*, compounds having "gap" and "wing" constructions. Examples 17 through 18 illustrate certain useful aspects of the compounds of the invention. Examples 19 through 28 illustrate the identification, characterization and purification of the
30 double-stranded ribonucleases (dsRNases) of the invention. Example 29 illustrates affinity columns incorporating the dsRNase substrates of the invention.

In the illustrative examples, several different types of "gapmers" are exemplified. These include a first type
35 wherein the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked nucleosides and a second "open end" type wherein the "gap" segment is located at

either the 3' or the 5' terminus of the oligomeric compound. In the illustrative examples, for all chimeric oligoribonucleotides and oligoribonucleosides, unless otherwise indicated, 2'-O-methyl nucleosides are utilized in the "wing" segments and 5 2'-OH nucleosides are utilized in the "gap" segments of the respective oligoribonucleotides or oligoribonucleosides.

For the purposes of the illustrative examples the following short hand conventions are used. Structure set forth in brackets, i.e. [], are nucleoside abbreviations, while 10 structures set forth following a slash mark, i.e. /, are linkers used to connect the nucleosides, i.e. backbone structures that link the nucleosides together in either oligoribonucleotide or oligoribonucleoside compounds.

Using this nomenclature, the following abbreviations 15 are used for phosphate linkages between nucleosides: PO for phosphodiester; PS for phosphorothioate, P2S for phosphorodithioate, PSe for phosphoroselenates, PMe for methyl phosphonate, POMe for methyl phosphotriester, PN for phosphoramidate, 3'NPN for 3'-deoxy-3'-amino phosphoramidate, 20 PI for phosphinate, MePS for alkylphosphonothioate, BP for borano phosphate are used. For non-phosphate linkages between nucleosides the abbreviations used are: MMI for methylenemethylimino, MDH for methylenedimethylhydrazo, FA for formacetal, TFA for thioformacetal, ETO for ethylene oxide and 25 amide-3 for methylenecarbonylamino. 2'-OH is utilized as an abbreviation for unmodified ribo sugars, i.e. pentoribofuranosyl sugars. For modified nucleosides the abbreviations used are: 2'-O-alkyl for general alkyl groups at the 2' position of a pentoribofuranosyl moiety with specific 30 alkyl being noted as 2'-O-Me, 2'-O-Et, 2'-O-Pr and 2'-O-EtOMe for methyl, ethyl, propyl and methoxyethyl, respectively; 2'-F for a fluoro moiety at the 2' position of a pentoribofuranosyl moiety, Mod-Purine for a purine nucleobase substitution as, for example, per the disclosure of U.S. Patent 5,459,255 or; and 35 Mod-Pyr for a pyrimidine nucleobase substitution as, for example, per the disclosure of U.S. Patent 5,484,908; SS for

a sugar surrogate as, for example, per the disclosure of U.S. Patent 5,359,044.

EXAMPLE 1

Amidites for oligonucleotide/oligonucleoside synthesis

5 2'-O-Methyl nucleoside amidites and 2'-OH (blocked as 2'-*t*-butyldimethylsilyl derivative) nucleoside amidites are available from Glen Research, Sterling, VA. Other 2'-O-alkyl substituted nucleoside amidites are prepared as is described in U.S. Patents 5,506,351, 5,466,786 or 5,514,786, herein 10 incorporated by reference. Cyclobutyl sugar surrogate compounds are prepared as is described in U.S. Patent 5,359,044, herein incorporated by reference. Pyrrolidine sugar surrogate are prepared as is described in U.S. Patent 5,519,134, herein incorporated by reference. Morpholino sugar 15 surrogates are prepared as is described in U.S. Patents 5,142,047 and 5,235,033, herein incorporated by reference, and other related patent disclosures. N-2 substituted purine nucleoside amidites are prepared as is described in U.S. Patent 5,459,255, herein incorporated by reference. 3-Deaza purine 20 nucleoside amidites are prepared as is described in U.S. Patent 5,457,191, herein incorporated by reference. 5,6-Substituted pyrimidine nucleoside amidites are prepared as is described in U.S. Patent 5,614,617 herein incorporated by reference. 5-Propynyl pyrimidine nucleoside amidites are prepared as is 25 described in U.S. Patent 5,484,908, herein incorporated by reference.

EXAMPLE 2

2'-O-(Methoxyethyl) nucleoside amidites

2'-O-Ethyl-O-methyl substituted nucleoside amidites 30 are prepared as follows in Examples 2-a through 2-h or alternately, as per the methods of Martin, P., *Helvetica Chimica Acta*, 1995, 78, 486-504.

EXAMPLE 2-a**2,2'-Anhydro[1-(β -D-arabinofuranosyl)-5-methyluridine]**

5-Methyluridine (ribosylthymine, commercially available through Yamasa, Choshi, Japan) (72.0 g, 0.279 M), 5 diphenylcarbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) were added to DMF (300 mL). The mixture was heated to reflux, with stirring, allowing the evolved carbon dioxide gas to be released in a controlled manner. After 1 hour, the slightly darkened solution was concentrated under reduced 10 pressure. The resulting syrup was poured into diethylether (2.5 L), with stirring. The product formed a gum. The ether was decanted and the residue was dissolved in a minimum amount of methanol (ca. 400 mL). The solution was poured into fresh ether (2.5 L) to yield a stiff gum. The ether was decanted and 15 the gum was dried in a vacuum oven (60°C at 1 mm Hg for 24 h) to give a solid which was crushed to a light tan powder (57 g, 85% crude yield). The NMR spectrum was consistent with the structure, contaminated with phenol as its sodium salt (ca. 5%). The material was used as is for further reactions (or it 20 can be purified further by column chromatography using a gradient of methanol in ethyl acetate (10-25%) to give a white solid, mp 222-4°C).

EXAMPLE 2-b**2'-O-Methoxyethyl-5-methyluridine**

25 2,2'-Anhydro-5-methyluridine (195 g, 0.81 M), tris(2-methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) were added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160°C. After heating for 48 hours at 155-160°C, the vessel was opened and the solution 30 evaporated to dryness and triturated with MeOH (200 mL). The residue was suspended in hot acetone (1 L). The insoluble salts were filtered, washed with acetone (150 mL) and the filtrate evaporated. The residue (280 g) was dissolved in CH₃CN (600 mL) and evaporated. A silica gel column (3 kg) was 35 packed in CH₂Cl₂/acetone/MeOH (20:5:3) containing 0.5% Et₃NH. The residue was dissolved in CH₂Cl₂ (250 mL) and adsorbed onto

silica (150 g) prior to loading onto the column. The product was eluted with the packing solvent to give 160 g (63%) of product. Additional material was obtained by reworking impure fractions.

5 EXAMPLE 2-c

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine

2'-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was co-evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L). A first aliquot of 10 dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the mixture stirred at room temperature for one hour. A second aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the reaction stirred for an additional one hour. Methanol (170 mL) was then added to stop the reaction. HPLC showed the 15 presence of approximately 70% product. The solvent was evaporated and triturated with CH₃CN (200 mL). The residue was dissolved in CHCl₃ (1.5 L) and extracted with 2x500 mL of saturated NaHCO₃ and 2x500 mL of saturated NaCl. The organic phase was dried over Na₂SO₄, filtered and evaporated. 275 g of 20 residue was obtained. The residue was purified on a 3.5 kg silica gel column, packed and eluted with EtOAc/Hexane/Acetone (5:5:1) containing 0.5% Et₃NH. The pure fractions were evaporated to give 164 g of product. Approximately 20 g additional was obtained from the impure fractions to give a 25 total yield of 183 g (57%).

EXAMPLE 2-d

3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-30 methyluridine (106 g, 0.167 M), DMF/pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at room temperature for 24 hours. The reaction was monitored by tlc by first quenching the tlc sample with the addition of 35 MeOH. Upon completion of the reaction, as judged by tlc, MeOH

(50 mL) was added and the mixture evaporated at 35°C. The residue was dissolved in CHCl₃ (800 mL) and extracted with 2x200 mL of saturated sodium bicarbonate and 2x200 mL of saturated NaCl. The water layers were back extracted with 200 5 mL of CHCl₃. The combined organics were dried with sodium sulfate and evaporate to give 122 g of residue (approx. 90% product). The residue was purified on a 3.5 kg silica gel column and eluted using EtOAc/Hexane (4:1). Pure product fractions were evaporated to yield 96 g (84%). An additional 10 1.5 g was recovered from later fractions.

EXAMPLE 2-e**3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine**

A first solution was prepared by dissolving 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine 15 (96 g, 0.144 M) in CH₃CN (700 mL) and set aside. Triethylamine (189 mL, 1.44 M) was added to a solution of triazole (90 g, 1.3 M) in CH₃CN (1 L), cooled to -5°C and stirred for 0.5 h using an overhead stirrer. POCl₃ was added dropwise, over a 30 20 minute period, to the stirred solution maintained at 0-10°C, and the resulting mixture stirred for an additional 2 hours. The first solution was added dropwise, over a 45 minute period, to the later solution. The resulting reaction mixture was stored overnight in a cold room. Salts were filtered from the 25 reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was washed with 1x300 mL of NaHCO₃ and 2x300 mL of saturated NaCl, dried over sodium sulfate and evaporated. The residue was triturated with EtOAc 30 to give the title compound.

EXAMPLE 2-f**2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine**

A solution of 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M) in 35 dioxane (500 mL) and NH₄OH (30 mL) was stirred at room

temperature for 2 hours. The dioxane solution was evaporated and the residue azeotroped with MeOH (2x200 mL). The residue was dissolved in MeOH (300 mL) and transferred to a 2 liter stainless steel pressure vessel. MeOH (400 mL) saturated with 5 NH₃ gas was added and the vessel heated to 100°C for 2 hours (tlc showed complete conversion). The vessel contents were evaporated to dryness and the residue was dissolved in EtOAc (500 mL) and washed once with saturated NaCl (200 mL). The organics were dried over sodium sulfate and the solvent was 10 evaporated to give 85 g (95%) of the title compound.

EXAMPLE 2-g**N⁴-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine**

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (85 g, 0.134 M) was dissolved in DMF (800 mL) and benzoic anhydride (37.2 g, 0.165 M) was added with stirring. After stirring for 3 hours, tlc showed the reaction to be approximately 95% complete. The solvent was evaporated and the residue azeotroped with MeOH (200 mL). The residue was 15 dissolved in CHCl₃ (700 mL) and extracted with saturated NaHCO₃ (2x300 mL) and saturated NaCl (2x300 mL), dried over MgSO₄ and evaporated to give a residue (96 g). The residue was chromatographed on a 1.5 kg silica column using EtOAc/Hexane 20 (1:1) containing 0.5% Et₃NH as the eluting solvent. The pure product fractions were evaporated to give 90 g (90%) of the title compound.

EXAMPLE 2-h**N⁴-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine-3'-amidite**

30 N⁴-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (74 g, 0.10 M) was dissolved in CH₂Cl₂ (1 L). Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy-tetra-(isopropyl)phosphite (40.5 mL, 0.123 M) were added with stirring, under a nitrogen atmosphere. The resulting mixture 35 was stirred for 20 hours at room temperature (tlc showed the

reaction to be 95% complete). The reaction mixture was extracted with saturated NaHCO₃ (1x300 mL) and saturated NaCl (3x300 mL). The aqueous washes were back-extracted with CH₂Cl₂ (300 mL), and the extracts were combined, dried over MgSO₄ and 5 concentrated. The residue obtained was chromatographed on a 1.5 kg silica column using EtOAc\Hexane (3:1) as the eluting solvent. The pure fractions were combined to give 90.6 g (87%) of the title compound.

EXAMPLE 3**10 Preparation of long chain, i.e. (C₂₀), substituted nucleoside amidites**

Synthesis of nucleoside amidites having long chains, e.g. C₂₀, substituents at their 2' position is shown in Examples 3-a through 3-c.

15 EXAMPLE 3-a**Synthesis of 2,6-Diamino-9-(2-O-octadecyl-β-D-ribofuranosyl)purine**

2,6-Diamino-9-(β-D-ribofuranosyl)purine (50 g, 180 mmol) and sodium hydride (7 g) in DMF (1 L) were heated to 20 boiling for 2 hr. Iodoctadecane (100 g) was added at 150°C and the reaction mixture allowed to cool to RT. The reaction mixture was stirred for 11 days at RT. The solvent was evaporated and the residue purified by silica gel chromatography. The product was eluted with 5% MeOH/CH₂Cl₂. 25 The appropriate fractions were evaporated to yield the product (11 g). ¹H NMR (DMSO-d₆) δ 0.84 (t, 3, CH₂) ; 1.22 (m, 32, O-CH₂-CH₂-(CH₂)₁₆) ; 1.86 (m, 2, O-CH₂CH₂) ; 3.25 (m, 2, O-CH₂) ; 3.93 (d, 1, 4'H) , 4.25 (m, 1, 3'H) ; 4.38 (t, 1, 2'H) ; 5.08 (d, 1, 3'-OH) ; 5.48 (t, 1, 5'-OH) ; 5.75 (s, 2, 6-NH₂) ; 5.84 (d, 1, 1'-H) ; 6.8 (s, 2, 2-NH₂) ; and 7.95 (s, 1, 8-H) . 30

EXAMPLE 3-b**Synthesis of 2'-O-Octadecylguanosine**

2,6-Diamino-9-(2-O-octadecyl-β-D-ribofuranosyl)purine (10 g) in 0.1 M sodium phosphate buffer (50 mL, pH 7.4), 35 0.1 M tris buffer (1000 mL, pH 7.4) and DMSO (1000 mL) was

treated with adenosine deaminase (1.5 g) at RT. At day 3, day 5 and day 7 an additional aliquot (500 mg, 880 mg and 200 mg, respectively) of adenosine deaminase was added. The reaction was stirred for a total of 9 day and purification by silica gel chromatography yielded the product (2 g). An analytical sample was recrystallized from MeOH. ^1H NMR (DMSO-d₆) δ 0.84 (t, 3, CH₃), 1.22 [s, 32, O-CH₂-CH₂-(CH₂)₁₆], 5.07 (m, 2, 3'-OH and 5'-OH); 5.78 (d, 1, 1'-H); 6.43 (s, 2, NH₂), 7.97 (s, 1, 8-H) and 10.64 (s, 1, NH₂). Anal. Calcd. for C₂₈H₄₉N₅O₅: C, 62.80; H, 9.16; N, 12.95. Found: C, 62.54; H, 9.18; N, 12.95.

EXAMPLE 3-C**Synthesis of N²-Isobutyryl-2'-O-octadecylguanosine**

2'-O-Octadecylguanosine (1.9 g) in pyridine (150 mL) was cooled in an ice bath, and treated with trimethylsilyl chloride (2 g, 5 eq) and isobutyryl chloride (2 g, 5 eq). The reaction mixture was stirred for 4 hours, during which time it was allowed to warm to room temperature. The solution was cooled, water added (10 mL) and stirred for an additional 30 minutes. Concentrated ammonium hydroxide (10 mL) was added and the solution concentrated *in vacuo*. The residue was purified by silica gel chromatography (eluted with 3% MeOH/EtOAc) to yield 1.2 g of product. ^1H NMR (DMSO-d₆) δ 0.85 (t, 3, CH₃), 1.15 (m, 38, O-CH₂CH₂(CH₂)₁₆, CH(CH₃)₂), 2.77 (m, 1, CH(CH₃)₂), 4.25 (m, 2, 2'-H and 3'-H); 5.08 (t, 1, 5'-OH), 5.12 (d, 1, 3'-OH), 5.87 (d, 1, 1'-H), 8.27 (s, 1, 8-H), 11.68 (s, 1, NH₂) and 12.08 (s, 1, NH₂). Anal. Calcd. for C₃₂H₅₅N₅O₆: C, 63.47; H, 9.09; N, 11.57. Found: C, 63.53; H, 9.20; N, 11.52. Prior to incorporating this product into an oligonucleotide, it was converted to N²-Isobutyryl-5'-dimethoxytrityl-2'-O-octadecylguanosine and then to a phosphoramidite according to the procedures described in International Publication Number WO 94/02501, published February 3, 1994.

EXAMPLE 4**2'-Fluoro nucleoside amidites**

35 2'-fluoro substituted nucleoside amidites are

prepared as follows in Examples 4-a through 4-d or alternately as per the method of Kawasaki et. al., *J. Med. Chem.*, 1993, 36, 831-841.

EXAMPLE 4-a

5 i. ***N*⁶-Benzoyl-9- β -D-arabinofuranosyladenine.**

9- β -D-arabinofuranosyladenine (1.07 g, 4.00 mmol) was dissolved in anhydrous pyridine (20 mL) and anhydrous dimethylformamide (20 mL) under an argon atmosphere. The 10 solution was cooled to 0°C and chlorotrimethylsilane (3.88 mL, 30.6 mmol) was added slowly to the reaction mixture via a syringe. After stirring the reaction mixture at 0°C for 30 minutes, benzoyl chloride (2.32 mL, 20 mmol) was added slowly. The reaction mixture was allowed to warm to 20°C and stirred 15 for 2 hours. After cooling the reaction mixture to 0°C, cold water (8 mL) was added and the mixture was stirred for 15 minutes. Concentrated ammonium hydroxide (8 mL) was slowly added to the reaction mixture to give a final concentration of 2 M of ammonia. After stirring the cold reaction mixture for 20 30 minutes, the solvent was evaporated *in vacuo* (60 torr) at 20°C followed by evaporation *in vacuo* (1 torr) at 40°C to give an oil. This oil was triturated with diethyl ether (50 mL) to give a solid which was filtered and washed with diethyl ether three times. This crude solid was triturated in methanol (100 25 mL) at reflux temperature three times and the solvent was evaporated to yield *N*⁶-Benzoyl-9- β -D-arabino- furanosyladenine as a solid (1.50 g, 100%).

ii. ***N*⁶-Benzoyl-9-[3',5'-di-O-tetrahydropyran-2-yl]- β -D-arabino furanosyl] adenine.**

30 *N*⁶-Benzoyl-9- β -D-arabinofuranosyladenine (2.62 g, 7.06 mmol) was dissolved in anhydrous dimethylformamide (150 mL) under argon and *p*-toluenesulfonic acid monohydrate (1.32 g, 6.92 mmol) was added. This solution was cooled to 0°C and dihydropyran (1.26 mL, 13.8 mmol) was added via a syringe. The 35 reaction mixture was allowed to warm to 20°C. Over a period of

5 hours a total of 10 equivalents of dihydropyran were added in 2 equivalent amounts in the fashion described. The reaction mixture was cooled to 0°C and saturated aqueous sodium bicarbonate was added slowly to a pH of 8, then water was added 5 to a volume of 750 mL. The aqueous mixture was extracted with methylene chloride (4 x 200 mL), and the organic phases were combined and dried over magnesium sulfate. The solids were filtered and the solvent was evaporated *in vacuo* (60 torr) at 30°C to give a small volume of liquid which was evaporated in 10 *in vacuo* (1 torr) at 40°C to give an oil. This oil was coevaporated with *p*-xylene *in vacuo* at 40°C to give an oil which was dissolved in methylene chloride (100 mL). Hexane (200 mL) was added to the solution and the lower-boiling solvent was evaporated *in vacuo* at 30°C to leave a white solid 15 suspended in hexane. This solid was filtered and washed with hexane (3 x 10 mL) then purified by column chromatography using silica gel and methylene chloride-methanol (93:7) as the eluent. The first fraction yielded the title compound 3 as a white foam (3.19 g, 83 %) and a second fraction gave a white 20 foam (0.81 g) which was characterized as the 5'-monotetrahydropyranyl derivative of N⁶-Benzoyl-9- β -D-arabinofuranosyladenine.

iii. N⁶-Benzoyl-9-[2'-O-trifluoromethylsulfonyl-3',5'-di-O-tetrahydropyran-2-yl]- β -D-arabinofuranosyl]adenine.

25 N⁶-Benzoyl-9-[3',5'-di-O-tetrahydropyran-2-yl]- β -D-arabinofuranosyl]adenine (2.65 g, 4.91 mmol) was dissolved in anhydrous pyridine (20 mL) and the solvent was evaporated *in vacuo* (1 mm Hg) at 40°C. The resulting oil was dissolved in anhydrous methylene chloride (130 mL) under argon anhydrous 30 pyridine (3.34 mL, 41.3 mmol) and N,N-dimethylaminopyridine (1.95 g, 16.0 mmol) were added. The reaction mixture was cooled to 0°C and trifluoromethanesulfonic anhydride (1.36 mL, 8.05 mmol) was added slowly via a syringe. After stirring the reaction mixture at 0°C for 1 hour, it was poured into cold 35 saturated aqueous sodium bicarbonate (140 mL). The mixture was shaken and the organic phase was separated and kept at 0°C.

The aqueous phase was extracted with methylene chloride (2 x 140 mL). The organic extracts which were diligently kept cold were combined and dried over magnesium sulfate. The solvent was evaporated *in vacuo* (60 torr) at 20°C then evaporated *in vacuo* (1 torr) at 20°C to give N^6 -Benzoyl-9-[2'-O-trifluoromethylsulfonyl-3',5'-di-O-tetrahydropyran-2-yl]- β -D-arabinofuranosyl]adenine as a crude oil which was not purified further.

iv. N^6 -Benzoyl-9-[2'-fluoro-3',5'-di-O-tetrahydropyran-2-yl]- β -D-arabinofuranosyl]adenine.'

N^6 -Benzoyl-9-[2'-O-trifluoromethylsulfonyl-3',5'-di-O-tetrahydropyran-2-yl]- β -D-arabinofuranosyl]adenine (4.9 mmol) as a crude oil was dissolved in anhydrous tetrahydrofuran (120 mL) and this solution was cooled to 0°C under argon. Tetrabutylammonium fluoride as the hydrate (12.8 g, 49.1 mmol) was dissolved in anhydrous tetrahydrofuran (50 mL) and half of this volume was slowly added via a syringe to the cold reaction mixture. After stirring at 0°C for 1 hour, the remainder of the reagent was added slowly. The reaction mixture was stirred at 0°C for an additional 1 hour, then the solvent was evaporated *in vacuo* (60 torr) at 20°C to give an oil. This oil was dissolved in methylene chloride (250 mL) and washed with brine three times. The organic phase was separated and dried over magnesium sulfate. The solids were filtered and the solvent was evaporated to give an oil. The crude product was purified by column chromatography using silica gel in a sintered-glass funnel and ethyl acetate was used as the eluent. N^6 -Benzoyl-9-[2'-fluoro-3',5'-di-O-tetrahydropyran-2-yl]- β -D-arabinofuranosyl]adenine was obtained as an oil (2.03 g, 76%).

30 v. N^6 -Benzoyl-9-(2'-fluoro- β -D-ribofuranosyl)adenine.

N^6 -Benzoyl-9-[2'-fluoro-3',5'-di-O-tetrahydropyran-2-yl]- β -D-arabinofuranosyl]adenine (1.31 g, 2.42 mmol) was dissolved in methanol (60 mL), and Dowex 50W x 2-100 (4 cm³, 2.4 m.eq) was added to the reaction mixture. The reaction mixture was stirred at 20°C for 1 hour then cooled to 0°C.

Triethylamine (5 mL) was then slowly added to the cold reaction mixture to a pH of 12. The resin was filtered and washed with 30% triethylamine in methanol until the wash no longer contained UV absorbing material. Toluene (50 mL) was added to 5 the washes and the solvent was evaporated at 24°C *in vacuo* (60 torr, then 1 torr) to give a residue. This residue was partially dissolved in methylene chloride (30 mL) and the solvent was transferred to a separatory funnel. The remainder of the residue was dissolved in hot (60°C) water and after 10 cooling the solvent it was also added to the separatory funnel. The biphasic system was extracted, and the organic phase was separated and extracted with water (3 x 100 mL). The combined aqueous extracts were evaporated *in vacuo* (60 torr, then 1 torr Hg) at 40°C to give an oil which was evaporated with anhydrous 15 pyridine (50 mL). This oil was further dried *in vacuo* (1 torr Hg) at 20°C in the presence of phosphorous pentoxide overnight to give N⁶-benzoyl-9-(2'-fluoro-*b*-D-ribofuranosyl)adenine as a yellow foam (1.08 g, 100 %) which contained minor impurities.

vi. N⁶-Benzoyl-9-[2'-fluoro-5'-O-(4,4'-dimethoxy- trityl)-*β*-D- 20 ribofuranosyl]adenine.

N⁶-Benzoyl-9-(2'-fluoro-*b*-D-ribofuranosyl)adenine (1.08 g, 2.89 mmol) which contained minor impurities was dissolved in anhydrous pyridine (20 mL) under argon and dry triethylamine (0.52 mL, 3.76 mmol) was added followed by 25 addition of 4,4'-dimethoxytrityl chloride (1.13 g, 3.32 mmol). After 4 hours of stirring at 20°C the reaction mixture was transferred to a separatory funnel and diethyl ether (40 mL) was added to give a white suspension. This mixture was washed with water three times (3 x 10 mL), the organic phase was 30 separated and dried over magnesium sulfate. Triethylamine (1 mL) was added to the solution and the solvent was evaporated *in vacuo* (60 torr Hg) at 20°C to give an oil which was evaporated with toluene (20 mL) containing triethylamine (1 mL). This crude product was purified by column chromatography 35 using silica gel and ethyl acetate-triethylamine (99:1) followed by ethyl acetate-methanol-triethylamine (80:19:1) to

give the product in two fractions. The fractions were evaporated *in vacuo* (60 torr, then 1 torr Hg) at 20°C to give a foam which was further dried *in vacuo* (1 torr Hg) at 20°C in the presence of sodium hydroxide to give 5 N⁶-Benzoyl-9-[2'-fluoro-5'-O-(4,4'-dimethoxytrityl)- β -D-ribofuranosyl]adenine as a foam (1.02 g, 52 %).

vii. N⁶-Benzoyl-[2'-fluoro-5'-O-(4,4'-dimethoxy trityl)]-adenosine-3'-O-N,N-diisopropyl- β -cyanoethyl phosphoramidite.

10 N⁶-Benzoyl-9-[2'-fluoro-5'-O-(4,4'-dimethoxytrityl)- β -D-ribofuranosyl]adenine (1.26 g, 1.89 mmol) was dissolved in anhydrous dichloromethane (13 mL) under argon, diisopropylethylamine (0.82 mL, 4.66 mmol) was added, and the reaction mixture was cooled to 0°C. Chloro(diisopropylamino)-15 β -cyanoethoxyphosphine (0.88 mL, 4.03 mmol) was added to the reaction mixture which was allowed to warm to 20°C and stirred for 3 hours. Ethylacetate (80 mL) and triethylamine (1 mL) were added and this solution was washed with brine (3 x 25 mL). The organic phase was separated and dried over magnesium 20 sulfate. After filtration of the solids the solvent was evaporated *in vacuo* at 20°C to give an oil which was purified by column chromatography using silica gel and hexanes-ethyl acetate-triethyl-amine (50:49:1) as the eluent. Evaporation of the fractions *in vacuo* at 20°C gave a foam which was 25 evaporated with anhydrous pyridine (20 mL) *in vacuo* (1 torr) at 26°C and further dried *in vacuo* (1 torr Hg) at 20°C in the presence of sodium hydroxide for 24 h to give N⁶-Benzoyl-[2'-deoxy-2'-fluoro-5'-O-(4,4'-dimethoxytrityl)]-adenosine-3'-O-(N,N-diisopropyl- β -cyanoethylphosphoramidite 30 as a foam (1.05 g, 63 %).

EXAMPLE 4-b

2'-Deoxy-2'-fluoro-5'-O-(4,4'-dimethoxytrityl)-uridine3'O(N,N-diisopropyl- β -cyanoethyl-phosphoramidite).

2,2'-Cyclouridine is treated with a solution of 70% 35 hydrogen fluoride/pyridine in dioxane at 120°C for ten hours

to provide after solvent removal a 75% yield of 2'-deoxy-2'-fluorouridine. The 5'-DMT and 3'-cyanoethoxydiisopropyl-phosphoramidite derivitized nucleoside is obtained by standard literature procedures [Gait, Ed., *Oligonucleotide Synthesis. 5 A Practical Approach*, IRL Press, Washington, DC (1984)], or according to the procedure of Example 4-a.

EXAMPLE 4-C

2'-Deoxy-2'-fluoro-5'-O-(4,4'-dimethoxytrityl)-cytidine-3'-O-(N,N-diisopropyl- β -cyanoethyl phosphoramidite).

10 2'-Deoxy-2'-fluorouridine (2.51 g, 10.3 mmol) was converted to corresponding cytidine analog via the method of C.B. Reese, et al., *J. Chem. Soc. Perkin Trans I*, pp. 1171-1176 (1982), by acetylation with acetic anhydride (3.1 mL, 32.7 mmol) in anhydrous pyridine (26 mL) at room temperature. The 15 reaction was quenched with methanol, the solvent was evaporated in vacuo (1 torr) to give an oil which was coevaporated with ethanol and toluene. 3',5'-O- diacetyl-2'-deoxy-2'-fluoro-uridine was crystallized from ethanol to afford colorless crystals (2.38 g, 81 %).

20 N-4-(1,2,4-triazol-1-yl)-3',5'-O-diacetyl-2'-deoxy-2'-fluorouridine was obtained in a 70% yield (2.37 g) by reaction of 3',5'-O-diacetyl-2'-deoxy-2'-fluorouridine (2.75 g, 9.61 mmol) with 1,2,4-triazole (5.97 g, 86.5 mmol), phosphorus oxychloride (1.73 mL, 18.4 mmol), and triethylamine (11.5 mL, 82.7 mmol) in anhydrous acetonitrile at room temperature. After 90 min the reaction mixture was cooled to ice temperature and triethylamine (7.98 ml, 56.9 mmol) was added followed by addition of water (4.0 ml). The solvent was evaporated in vacuo (1 torr) to give an oil which was dissolved 25 in methylene chloride and washed with saturated aqueous sodium bicarbonate. The aqueous phase was extracted with methylene chloride twice (2 x 100 mL) and the organic extracts dried with magnesium sulfate. Evaporation of the solvent afforded an oil from which the product N-4-(1,2,4-triazol-1-yl)-3',5'-O-diacetyl-2'-deoxy-2'-fluorouridine was obtained by 30 crystallization from ethanol. 35

2'-deoxy-2'-fluorocytidine was afforded by treatment of protected triazol-1-yl derivative with concentrated ammonium hydroxide (4.26 mL, 81.2 mmol) in dioxane at room temperature for 6 hours. After evaporation of the solvent the oil was 5 stirred in half-saturated (at ice temperature) ammonia in methanol for 16 hours. The solvent was evaporated and 2'-deoxy-2'-fluoro-cytidine crystallized from ethyl-acetate-methanol (v/v, 75:25) to give colorless crystals (1.24 g, 75 %).

10 N-4-benzoyl-2'-deoxy-2'-fluorocytidine was prepared by selective benzylation with benzoic anhydride in anhydrous dimethylformamide, V. Bhat, et al. *Nucleosides Nucleotides*, Vol. 8, pp. 179-183 (1989). The 5'-O-(4,4'-dimethoxytrityl)-3'-O-(N,N-diisopropyl-β-cyanoethyl-phosphoramidite) was 15 prepared in accordance with Example 4-a.

EXAMPLE 4-d

i. 9-(3',5'-(1,1,3,3-Tetraisopropyldisilox-1,3-diyl)-β-D-arabinofuranosyl)guanine.

The 3' and 5' positions of guanosine were protected 20 by the addition of a TPDS (1,1,3,3-tetraisopropyldisilox-1,3-diyl) protecting group as per the procedure of Robins et al. [Can. J. Chem., 61, 1911 (1983)]. To a stirred solution of DMSO (160 mL) and acetic anhydride (20 mL) was added the TPDS guanosine (21 g, 0.040 mol). The reaction was stirred at room 25 temperature for 36 hours and then cooled to 0°C. Cold ethanol (400 mL, 95%) was added and the reaction mixture further cooled to -78°C in a dry ice/acetone bath. NaBH₄ (2.0 g, 1.32 mol. eq.) was added. The reaction mixture was allowed to warm up to -2°C, stirred for 30 minutes and again cooled to -78°C. 30 This was repeated twice. After the addition of NaBH₄ was complete, the reaction was stirred at 0°C for 30 minutes and then at room temperature for 1 hour. The reaction was taken up in ethyl acetate (1 L) and washed twice with a saturated solution of NaCl. The organic layer was dried over MgSO₄ and 35 evaporated under reduced pressure. The residue was coevaporated twice with toluene and purified by silica gel

chromatography using CH_2Cl_2 -MeOH (9:1) as the eluent. Pure product (6.02 g) precipitated from the appropriate column fractions during evaporation of these fractions, and an additional 11.49 g of product was obtained as a residue upon 5 evaporation of the fractions.

ii. $\text{N}^2\text{-Isobutyryl-9-(2'-O-isobutyryl-3',5'-[1,1,3,3-tetraiso-}$
 $\text{propyldisilox-1,3-diyl]-}\beta\text{-D-arabinofuranosyl)guanine.}$

9-(3',5'-[1,1,3,3-Tetraisopropyldisilox-1,3-diyl]- β -D-arabinofuranosyl)guanine (6.5 g, 0.01248 mol) was dissolved 10 in anhydrous pyridine (156 mL) under argon. DMAP (9.15 g) was added. Isobutyric anhydride (6.12 mL) was slowly added and the reaction mixture stirred at room temperature overnight. The reaction mixture was poured into cold saturated NaHCO_3 (156 mL) and stirred for 10 minutes. The aqueous solution was extracted 15 three times with ethyl acetate (156 mL). The organic phase was washed three times with saturated NaHCO_3 , and evaporated to dryness. The residue was coevaporated with toluene and purified by silica gel column chromatography using CH_2Cl_2 -acetone (85:15) to yield 5.67 g of product.

20 iii. $\text{N}^2\text{-Isobutyryl-9-(2'-O-isobutyryl-}\beta\text{-D-arabinofuranosyl)-}$
 guanine.

$\text{N}^2\text{-Isobutyryl-9-(2'-isobutyryl-3',5'-[1,1,3,3-tetra-}$
 $\text{isopropyldisilox-1,3-diyl]-}\beta\text{-D-arabinofuranosyl)guanine}$ (9.83 g, 0.01476 mol) was dissolved in anhydrous THF (87.4 mL) at 25 room temperature under argon. 1 M $(\text{nBu})_4\text{N}^+\text{F}^-$ in THF (29.52 mL, 2 eq.) was added and the reaction mixture stirred for 30 minutes. The reaction mixture was evaporated at room temperature and the residue purified by silica gel column chromatography using EtOAc-MeOH (85:15) to yield 4.98 g (80%) 30 of product.

iv. $\text{N}^2\text{-Isobutyryl-9-(2'-O-isobutyryl-3',5'-di-O-[tetrahydro-}$
 $\text{pyran-2-yl]-}\beta\text{-D-arabinofuranosyl)guanine.}$

$\text{N}^2\text{-Isobutyryl-9-(2'-isobutyryl-}\beta\text{-D-arabinofuranosyl)-}$
 guanine (4.9 g) was dissolved in anhydrous 1,4-dioxane (98 mL)

at room temperature under argon. *p*-Toluenesulphonic acid monohydrate (0.97 g) was added followed by 3,4-dihydro-2H-pyran (DHP, 9.34 mL, 8.8 eq.). The reaction mixture was stirred for 2 hours, then cooled to 0°C and saturated NaHCO₃ (125 mL) was 5 added to quench the reaction. The reaction mixture was extracted three times with 125 mL portions of CH₂Cl₂ and the organic phase dried over MgSO₄. The organic phase was evaporated and the residue dissolved in minimum volume of CH₂Cl₂, but in an amount sufficient to yield a clear liquid not 10 a syrup, and then dripped into hexane (100 times the volume of CH₂Cl₂). The precipitate was filtered to yield 5.59 (81.5%) of product.

v. N²-Isobutyryl-9-(3',5'-di-O-[tetrahydropyran-2-yl]-β-D-arabinofuranosyl)guanine.

15 N²-Isobutyryl-9-(2'-isobutyryl-3',5'-di-O-[tetrahydropyran-2-yl]-β-D-arabinofuranosyl)guanine (5.58 g) was dissolved in pyridine-MeOH-H₂O (65:30:15, 52 mL) at room temperature. The solution was cooled to 0°C and 52 mL of 2 N NaOH in EtOH-MeOH (95:5) was added slowly, followed by stirring 20 for 2 hours at 0°C. Glacial acetic acid was added to pH 6, and saturated NaHCO₃ was added to pH 7. The reaction mixture was evaporated under reduced pressure and the residue coevaporated with toluene. The residue was then dissolved in EtOAc (150 mL) and washed 3X with saturated NaHCO₃. The organic phase was 25 evaporated and the residue purified by silica gel column chromatography using EtOAc-MeOH (95:5) as the eluent, yielding 3.85 g (78.3%) of product.

vi. N²-Isobutyryl-9-(3',5'-di-O-[tetrahydropyran-2-yl]-2'-O-trifluoromethylsulfonyl-β-D-arabinofuranosyl)guanine.

30 N²-Isobutyryl-9-(3',5'-di-O-[tetrahydropyran-2-yl]-β-D-arabinofuranosyl)guanine (3.84 g) was dissolved in anhydrous CH₂Cl₂ (79 mL), anhydrous pyridine (5 mL) and DMAP (2.93 g) at room temperature under argon. The solution was cooled to 0°C and trifluoromethanesulfonic anhydride (1.99 mL) was slowly 35 added with stirring. The reaction mixture was stirred at room

temperature for 1 hour then poured into 100 mL of saturated NaHCO_3 . The aqueous phase was extracted three times with cold CH_2Cl_2 . The organic phase was dried over MgSO_4 , evaporated and coevaporated with anhydrous MeCN to yield a crude product.

5 vii. N^2 -Isobutyryl-9-(2'-deoxy-2'-fluoro-3',5'-di-O-[tetrahydropyran-2-yl]-2'-O-trifluoromethylsulfonyl- β -D-ribofuranosyl)guanine.

Crude N^2 -isobutyryl-9-(3',5'-di-O-[tetrahydropyran-2-yl]-2'-O-trifluoromethylsulfonyl- β -D-arabinofuranosyl)guanine 10 was dissolved in anhydrous THF' (113 mL) under argon at 0°C. 1 M $(\text{nBu})_4\text{N}^+\text{F}^-$ (dried by coevaporation with pyridine) in THF' (36.95 mL) was added with stirring. After 1 hour, a further aliquot of $(\text{nBu})_4\text{N}^+\text{F}^-$ in THF' (36.95 mL) was added. The reaction mixture was stirred at 0°C for 5 hours and stored overnight at 15 -30°C. The reaction mixture was evaporated under reduced pressure and the residue dissolved in CH_2Cl_2 (160 mL) and extracted five times with deionized water. The organic phase was dried over MgSO_4 and evaporated. The residue was purified by silica gel column chromatography using EtOAc-MeOH (95:5) to 20 yield 5.25 g of product.

viii. N^2 -Isobutyryl-9-(2'-deoxy-2'-fluoro- β -D-ribofuranosyl)-guanine.

N^2 -isobutyryl-9-(2'-deoxy-2'-fluoro-3',5'-di-O-[tetrahydropyran-2-yl]- β -D-ribofuranosyl)guanine (3.85 g) was 25 dissolved in MeOH (80 mL) at room temperature. Pre-washed Dowex 50W resin (12.32 cm^3) was added and the reaction mixture stirred at room temperature for 1 hour. The resin was filtered and the filtrate evaporated to dryness. The resin was washed with pyridine-triethylamine- H_2O (1:3:3) until filtrate was 30 clear. This filtrate was evaporated to obtain an oil. The residues from both filtrates were combined in H_2O (200 mL) and washed with CH_2Cl_2 (3 X 100 mL). The aqueous phase was evaporated to dryness and the residue recrystallized from hot MeOH to yield 0.299 g of product as a white powder. The 35 remaining MeOH solution was purified by silica gel column

chromatography to further yield 0.783 g of product by elution with EtOH-MeOH (4:1).

ix. N^2 -Isobutyryl-9-(2'-deoxy-2'-fluoro-5'-O-[4,4-dimethoxytrityl]- β -D-ribofuranosyl)guanine.

5 N^2 -isobutyryl-9-(2'-deoxy-2'-fluoro- β -D-ribofuranosyl)guanine (1.09 g) was dissolved in pyridine (20 mL) and triethylamine (0.56 mL) at room temperature under argon. 4,4'-Dimethoxytrityl chloride (1.20 g, 1.15 molar eq.) was added and the reaction mixture stirred at room temperature for 10 5 hours. The mixture was transferred to a separatory funnel and extracted with diethyl ether (100 mL). The organic phase was washed with saturated $NaHCO_3$ (3 X 70 mL), and the aqueous phase back-extracted three times with diethyl ether. The combined organic phases were dried over $MgSO_4$ and triethylamine 15 (4 mL) was added to maintain the solution at basic pH. The solvent was evaporated and the residue purified by silica gel column chromatography using EtOAc-triethylamine (100:1) and then EtOAc-MeOH-triethylamine (95:5:1) as eluents yielding 1.03 g of product.

20 x. N^2 -Isobutyryl-9-(2'-deoxy-2'-fluoro-5'-O-[4,4-dimethoxytrityl]-guanosine-3'-O-N,N-diisopropyl- β -D-cyanoethyl phosphoramidite.

25 N^2 -isobutyryl-9-(2'-deoxy-2'-fluoro-5'-O-[4,4'-dimethoxytrityl])- β -D-ribofuranosyl)guanine (0.587 g) was dissolved in anhydrous CH_2Cl_2 (31 mL) and diisopropylethylamine (0.4 mL) at room temperature under argon. The solution was cooled to 0°C and chloro(diisopropylamino)- β -cyanoethoxyphosphine (0.42 mL) was slowly added. The reaction mixture was allowed to warm to room temperature and stirred for 3.5 hours. 30 CH_2Cl_2 -triethylamine (100:1, 35 mL) was added and the mixture washed with saturated $NaHCO_3$ (6 mL). The organic phase was dried over $MgSO_4$ and evaporated under reduced pressure. The residue was purified by silica gel column chromatography using hexane-EtOAc-triethylamine (75:25:1) for 2 column volumes, then 35 hexane-EtOAc-triethylamine (25:75:1), and finally EtOAc-

triethylamine. The product-containing fractions were pooled and the solvent evaporated under reduced pressure. The resulting oil was coevaporated twice with MeCN and dried under reduced pressure. The resulting white solid was dissolved in 5 CH_2Cl_2 (3 mL) and dripped into stirring hexane (300 mL). The resulting precipitate was filtered and dried under reduced pressure to yield 0.673 g (88%) of product.

EXAMPLE 5

Nucleoside amidites having substitution on their 10 sugar and their base fragments are shown in Examples 5-a through 5-k.

EXAMPLE 5-a**Other nucleoside amidites**

i. 1-(2-Fluoro- β -D-erythro-pentofuranosyl)-5-methyluridine
15 2,2'-Anhydro-[1-(β -D-arabinofuranosyl)-5-methyluridine] (71g, 0.32 mmol) (from Example 2-a) and dioxane (700 mL) are placed in a 2 liter stainless steel bomb and HF/pyridine (100g, 70%) was added. The mixture was heated for 16 hours at 120-125 °C and then cooled in an ice bath. The 20 bomb was opened and the mixture was poured onto 3 liters of ice. To this mixture was added cautiously sodium hydrogen carbonate (300g) and saturated sodium bicarbonate solution (400 mL). The mixture was filtered and the filter cake was washed with water (2x100mL) and methanol (2x500mL). The water and 25 methanol washes were concentrated to dryness in vacuo. Methanol (200 mL) and coarse silica gel (80g) were added to the residue and the mixture was concentrated to dryness in vacuo. The resulting material was concentrated onto the silica gel and purified by silica gel column chromatography using a gradient 30 of ethyl acetate and methanol (100:0 to 85:15). Pooling and concentration of the product fractions gave 36.9g (51%, 2 step yield) of the title compound.

Also isolated from this reaction was 1-(2-phenyl- β -D-erythro-pentofuranosyl)-5-methyluridine (10.3 g). This 35 material is formed from the phenol and its sodium salt from the

anhydro reaction above when the bomb reaction is carried out on impure material. When the anhydro material is purified this product is not formed. The formed 1-(2-phenyl- β -D-erythro-pentofuranosyl)-5-methyluridine was converted into its 5 DMT/phosphoramidite using the same reaction conditions as for the 2'-Fluoro material.

ii. 1-(5-O-Dimethoxytrityl-2-fluoro- β -D-erythro-pento-furanosyl)-5-methyluridine

1-(2-fluoro- β -D-erythro-pentofuranosyl)-5-methyl-10 uridine (31.15g, 0.12 mol) was suspended in pyridine (150 mL) and dimethoxytrityl chloride (44.62g, 0.12 mol) was added. The mixture was stirred in a closed flask for 2 hours and then methanol (30 mL) was added. The mixture was concentrated in vacuo and the resulting residue was partitioned between 15 saturated bicarbonate solution (500 mL) and ethyl acetate (3x500ml). The ethyl acetate fractions were pooled and dried over magnesium sulfate, filtered and concentrated in vacuo to a thick oil. The oil was dissolved in dichloromethane (100 mL), applied to a silica gel column and eluted with ethyl 20 acetate:hexane:triethylamine, 60/39/1 increasing to 75/24/1. The product fractions were pooled and concentrated in vacuo to give 59.9g (89%) of the title compound as a foam.

iii. 1-(5-O-Dimethoxytrityl-2-fluoro-3-O-N,N-diisopropylamino-25 2-cyanoethylphosphite- β -D-erythro-pentofuranosyl)-5-methyluridine

1-(5-O-Dimethoxytrityl-2-fluoro- β -D-erythro-pento-furanosyl)-5-methyluridine (59.8g, 0.106 mol) was dissolved in dichloromethane and 2-cyanoethyl N,N,N',N'-tetraisopropyl-phosphorodiamidite (46.9 mL, 0.148 mol) and diisopropylamine 30 tetrazolide (5.46g, 0.3 eq.) was added. The mixture was stirred for 16 hours. The mixture was washed with saturated sodium bicarbonate (1 L) and the bicarbonate solution was back extracted with dichloromethane (500 mL). The combined organic layers were washed with brine (1 L) and the brine was back 35 extracted with dichloromethane (100 mL). The combined organic

layers were dried over sodium sulfate, filtered, and concentrated to a vol of about 200 mL. The resulting material was purified by silica gel column chromatography using hexane/ethyl acetate/triethyl amine 60/40/1. The product 5 fractions were concentrated in vacuo, dissolved in acetonitrile (500 ml), filtered, concentrated in vacuo, and dried to a foam. The foam was chopped and dried for 24 hour to a constant weight to give 68.2g (84%) of the title compound. ^1H NMR: (CDCl_3) δ 0.9-1.4 (m, 14 H, 4x CH_3 , 2xCH), 2.3-2.4 (t, 1 H, CH_2CN), 2.6-10 2.7 (t, 1 H, CH_2CN), 3.3-3.8 (m, 13 H, 2x CH_3OAr , 5' CH_2 , CH_2OP , C-5 CH_3), 4.2-4.3 (m, 1 H, 4'), 4.35-5.0 (m, 1 H, 3'), 4.9-5.2 (m, 1 H, 2'), 6.0-6.1 (dd, 1 H, 1'), 6.8-7.4 (m, 13 H, DMT), 7.5-7.6 (d, 1 H, C-6), 8.8 (bs, 1 H, NH). ^{31}P NMR (CDCl_3); 151.468, 151.609, 151.790, 151.904.

15 iv. 1-(3',5'-di-O-acetyl-2-fluoro- β -D-erythro-pentofuranosyl)-5-methyluridine

1-(2-fluoro- β -D-erythro-pentofuranosyl)-5-methyluridine (22.4g, 92 mmol, 85% purity), prepared as per the procedure of Example 5-a-i., was azeotroped with pyridine 20 (2x150 mL) and dissolved in pyridine (250 mL). Acetic anhydride (55 mL, .58 mol) was added and the mixture was stirred for 16 hours. Methanol (50 mL) was added and stirring was continued for 30 minutes. The mixture was evaporated to a syrup. The syrup was dissolved in a minimum amount of 25 methanol and loaded onto a silica gel column. Hexane/ethyl acetate, 1:1, was used to elute the product fractions. Purification gave 19.0g (74%) of the title compound.

EXAMPLE 5-b

i. 4-Triazine-1-(3',5'-di-O-acetyl-2-fluoro- β -D-erythro-pentofuranosyl)-5-methyluridine

1,2,4-Triazole (106g, 1.53 mol) was dissolved in acetonitrile (150 mL) followed by triethylamine (257 mL, 1.84 mol). The mixture was cooled to between 0 and 10 oC using an ice bath. POCl_3 (34.5 mL, .375 mol) was added 35 slowly via addition funnel and the mixture was stirred for

an additional 45 minutes. In a separate flask, 1-(3',5'-Di-O-acetyl-2-fluoro- β -D-erythro-pentofuranosyl)-5-methyluridine (56.9g, .144 mol) was dissolved in acetonitrile (150 mL). The solution containing the 1-(3',5'-Di-O-acetyl-2-fluoro- β -D-erythro-pentofuranosyl)-5-methyluridine was added via cannula to the triazole solution slowly. The ice bath was removed and the reaction mixture was allowed to warm to room temperature for 1 hour. The acetonitrile was removed in vacuo and the residue was partitioned between saturated sodium bicarbonate solution (400 mL) and dichloromethane (4x400 mL). The organic layers were combined and concentrated in vacuo. The resulting residue was dissolved in ethyl acetate (200 mL) and started to precipitate a solid. Hexanes (300 mL) was added and additional solid precipitated. The solid was collected by filtration and washed with hexanes (2x200 mL) and dried in vacuo to give 63.5g which was used as is without further purification.

ii. 5-methyl-1-(2-fluoro- β -D-erythro-pentofuranosyl)-
20 cytosine

4-Triazine-1-(3',5'-di-O-acetyl-2-fluoro- β -D-erythro-pentofuranosyl)-thymine (75.5g, .198 mol) was dissolved in ammonia (400 mL) in a stainless steel bomb and sealed overnight. The bomb was cooled and opened and the ammonia was evaporated. Methanol was added to transfer the material to a flask and about 10 volumes of ethyl ether was added. The mixture was stirred for 10 minutes and then filtered. The solid was washed with ethyl ether and dried to give 51.7g (86%) of the title compound.

30 iii. 4-N-Benzoyl-5-methyl-1-(2-fluoro- β -D-erythro-pento-furanosyl)cytosine

5-Methyl-1-(2-fluoro- β -D-erythro-pentofuranosyl)-cytosine (54.6g, 0.21 mol) was suspended in pyridine (700 mL) and benzoic anhydride (70g, .309 mol) was added. The mixture was stirred for 48 hours at room temperature. The

pyridine was removed by evaporation and methanol (800 mL) was added and the mixture was stirred. A precipitate formed which was filtered, washed with methanol (4x50mL), washed with ether (3x100 mL), and dried in a vacuum oven at 45 oC 5 to give 40.5g of the title compound. The filtrate was concentrated in vacuo and treated with saturated methanolic ammonia in a bomb overnight at room temperature. The mixture was concentrated in vacuo and the resulting oil was purified by silica gel column chromatography. The recycled 10 starting material was again treated as above to give an additional 4.9 g of the title compound to give a combined 45.4g (61%) of the title compound.

iv. 4-N-Benzoyl-5-methyl-1-(2-fluoro-5-O-dimethoxytrityl- β -15 D-erythro-pentofuranosyl)cytosine

4-N-Benzoyl-5-methyl-1-(2-fluoro- β -D-erythro-pentofuranosyl)-cytosine (45.3g, .124 mol) was dissolved in 250 ml dry pyridine and dimethoxytrityl chloride (46.4g, .137 mol) was added. The reaction mixture was stirred at 20 room temperature for 90 minutes and methanol (20 mL) was added. The mixture was concentrated in vacuo and partitioned between ethyl acetate (2x1 L) and saturated sodium bicarbonate (1 L). The ethyl acetate layers were combined, dried over magnesium sulfate and evaporated in 25 vacuo. The resulting oil was dissolved in dichloromethane (200 mL) and purified by silica gel column chromatography using ethyl acetate/hexane/triethyl amine 50:50:1. The product fractions were pooled concentrated in vacuo dried to give 63.6g (76.6%) of the title compound.

30

v. 4-N-Benzoyl-5-methyl-1-(2-fluoro-3-O-N,N-diisopropyl-amino-2-cyanoethylphosphite-5-O-dimethoxytrityl- β -D-erythro-pentofuranosyl)cytosine

4-N-Benzoyl-5-methyl-1-(2-fluoro-5-O-dimethoxy-35 trityl- β -D-erythro-pentofuranosyl)-cytosine (61.8g, 92.8 mmol) was stirred with dichloromethane (300 mL), 2-cyanoethyl N,N,N',N'-tetraisopropylphosphorodiamidite (40.9

mL, .130 mol) and diisopropylamine tetrazolide (4.76g, 0.3 eq.) at room temperature for 17 hours. The mixture was washed with saturated sodium bicarbonate (1 L) and the bicarbonate solution was back extracted with dichloromethane 5 (500 mL). The combined organic layers were washed with brine (1 L) and the brine was back extracted with dichloromethane (100 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to a vol of about 200 mL. The resulting material was purified by 10 silica gel column chromatography using hexane/ethyl acetate/triethyl amine 60/40/1. The product fractions were concentrated in vacuo, dissolved in acetonitrile (500 ml), filtered, concentrated in vacuo, and dried to a foam. The foam was chopped and dried for 24 hours to a constant weight 15 to give 72.4g (90%) of the title compound. ^1H NMR: (CDCl_3) δ 1.17-1.3 (m, 12 H, $4\times\text{CH}_3$), 1.5-1.6 (m, 2 H, $2\times\text{CH}$), 2.3-2.4 (t, 1 H, CH_2CN), 2.6-2.7 (t, 1 H, CH_2CN), 3.3-3.9 (m, 13 H, $2\times\text{CH}_3\text{OAr}$, 5' CH_2 , CH_2OP , C-5 CH_3), 4.2-4.3 (m, 1 H, 4'), 4.3-20 4.7 (m, 1 H, 3'), 5.0-5.2 (m, 1 H, 2'), 6.0-6.2 (dd, 1 H, 1'), 6.8-6.9 (m, 4 H, DMT), 7.2-7.6 (m, 13 H, DMT, Bz), 7.82-7.86 (d, 1 H, C-6), 8.2-8.3 (d, 2 H, Bz). ^{31}P NMR (CDCl_3); bs, 151.706; bs, 151.941.

EXAMPLE 5-c**i. 1-(2,3-di-O-Butyltin- β -D-erythro-pentofuranosyl)-5-25 methyluridine**

5-Methyluridine (7.8g, 30.2 mmol) and dibutyltin oxide (7.7g, 30.9 mmol) were suspended in methanol (150 mL) and heated to reflux for 16 hours. The reaction mixture was cooled to room temperature, filtered, and the solid washed 30 with methanol (2 x 150 mL). The resulting solid was dried to give 12.2g (80.3%) of the title compound. This material was used without further purification in subsequent reactions. NMR was consistent with structure.

ii. 1-(2-O-Propyl- β -D-*erythro*-pentofuranosyl)-5-methyluridine

1-(2,3-di-O-butylin- β -D-*erythro*-pentofuranosyl)-5-methyluridine (5.0g, 10.2 mmol) and iodopropane (14.7g, 5 72.3 mmol) were stirred in DMF at 100 °C for 2 days. The reaction mixture was cooled to room temperature and filtered and concentrated. The residual DMF was coevaporated with acetonitrile. After drying the residue there was obtained 2.40g (78%) of the title compound and the 3'-O-propyl isomer 10 as a crude mixture. This material was used without further purification in subsequent reactions.

iii. 1-(2-O-Propyl-5-O-Dimethoxytrityl- β -D-*erythro*-pentofuranosyl)-5-methyluridine

1-(2-O-Propyl- β -D-*erythro*-pentofuranosyl)-5-methyluridine and the 3'-O-propyl isomer as a crude mixture (2.4g, 8.4 mmol) was coevaporated with pyridine (2 x 40 mL) and dissolved in pyridine (60 mL). The solution was stirred at room temperature under argon for 15 minutes and dimethoxytrityl chloride (4.27g, 12.6 mmol) was added. The 15 mixture was checked periodically by tlc and at 3 hours was completed. Methanol (10 mL) was added and the mixture was stirred for 10 minutes. The reaction mixture was 20 concentrated in vacuo and the resulting residue purified by silica gel column chromatography using 60:40 hexane/ethyl acetate with 1% triethylamine used throughout. The pooling 25 and concentration of appropriate fractions gave 1.32g (26%) of the title compound.

iv. 1-(2-O-Propyl-3-O-N,N-Diisopropylamino-2-cyanoethyl-phosphite-5-O-Dimethoxytrityl- β -D-*erythro*-Pentofuranosyl)-5-methyluridine

1-(2-O-Propyl-5-O-dimethoxytrityl- β -D-*erythro*-pentofuranosyl)-5-methyluridine (50.0g, 86 mmol), 2-cyanoethyl-N,N,N',N'-tetra-isopropylphosphorodiamidite (38 mL, 120 mmol), and diisopropylamine tetrazolide (4.45g, 25.8 35 mmol) were dissolved in dichloromethane (500 mL) and stirred

at room temperature for 40 hours. The reaction mixture was washed with saturated sodium bicarbonate solution (2 x 400 mL) and brine (1 x 400 mL). The aqueous layers were back extracted with dichloromethane. The dichloromethane layers 5 were combined, dried over sodium sulfate, filtered, and concentrated in vacuo. The resultant residue was purified by silica gel column chromatography using ethyl acetate/hexane 40:60 and 1% triethylamine. The appropriate fractions were pooled, concentrated, and dried under high vacuum to give 10 43g (67%).

v. 1-(2-O-Propyl-3-O-acetyl-5-O-dimethoxytrityl- β -D-erythro-pentofuranosyl)-5-methyluridine

1-(2-O-Propyl-5-dimethoxytrityl- β -D-erythro-pento-furanosyl)-5-methyluridine (10.0g, 16.6 mmol) was dissolved 15 in pyridine (50 mL) and acetic anhydride (4.7 ml, 52.7 mmol) was added. The reaction mixture was stirred for 18 hours and excess acetic anhydride was neutralized with methanol (10 mL). The mixture was concentrated in vacuo and the resulting residue dissolved in ethyl acetate (150 mL). The 20 ethyl acetate was washed with saturated NaHCO_3 (150 mL) and the saturated NaHCO_3 wash was back extracted with ethyl acetate (50 mL). The ethyl acetate layers were combined and concentrated in vacuo to yield a white foam 11.3g. The crude yield was greater than 100% and the NMR was consistent 25 with the expected structure of the title compound. This material was used without further purification in subsequent reactions.

EXAMPLE 5-d

i. 1-(2-O-Propyl-3-O-acetyl-5-O-dimethoxytrityl- β -D-30 erythro-pentofuranosyl)-4-triazolo-5-methylpyrimidine

Triazole (10.5g, 152 mmol) was dissolved in acetonitrile (120 ml) and triethylamine (23 mL) with stirring under anhydrous conditions. The resulting solution was cooled in a dry ice acetone bath and phosphorous 35 oxychloride (3.9 mL, 41 mmol) was added slowly over a period

of 5 minutes. The mixture was stirred for an additional 10 minutes becoming a thin slurry indicative of product formation. 1-(2-O-Propyl-3-O-acetyl-5-O-dimethoxytrityl- β -D-erythro-pentofuranosyl)-5-methyluridine (11.2g, 165mmol) 5 was dissolved in acetonitrile (150 mL) and added to the slurry above, maintaining dry ice acetone bath temperatures. The reaction mixture was stirred for 30 minutes and then allowed to warm to room temperature and stirred for an additional 2 hours. The mixture was placed in a freezer at 10 0 oC for 18 hours and then removed and allowed to warm to room temperature. Tlc in ethyl acetate/hexane 1:1 of the mixture showed complete conversion of the starting material. The reaction mixture was concentrated in vacuo and redissolved in ethyl acetate (300 mL) and extracted with 15 saturated sodium bicarbonate solution (2 x 400 mL) and brine (400 mL). The aqueous layers were back extracted with ethyl acetate (200 mL). The ethyl acetate layers were combined, dried over sodium sulfate, and concentrated in vacuo. The crude yield was 11.3g (95%). The NMR was consistent with 20 the expected structure of the title compound. This material was used without further purification in subsequent reactions.

ii. 1-(2-O-Propyl-5-O-dimethoxytrityl- β -D-erythro-pento-furanosyl)-5-methylcytidine

25 1-(2-O-Propyl-3-O-acetyl-5-O-dimethoxytrityl- β -D-erythro-pentofuranosyl)-4-triazolo-5-methylpyrimidine (11.2g, 16.1 mmol) was dissolved in liquid ammonia (50 mL) in a 100 mL bomb at dry ice acetone temperatures. The bomb was allowed to warm to room temperature for 18 hours and 30 then recooled to dry ice acetone temperatures. The bomb contents were transferred to a beaker and methanol (50 mL) was added. The mixture was allowed to evaporate to near dryness. Ethyl acetate (300 mL) was added and some solid was filtered off prior to washing with saturated sodium bi- 35 carbon ate solution (2 x 250 mL). The ethyl acetate layers were dried over sodium sulfate, filtered, combined with the

solid previously filtered off, and concentrated in *vacuo* to give 10.1g of material. The crude yield was greater than 100% and the NMR was consistent with the expected structure of the title compound. This material was used without 5 further purification in subsequent reactions.

iii. 1-(2-O-Propyl-5-O-dimethoxytrityl- β -D-*erythro*-pentofuranosyl)-4-N-benzoyl-5-methylcytidine

1-(2-O-Propyl-5-O-dimethoxytrityl- β -D-*erythro*-pentofuranosyl)-5-methylcytidine (7.28g, 10.1 mmol) and 10 benzoic anhydride (4.5g, 20 mmol) were dissolved in DMF (60 mL) and stirred at room temperature for 18 hours. The reaction mixture was concentrated in *vacuo* and redissolved in ethyl acetate (300 mL). The ethyl acetate solution was washed with saturated sodium bicarbonate solution (2 x 400 mL), dried over sodium sulfate, filtered, and concentrated in *vacuo*. The residue was purified by silica gel column 15 chromatography using ethyl acetate/hexane 1:2 and 1% triethylamine. The appropriate fractions were pooled, concentrated, and dried under high vacuum to give 5.1g (59% 20 for 4 steps starting with the 1-(2-O-propyl-dimethoxytrityl- β -D-*erythro*-pentofuranosyl)-5-methyluridine).

iv. 1-(2-O-Propyl-3-O-N,N-diisopropylamino-2-cyanoethyl-phosphite-5-O-dimethoxytrityl- β -D-*erythro*-pentofuranosyl)-4-N-benzoyl-5-methylcytidine

25 1-(2-O-Propyl-5-O-dimethoxytrityl- β -D-*erythro*-pentofuranosyl)-4-N-benzoyl-5-methylcytidine (5.0g, 7mmol), 2-cyanoethyl-N,N,N',N'-tetra-isopropylphosphorodiamidite (3.6 mL, 11.3 mmol), and diisopropylaminotetrazolide (0.42g, 2.4 mmol) were dissolved in dichloromethane (80 mL) and 30 stirred at room temperature for 40 hours. The reaction mixture was washed with saturated sodium bicarbonate solution (2 x 40 mL) and brine (1 x 40 mL). The aqueous layers were back extracted with dichloromethane. The dichloromethane layers were combined, dried over sodium 35 sulfate, filtered, and concentrated in *vacuo*. The resultant

residue was purified by silica gel column chromatography using ethyl acetate/hexane 40:60 and 1% triethylamine. The appropriate fractions were pooled, concentrated, and dried under high vacuum to give 7.3g (98%).

5 EXAMPLE 5-e

i. 2'-O-Methyl-5-methyluridine

Procedure 1:

Crude 2,2'-anhydro-5-methyluridine (10.0 g, 0.0416 mol) (Example 2-a) was dissolved in methanol (80 mL) in a 10 stainless steel bomb (100 mL capacity). Trimethyl borate (5.6 mL, 0.049 mol) was added (Note 1). The bomb was sealed and placed in an oil bath at 150 °C which generated a pressure of about 5 atm. After 40 h, the bomb was cooled in ice, opened and the contents concentrated under reduced 15 pressure to a tan foam, 12 g. NMR of the crude was consistent with the product contaminated with impurities in the starting material and a trace of thymine and starting material (Note 2). The crude product was used as is for the next step.

20 The trialkyl borates can be conveniently generated by adding solutions (eg 1 M in THF) of borane to the desired alcohol and allowing the resulting hydrogen gas to evolve.) The nucleoside can be purified at this point by column chromatography using a gradient of methanol in ethyl acetate 25 (0-10%) and crystallizing the product from absolute ethanol to give white needles, mp 192-193° (mp 197-198°). Literature reference for the melting point of this compound is contained in E. Ootsuka, H. Inoue, Japanese Patent 89-85456, 4 April 1989.

30 Procedure 2:

Pure 2,2'-anhydro-5-methyluridine (1.0 g, 4.16 mmol) and trimethylborate (0.56 mL, 4.9 mmol) was dissolved in methanol (20 mL) in a stainless steel bomb (100 mL). The bomb was placed in an oil bath at 150 °C. After 80 h, 35 TLC indicating the reaction to be mostly complete. The solvent was removed yielding a white foam. NMR indicated

product to starting material ratio of 93:7 with no other impurities noted. The residue was purified by silica gel column chromatography using a methanol gradient in ethyl acetate (0-10%) yielding 850 mg (75%) of pure product and 5 250 mg of still contaminated product. An analytically pure sample was prepared for NMR. ^1H NMR (DMSO- d_6): δ 1.79 (s, 3H, 5-CH₃), 3.35 (s, 3H, OCH₃), 3.5-3.7 (m, 2H, H-5'), 3.7- 3.9 (m, 2H, H-3', 4'), 4.15 (m, 1H, H-2'), 5.17 (m, 2H, 3', 5'-OH), 5.87 (d, J=5Hz, 1H, H-1'), 7.80 (s, 1H, H-6), 10 11.37 (br s, 1H, N-H). Anal. Calcd for C₁₁H₁₆N₂O₆ (272.26): C, 48.52; H, 5.92; N, 10.29. Found: C, 48.56; H, 5.88; N, 10.22.

Procedure 3:

The same as described for procedure 2 except 30 mg 15 of sodium bicarbonate was added to the reaction (to match the sodium content of the crude anhydro) which allowed the reaction to be complete in 24 h. Ammonium chloride (50 mg) was added to neutralize the base and the solution was stripped to dryness. NMR of the crude indicated three minor 20 nucleoside impurities (total about 6%). After a similar column and then crystallizing the residue from methanol/ethyl acetate, there remained 850 mg of first crop material and 120 mg of second crop material both with 2-3% of unknown nucleoside impurities for a still contaminated 25 yield of 85%.

ii. 5'-O-Dimethoxytriphenylmethyl-2'-O-methyl-5-methyl-uridine

Crude 2'-O-methyl-5-methyl uridine (12 g) was 30 coevaporated in pyridine (2x 50 mL) and dissolved in dry pyridine (50 mL). Dimethoxytriphenylmethyl chloride (18.1 g, 0.054 mol) was added. the flask was stoppered and allowed to stand for 45 min at room temperature. Methanol (10 mL) was added to quench the reaction and the solution was concentrated under reduced pressure to an oil. The 35 residue was partitioned between ethyl acetate (2x400 mL) and

saturated sodium bicarbonate solution (500 mL). The organic layers were combined, dried (sodium sulfate), filtered and concentrated to a yellow foam. The foam was dissolved in methylene chloride (60 mL) and put onto a silica gel column (300 g) and eluted with ethyl acetate-hexanes-triethylamine, 60:40:1. The product containing fractions were combined, concentrated and coevaporated with dry acetonitrile (2x 50 mL). The resulting residue was dried at 1 mm Hg for 24 h to a crisp white foam, 17.0 g (60.4% in three steps from 5-methyluridine).

EXAMPLE 5-f**i. 2,3,5-Tri-O-benzoyl-2-thio-5-methyluridine**

In a 250 ml 3 neck round bottomed flask 1-O-acetyl-2,3,5-tri-O-benzoyl ribose (0.500g, 1 mmol) and 5-methyl-2-thiouracil (0.156g, 1.1 mmol) was dried under vacuum overnight. These components were dissolved in 10 mL of dry acetonitrile and heated to 80 °C. To this warm solution was added N-O-bis(trimethylsilyl)acetamide (0.509g, 2.5 mmol) and the reaction stirred for 1 hr at 80 °C. The reaction mixture was removed from the heat and allowed to cool to room temperature, and trimethyl silyl triflate (0.334g, 1.5 mmol) was added dropwise. The reaction mixture was then heated to 50 °C and stirred for 4 hours. The reaction mixture was checked by TLC using ethyl acetate/hexane 1:1, which showed the reaction had gone to completion. The solution was cooled to room temperature and partitioned between 50 mL of dichloromethane and 50 mL of saturated sodium bicarbonate solution. The aqueous phase was extracted two more times with dichloromethane and the organic layers combined, dried with magnesium sulfate and concentrated to a pale yellow foam. This foam was used without further purification.

ii. 2-Thio-5-methyluridine

The crude 2,3,5-tri-O-benzoyl-2-thio-5-methyl uridine (20g, 37 mmoles) was dissolved in 500 mL of

methanol. To this solution was added sodium methoxide (2.0g, 37 mmoles) and the reaction stirred for 2 hours. The reaction was checked by TLC using ethyl acetate/hexane 1:1 and ethyl acetate/methanol 9:1, which showed the reaction 5 had gone to completion. Dowex 50 H⁺ resin was added until the solution was neutral by pH paper and the resin filtered. The resin was then washed with 100 ml of additional methanol and the combined filtrates were concentrated to give the title compound 8.5g, (84 %) as a pale yellow foam.

10 **EXAMPLE 5-g**

2'-O-Methyl-5-methyl-2-thiouridine

To a stirred solution of 5-methyl-2-thiouridine (0.500 g, 1.8 mmol) in DMF (10 ml) is added dibutyltin oxide (0.500 g, 2.0 mmol), tetrabutyl ammonium iodide (0.738 g, 2 15 mmol), and methyl iodide (1.022 g, 7.2 mmol). The reaction flask is sealed and heated at 50 °C for 16 hours. The mixture is cooled and another portion of methyl iodide is added (1.022 g, 7.2 mmol) and the reaction heated for an additional 16 hours. At the end of this time, the reaction 20 mixture is cooled to room temperature and diluted with methylene chloride and chromatographed using a methylene chloride/methanol gradient. The appropriate fractions are collected and concentrated to give 2'-O-methyl-5-methyl-2-thiouridine.

25 **EXAMPLE 5-h**

2'-O-Propyl-5-methyl-2-thiouridine

The title compound is prepared as per the procedures of Example 5-g by substituting propyl iodide (1.22 g, 7.2 mmoles) in place of methyl iodide.

30 **Example 5-i**

i. **2'-O-phthalimidopropyl-5-methyl-2-thiouridine**

The title compound was prepared as per the procedures of Example 5-g by substituting bromo-propyl phthalimide (0.67g, 2.5 mmoles) in place of methyl iodide,

with an additional (0.300 g) added on the second day.

ii. 5'-O-Dimethoxytrityl-2'-O-propylamine-5-methyl-2-thiouridine

2'-O-Phthalimidopropyl-5-methyl-2-thiouridine

5 (2.6g, 3.6 mmol) was dissolved in dry pyridine and co-evaporated twice. The resulting foam was dissolved in 25 mL of dry pyridine and dimethoxy-trityl chloride (1.8g, 5.5 mmol) was added followed by 4,4-dimethylaminopyridine (0.050g, 0.4 mmol). The reaction was allowed to stir 10 overnight at room temperature. To the reaction mixture was added 1 mL of methanol. The solution was partitioned between 75 mL of saturated sodium bicarbonate and 50 mL of chloroform. The aqueous layer was extracted with two additional portions of chloroform and the organic layers 15 combined and dried with magnesium sulfate. After removal of the drying agent via filtration the filtrate was concentrated to an orange oil and purified by silica gel column chromatography using methanol/chloroform gradient with 0.5% pyridine added to neutralize the silica gel.

20 iii. 5'-O-Dimethoxytrityl-2'-O-propylamine-5-methyl-2S-toluoyl-2-thiouridine

5'-O-Dimethoxytrityl-2'-O-propylamine-5-methyl-2-thiouridine (1g, 1.6 mmol) was dissolved in DMF and cooled to 0 °C. To this solution was added triethyl amine (0.300g, 3 m.mol) followed by toluoyl chloride (0.300g, 1.92 mmol) dropwise over 5 minutes. The reaction was then allowed to warm to room temperature and stirred overnight, when complete the reaction was quenched with methanol and concentrated to an oil. The oil was then partitioned 30 between 250 mL of a solution of saturated sodium bicarbonate/chloroform 1:1. The aqueous layer was extracted with two additional, 75 mL portions of chloroform, and the organic layers were dried and concentrated to an oil. The protected nucleoside was purified by silica gel column 35 chromatography using a hexane/ethyl acetate gradient. The

desired product was collected as a mixture of N-3 toluoyl and S-2 Toluoyl compounds. This mixture was used as is for the phosphorylation procedure.

iv. 5'-O-Dimethoxytrityl-2'-O-propylamine-3'-O-[(N,N-
5 diisopropylamino)-2-cyanoethoxyphosphite]-5-methyl-2-S-
toluoyl-2-thiouridine

To a solution of 5'-O-dimethoxytrityl-2'-O-propylamine-5-methyl-2-S-toluoyl-2-thiouridine (16.01g, 22mmol) and diisopropylethylamine (10 ml) in THF (200ml), at 0°C, is
10 added chloro- β -cyanoethoxy-N,N-diisopropylaminophosphine (5.6 ml, 25mmol). The reaction mixture was stirred at room temperature for 20 hours. The reaction was concentrated and the residue purified by silica gel column chromatography. Elution with an ethyl acetate/hexane gradient while
15 maintaining 1% triethylamine, pooling of appropriate fractions and evaporation will give the title compound.

EXAMPLE 5-j

i. 2'-O-Aminopropyl-5-methyl-2-thiouridine

2'-O-Phthalimidopropyl-5-methyl-2-thiouridine
20 (5.0g, 15.8 mmol) is dissolved in 100 ml methanol in a 500 ml flask. Hydrazine (2.02g, 63.2 mmol) is added and the mixture is heated to reflux (60-65 °C) with stirring for 14 hours. The solvent is evaporated *in vacuo* and the residue is dissolved in dichloromethane (150 ml) and extracted twice
25 with an equal volume NH₄OH. The organic layer is evaporated to yield the crude product. NMR is used to assay product purity. The product is used in subsequent reactions without further purification.

ii. 2'-O-Trifluoroacetylaminopropyl-5-methyl-2-thiouridine

30 2'-O-Aminopropyl-5-methyl-2-thiouridine is dissolved in MeOH and 5 equivalents of triethylamine are added followed by 10 equivalents of ethyl trifluoroacetate. The title compound is isolated after purification.

iii. 2'-O-Trifluoroacetylaminopropyl-5'-O-dimethoxytrityl-5-methyl-2-thiouridine

2'-O-Trifluoroacetylaminopropyl-5-methyl-2-thiouridine (2.5g, 3.6 mmol) is dissolved in dry pyridine and 5 co-evaporated twice. The resulting yellow foam is dissolved in 25 mL of dry pyridine and dimethoxytrityl chloride (1.8g, 5.5 mmol) is added followed by 4,4-dimethylaminopyridine (0.050g, 0.4 mmol). The reaction is allowed to stir overnight at room temperature. To the reaction mixture is 10 added 1 mL of methanol. The solution is partitioned between 75 mL of saturated sodium bicarbonate and 50 mL of chloroform. The aqueous layer is extracted with two additional portions of chloroform and the organic layers combined and dried with magnesium sulfate. After removal of 15 the drying agent via filtration the filtrate is concentrated to an oil and purified by silica gel column chromatography using methanol/chloroform gradient with 0.5% pyridine added to neutralize the silica gel to give the title compound.

iv. 2'-O-Trifluoroacetylaminopropyl-3'-O-[(N,N-diisopropylamino)-2-cyanoethoxyphosphite]-5'-O-dimethoxytrityl-5-methyl-2-thiouridine

The title compound is prepared as per the procedure of Example 5-i-iv. using the title compound from 25 Example 5-j-iii.

EXAMPLE 5-k

i. 5'-O-Dimethoxytrityl-2-thio-5-methyluridine

2-Thio-5-methyl uridine (1g, 3.6 mmol) was dissolved in dry pyridine and co-evaporated twice. The 30 resulting yellow foam was dissolved in 25 mL of dry pyridine and dimethoxy-trityl chloride (1.8g, 5.5 mmol) was added followed by 4,4-dimethylaminopyridine (0.050g, 0.4 mmol). The reaction was allowed to stir overnight at room temperature. To the reaction mixture was added 1 mL of 35 methanol. The solution was partitioned between 75 mL of saturated sodium bicarbonate and 50 mL of chloroform. The

aqueous layer was extracted with two additional portions of chloroform and the organic layers combined and dried with magnesium sulfate. After removal of the drying agent via filtration the filtrate was concentrated to an orange oil 5 and purified by silica gel column chromatography using methanol/chloroform gradient with 0.5% pyridine added to neutralize the silica gel.

ii. 5'-O-Dimethoxytrityl-3'-t-butyldimethylsilyl-5-methyl-2-thiouridine

10 5'-O-Dimethoxytrityl-2-thio-5-methyl uridine (1g, 1.73 mmol) was co-evaporated twice with dry DMF and then dissolved in dry DMF and imidazole (0.141g, 2.08 mmol) was added followed by (0.313 g, 2.08 mmol) of t-butyl-dimethylsilyl chloride. The reaction mixture was stirred 15 overnight. The reaction was checked by TLC using ethyl acetate/hexane 1:1, which showed the reaction had gone to completion. The reaction mixture was then poured into 5% sodium bicarbonate and extracted 3 times with chloroform. The combined organic solution was dried with magnesium 20 sulfate and concentrated to an oil. The resulting oil was purified by silica gel column chromatography using a methanol/chloroform gradient isolating separately the 2' and 3' silyl protected nucleoside.

iii. 5'-O-Dimethoxytrityl-3'-t-butyldimethylsilyl-2'-methanesulfonyl-5-methyl-2-thiouridine

25 5'-O-Dimethoxytrityl-3'-t-butyldimethylsilyl-5-methyl-2-thiouridine (1.0g, 1.45 mmoles) was dissolved in pyridine and cooled to 0 °C. To this solution was added methanesulfonyl chloride (0.183g, 1.6 mmoles) dropwise. The 30 reaction was then allowed to stir until complete by TLC. The reaction mixture is neutralized with methanol and concentrated to an oil. The title compound is used as is for further reactions.

iv. 5'-Dimethoxytrityl-3'-t-butyldimethylsilyl-2',2'-thio
anhydro-5-methyl-2-thiouridine

The mesylated nucleoside found in Example 5-k-iii is treated at room temperature with 5 equivalents of sodium 5 methoxide and allowed to stir until complete formation of the thioanhydro product. The solution is then neutralized with Dowex 50W (H⁺ form), the resin filtered off and the resulting solution concentrated to give the title compound.

v. 2'-Fluoro-3'-t-butyldimethylsilyl-5'-Dimethoxytrityl-5-
10 methyl-2-thiouridine

The thioanhydronucleoside found in Example 5-k-iv was dissolved in anhydrous dioxane. To this solution was added 6 equivalents of HF/Pyridine complex and the reaction stirred until complete by TLC. The reaction mixture is then 15 poured over an equal volume of ice and calcium carbonate is added until neutral. The solids are filtered off and the filtrate is concentrated. The residue is purified by silica gel column chromatography to give the title compound.

vi. 2'-Fluoro-3'-O-[(N,N-diisopropylamino)-2-cyanoethoxy-
20 phosphite]-5'-dimethoxytrityl-5-methyl-2-thiouridine

2'-Fluoro-3'-t-butyldimethylsilyl-5'-dimethoxytrityl-5-methyl-2-thiouridine is treated as per the procedure of Example 5-i-iv. to give the title compound.

EXAMPLE 6

25 **Oligoribonucleotide synthesis**

Unsubstituted and substituted phosphodiester oligoribonucleotides, also identified herein as PO linked oligoribonucleotides, were synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard 30 phosphoramidite chemistry with oxidation by iodine.

Phosphorothioate oligonucleotides, also identified herein as PS linked oligoribonucleotides, are synthesized as per the phosphodiester oligoribonucleotides except the standard oxidation bottle was replaced by 0.2 M solution of

3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the step wise thiation of the phosphite linkages. The thiation wait step was increased to 68 sec and was followed by the capping step. After cleavage from the CPG column and 5 deblocking in concentrated ammonium hydroxide at 55°C (18 hr), the oligonucleotides were purified by precipitating twice with 2.5 volumes of ethanol from a 0.5 M NaCl solution. Analytical gel electrophoresis was accomplished in 20% acrylamide, 8 M urea, 454 mM Tris-borate buffer, 10 pH=7.0. Oligonucleotides and phosphorothioates were judged, based on polyacrylamide gel electrophoresis, to be greater than 80% full-length material.

Phosphinate oligoribonucleotides, also identified herein as PI linked oligoribonucleotides, are prepared as is 15 described in U.S. Patent 5,508,270, herein incorporated by reference.

Alkyl phosphonate oligoribonucleotides, also identified herein as PMe linked oligoribonucleotides, are prepared as is described in U.S. Patent 4,469,863, herein 20 incorporated by reference.

Phosphoramidite oligoribonucleotides, also identified herein as PN linked oligoribonucleotides, are prepared as is described in U.S. Patent, 5,256,775 or U.S. Patent 5,366,878, herein incorporated by reference.

25 Alkylphosphonothioate oligoribonucleotides, also identified herein as MePS linked oligoribonucleotides, are prepared as is described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporate by 30 reference.

3' -Deoxy-3' -amino phosphoramidate oligoribonucleotide, also identified herein as 3'NPN linked oligoribonucleotides, are prepared as is described in U.S. Patent 5,476,925, herein incorporated by reference.

35 Phosphotriester oligoribonucleotides, also identified herein as POMe linked oligoribonucleotides, are prepared as is described in U.S. Patent 5,023,243, herein

incorporated by reference.

Borano phosphate oligoribonucleotide, also identified herein as BP linked oligoribonucleotides, are prepared as is described in U.S. Patents 5,130,302 and 5,177,198, both herein incorporated by reference.

EXAMPLE 7-a

Oligoribonucleoside synthesis

Methylenemethylimino linked oligoribonucleosides, also identified herein as MMI linked oligoribonucleosides, 10 methylenedimethylhydrazo linked oligoribonucleosides, also identified herein as MDH linked oligoribonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified herein as amide-3 linked oligoribonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also 15 identified herein as amide-4 linked oligoribonucleosides as well as mixed backbone compounds having, as for instance, alternating MMI and PO or PS linkages are prepared as is described in U.S. Patents 5,378,825, 5,386,023, 5,489,677 and in published PCT applications PCT/US92/04294 and 20 PCT/US92/04305 (published as WO 92/20822 WO and 92/20823, respectively), herein incorporated by reference.

Formacetal and thioformacetal linked oligoribonucleosides, also identified herein as FA and TFA oligoribonucleosides, respectively, are prepared as is described in 25 U.S. Patents 5,264,562 and 5,264,564, herein incorporated by reference.

Ethylene oxide linked oligoribonucleosides, also herein identified as ETO linked oligoribonucleosides, are prepared as is described in U.S. Patent 5,223,618, herein 30 incorporated by reference.

EXAMPLE 7-b

PNA

Peptide Nucleic Acids (PNAs) are known *per se* and are prepared in accordance with any of the various 35 procedures referred to in Peptide Nucleic Acids (PNA):

Synthesis, Properties and Potential Applications, *Bioorganic & Medicinal Chemistry*, 1996, 4, 5-23. They may also be prepared in accordance with U.S. Patent 5,539,083, corresponding to serial number 08/200,742, filed Feb. 23, 5 1994, and assigned to the same assignee as this application. These references are herein incorporated by reference.

EXAMPLE 8

Chimeric phosphorothioate oligoribonucleotides, e.g. [2'-O-Me]/PS·[2'-OH]/PS·[-2'-O-Me]/PS oligoribonucleotide

10 Chimeric oligoribonucleotides having 2'-O-alkyl phosphorothioate and 2'-OH phosphorothioate oligonucleotides segments were synthesized using an Applied Biosystems automated DNA synthesizer Model 380B, as above. Oligoribonucleotides were synthesized using the automated 15 synthesizer and 5'-dimethoxytrityl-2'-tert-butyldimethylsilyl 3'-O-phosphoramidite for the RNA portion and 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite for 5' and 3' wings. The protecting groups on the exocyclic amines were, phenoxyacetyl for rA and rG, benzoyl for rC and 20 2'-O-methyl A and 2'-O-methyl C, and isobutyryl for 2'-O-methyl G. The standard synthesis cycle was modified by increasing the wait step after the delivery of tetrazole and base to 600 s repeated four times for RNA and twice for 2'-O-methyl. The fully protected oligoribonucleotide was 25 cleaved from the support and the phosphate group was deprotected in 3:1 Ammonia/Ethanol at room temperature overnight then lyophilized to dryness. Treatment in methanolic ammonia for 24 hrs at room temperature was then done to deprotect all bases and sample was again lyophilized 30 to dryness. The pellet was resuspended in 1M TBAF in THF for 24 hrs at room temperature to deprotect the 2' positions. The reaction is then quenched with 1M TEAA and the sample is then reduced to 1/2 volume by rotovac before being desalted on a G25 size exclusion column. The oligo recovered was 35 then analyzed spectrophotometrically for yield and for

purity by capillary electrophoresis and by mass spectrometer.

EXAMPLE 9

Chimeric "gapmer" oligoribonucleotides

5 i. Chimeric methyl phosphonate oligoribonucleotide e.g.,
[2'-O-Me]/PMe·[2'-OH]/PMe·[-2'-O-Me]/PMe oligoribonucleotide
In the manner of Example 8, using oligoribo-
nucleotides of Example 6, a chimeric oligoribonucleotide
having a methyl phosphonate backbone is prepared.

10 ii. Chimeric phosphoramidate oligoribonucleotide, e.g.,
[2'-O-Me]/PN·[2'-OH]/PN·[-2'-O-Me]/PN oligoribonucleotide
In the manner of Example 8, using oligoribo-
nucleotides of Example 6, a chimeric oligoribonucleotide
having a phosphoramidate backbone is prepared.

15 iii. Chimeric phosphoramidate oligoribonucleotide, e.g.,
[2'-O-Me]/3'NPN·[2'-OH]/3'NPN·[-2'-O-Me]/3'NPN oligoribo-
nucleotide
In the manner of Example 8, using oligoribo-
nucleotides of Example 6, a chimeric oligoribonucleotide
20 having a 3'-deoxy-3'-amino phosphoramidate backbone is
prepared.

iv. Chimeric phosphinate oligoribonucleotide, e.g., [2'-O-
Me]/PI·[2'-OH]/PI·[-2'-O-Me]/PI oligoribonucleotide
In the manner of Example 8, using oligoribo-
25 nucleotides of Example 6, a chimeric oligoribonucleotide
having a phosphinate backbone is prepared.

v. Chimeric alkylphosphonothioate oligoribonucleotide,
e.g., [2'-O-Me]/MePS·[2'-OH]/MePS·[-2'-O-Me]/MePS
oligoribonucleotide
30 In the manner of Example 8, using oligoribo-
nucleotides of Example 6, a chimeric oligoribonucleotide
having a phosphonothioate backbone is prepared.

vi. Chimeric phosphorodithioate oligoribonucleotide, e.g., [2'-O-Me]/P2S·[2'-OH]/P2S·[-2'-O-Me]/P2S oligoribonucleotide

In the manner of Example 8, using oligoribonucleotides of Example 6, a chimeric oligoribonucleotide 5 having a phosphorodithioate backbone is prepared.

vii. Chimeric phosphoselenate oligoribonucleotide, e.g.,

[2'-O-Me]/PSe·[2'-OH]/PSe·[-2'-O-Me]/PSe oligoribonucleotide

In the manner of Example 8, using oligoribonucleotides of Example 6, a chimeric oligoribonucleotide having a 10 phosphoselenate backbone is prepared.

viii. Chimeric borano phosphate oligoribonucleotide, e.g.,

[2'-O-Me]/BP·[2'-OH]/BP·[-2'-O-Me]/BP oligoribonucleotide

In the manner of Example 8, using oligoribonucleotides of Example 6, a chimeric oligoribonucleotide 15 having a borano phosphate backbone is prepared.

ix. Chimeric methyl phosphotriester oligoribonucleotide,

e.g., [2'-O-Me]/POME·[2'-OH]/POME·[-2'-O-Me]/POME oligoribonucleotide

In the manner of Example 8, using oligoribonucleotides of Example 6, a chimeric oligoribonucleotide having a 20 methyl phosphotriester backbone is prepared.

EXAMPLE 10

Chimeric oligoribonucleosides

i. Chimeric methylenemethyimino oligoribonucleoside, e.g.

25 [2'-O-Me]/MMI·[2'-OH]/MMI·[-2'-O-Me]/MMI oligoribonucleoside

In the manner of Example 8 using the chemistry of Example 7, a chimeric oligoribonucleoside having methylene-methyimino linkages throughout the oligoribonucleoside is prepared.

ii. Chimeric methylenedimethyhydrazo oligoribonucleoside, e.g. [2'-O-Me]/MDH-[2'-OH]/MDH-[2'-O-Me]/MDH oligoribonucleoside

In the manner of Example 8 using the chemistry of Example 7, a chimeric oligoribonucleoside having methylenedimethylhydrazo linkages throughout the oligoribonucleoside is prepared.

iii. Chimeric formacetal oligoribonucleoside, e.g. [2'-O-Me]/FA-[2'-OH]/FA-[2'-O-Me]/FA oligoribonucleoside

In the manner of Example 8 using the chemistry of Example 7, a chimeric oligoribonucleoside having formacetal linkages throughout the oligoribonucleoside is prepared.

iv. Chimeric thioformacetal oligoribonucleoside, e.g. [2'-O-Me]/TFA-[2'-OH]/TFA-[2'-O-Me]/TFA oligoribonucleoside

In the manner of Example 8 using the chemistry of Example 7, a chimeric oligoribonucleoside having thioformacetal linkages throughout the oligoribonucleoside is prepared.

v. Chimeric ethyleneoxide oligoribonucleoside, e.g. [2'-O-Me]/ETO-[2'-OH]/ETO-[2'-O-Me]/ETO oligoribonucleoside

In the manner of Example 8 using the chemistry of Example 7, a chimeric oligoribonucleoside having ethylene oxide linkages throughout the oligoribonucleoside is prepared.

vi. Chimeric methylenecarbonylamino oligoribonucleoside, e.g. [2'-O-Me]/amide-3-[2'-OH]/amide-3-[2'-O-Me]/amide-3 oligoribonucleoside

In the manner of Example 8 using the chemistry of Example 7, a chimeric oligoribonucleoside having amide-3 linkages throughout the oligoribonucleoside is prepared.

EXAMPLE 11**Chimeric oligoribonucleotides/oligoribonucleosides**

i. **Methylenemethylimino/phosphorothioate chimera, e.g. [2'-O-Me]/PS·[2'-OH]/PS·[-2'-O-Me]/MMI oligoribonucleo-**

5 tide/oligoribonucleoside

In the manner of Example 8 using the chemistry of Examples 6 and 7, a chimeric compound having both oligoribonucleotide and oligoribonucleoside segments is prepared. The chimeric compounds has methylenemethylimino linkages in one "wing" and phosphorothioate linkages in a central "gap" and in the other "wing."

ii. **Chimeric Methyl phosphonate/methylenemethylimino/phosphorothioate oligoribonucleotide/oligoribonucleoside, e.g. [2'-O-Me]/PMe·[2'-OH]/PS·[-2'-O-Me]/MMI oligoribonucleo-**

15 tide/oligoribonucleoside

In the manner of Example 8 using the chemistry of Examples 6 and 7, a chimeric compound having both oligoribonucleotide and oligoribonucleoside portions is prepared. The chimeric compound has methylenemethylimino linkages in one "wing", a phosphorothioate linkages in a central "gap" and methyl phosphonate linkages in the other "wing."

iii. **Chimeric methylenecarbonylamino/phosphorothio-**

25 nucleoside, e.g. [2'-O-Me]/amide-3·[2'-OH]/PS·[-2'-O-

Me]/amide-3 oligoribonucleotide/oligoribonucleoside

In the manner of Example 8 using the chemistry of Examples 6 and 7, a chimeric compound having both oligoribonucleotide and oligoribonucleoside segments is prepared. The chimeric compound has methylenecarbonylaimino linkages in both "wings" and phosphorothioate linkages in a central "gap."

iv. **Chimeric**

methylene carbonyl amino/phosphorothioate/methylenemethylimino

35 oligoribonucleotide/oligoribonucleoside, e.g. [2'-O-

Me]/amide-3·[2'-OH]/PS·[-2'-O-Me]/MMI oligoribonucleotide/oligoribonucleoside

In the manner of Example 8 using the chemistry of Examples 6 and 7, a chimeric compound having both 5 oligoribonucleotide and oligoribonucleoside segments is prepared. The chimeric compound has methylenecarbonylaimino linkages in one "wing" segment, phosphorothioate linkages in a central "gap" segment and methylenecarbonylamino linkages in the other "wing" segment.

10 v. **Methylenemethylimino/phosphodiester/phosphorothioate chimera, e.g. [2'-O-Me]/MMI-PO·[2'-OH]/PS·[-2'-O-Me]/MMI-PO oligoribonucleotide/oligoribonucleoside**

In the manner of Example 8 using the chemistry of Examples 6 and 7, a chimeric compound having both 15 oligoribonucleotide and oligoribonucleoside segments is prepared. The chimeric compounds has alternating methylene-methylimino and phosphodiester linkages in its "wing" segments and phosphorothioate linkages in its central "gap" segment.

20 **EXAMPLE 12**

Chimeric "end" gapped phosphorothioate oligoribonucleotides

i. **"3'-End" gapped phosphorothioate chimera, e.g. [2'-O-Me]/PS·[2'-OH]/PS oligoribonucleotide**

In the manner of Example 8 a chimeric compound 25 having an "open gap" segment at its 3' terminus, " a "wing" segment at its 5' terminus and phosphorothioate linkages through out is prepared.

ii. **"5'-End" gapped phosphorothioate chimera, e.g. [2'-OH]/PS·[2'-O-Me]/PS oligoribonucleotide**

30 In the manner of Example 8 a chimeric compound having an "open gap" segment at its 5' terminus, " a "wing" segment at its 3' terminus and phosphorothioate linkages through out is prepared.

iii. "3'-End" gapped phosphorothioate chimera, e.g. [2'-F]/PS·[2'-OH]/PS oligoribonucleotide

In the manner of Example 8, a chimeric compound having an "open gap" at its 3' terminus", 2'-fluoro nucleosides in its 5' "wing" segment, 2'-OH nucleosides in its open "gap" segment and phosphorothioate linkages throughout is prepared.

EXAMPLE 13

Chimeric oligoribonucleotides with uniform backbone linkages and variable nucleoside subunits

i. Chimeric 2'-O-ethyl oligoribonucleotide, e.g., [2'-O-Et]/PS·[2'-OH]/PS·[2'-O-Et]/PS oligoribonucleotide

In the manner of Example 8 a chimeric compound having 2'-O-ethyl nucleosides in its "wing" segments, 2'-OH nucleosides in its "gap" segment and phosphorothioate linkages throughout is prepared.

ii. Chimeric 2'-O-propyl oligoribonucleotide, e.g., [2'-O-Pr]/PS·[2'-OH]/PS·[2'-O-Pr]/PS oligoribonucleotide

In the manner of Example 8 a chimeric compound having 2'-O-propyl nucleosides in its "wing" segments, 2'-OH nucleosides in its "gap" segment and phosphorothioate linkages throughout is prepared.

iii. [2'-O-F]/PS·[2'-OH]/PS·[2'-O-F]/PS oligoribonucleotide

In the manner of Example 8 a chimeric compound having 2'-fluoro nucleosides in its "wings" segments, 2'-OH nucleosides in its "gap" segment and phosphorothioate linkages throughout is prepared.

iv. [2'-O-EtOMe]/PS·[2'-OH]/PS·[2'-O-EtOMe]/PS oligoribonucleotide

In the manner of Example 8 a chimeric compound having 2'-O-methoxyethyl nucleosides in its "wings" segments, 2'-OH nucleosides in its "gap" segment and phosphorothioate linkages throughout is prepared.

v. $[2'-O-EtOMe]/PS \cdot [2'-OH]/PS \cdot [2'-F]/PS$ oligoribonucleotide

In the manner of Example 8 a chimeric compound having 2'-O-methoxyethyl nucleosides in its 5' "wing" segment, 2'-OH nucleosides in its "gap" segment, 2'-fluoro nucleosides in its 3' "wing" segment, and phosphorothioate linkages through out is prepared.

vi. $[2'-O-EtOMe]/PS \cdot [2'-OH]/PS \cdot [2'-O-Me]/PS$ oligoribonucleotide

In the manner of Example 8, a chimeric compound having 2'-O-methoxyethyl nucleosides in its 5' "wing" segment, 2'-OH nucleosides in its gap, 2'-O-methyl nucleosides in its 3' "wing" segment and phosphorothioate linkages through out is prepared.

EXAMPLE 14

15 Chimeric oligoribonucleotides having variable backbone linkages and variable nucleosides

i. $[2'-O-Me]/PMe \cdot [2'-OH]/PS \cdot [2'-F]/PS$ oligoribonucleotide

In the manner of Example 8 using chemistries of Example 6, a chimeric compound having 2'-O-methyl nucleosides in its 5' "wing" segment, 2'-OH nucleosides in its "gap," 2'-O-fluoro nucleosides in its 3' "wing" segment, phosphorothioate linkages in the "gap" segment and the 3' "wing" segment and methyl phosphonate linkages in the 5' "wing" segment is prepared.

25 ii. $[2'-O-Me]/PMe \cdot [2'-OH]/PS \cdot [2'-Pr]/PI$ oligoribonucleotide

In the manner of Example 8 using chemistries of Example 6, a chimeric compound having 2'-O-methyl nucleosides in its 5' "wing" segment, 2'-OH nucleosides in its "gap," 2'-O-propyl nucleosides in its 3' "wing" segment, phosphorothioate linkages in the "gap" segment, methyl phosphonate linkages in 5' "wing" segment and phosphinate linkages in the 3' "wing" segment is prepared.

EXAMPLE 15

Chimeric oligoribonucleotides that include surrogate nucleosides

i. Morpholino nucleoside surrogate containing oligoribonucleotide, e.g., [morpholino nucleoside surrogate] · [2'-OH] /PS· [morpholino nucleoside surrogate] oligoribonucleotide

In the manner of Examples 7 and 8, a chimeric compound having morpholino nucleosides prepared as per the teachings of U.S. Patent 5,506,337 in its "wing" segments and 2'-OH nucleosides linked via phosphorothioate linkages in its "gap" segment is prepared.

ii. Cyclobutyl nucleoside surrogate containing oligoribonucleotide, e.g., [cyclobutyl nucleoside surrogate] /PS· [2'-OH] /PS· [cyclobutyl nucleoside surrogate] /PS oligoribonucleotide

15

In the manner of Examples 7 and 8, a chimeric compound having cyclobutyl surrogate nucleosides prepared as per the teachings of U.S. Patent 5,359,044 in its "wing" segments, 2'-OH nucleosides in its "gap" segment and 20 phosphorothioate linkages through out is prepared.

iii. Pyrrolidine nucleoside surrogate containing oligoribonucleotide, e.g., [pyrrolidine nucleoside surrogate] /PS· [2'-OH] /PS· [pyrrolidine sugar] /PS oligoribonucleotide

In the manner of Examples 7 and 8, a chimeric compound having pyrrolidine surrogate nucleosides prepared as per the teachings of U.S. Patent 5,519,135 in its "wing" segments, 2'-OH nucleosides in its "gap" segment and 25 phosphorothioate linkages through out is prepared.

iv. "3'-End" gapped PNA·phosphorothioate chimera, e.g. 30 PNA· [2'-OH] /PS oligoribonucleotide

In the manner of Example 8 in combination with the chemistry of Examples 7-b, a chimeric compound having an "open gap" at its 3' terminus" formed from 2'-OH nucleosides

having phosphorothioate linkages and PNA surrogate nucleosides in the 5' "wing" segment, is prepared.

EXAMPLE 16

Chimeric oligoribonucleotides that include nucleosides

5 having modified bases

i. N-2 modified purine containing oligoribonucleotide,
e.g., [Mod-purine]/PS·[2'-OH]/PS·[Mod-purine]/PS
oligoribonucleotide

In the manner of Example 8, a chimeric compound
10 having 4,7,10,13-tetraazahexadec-1-yl guanosine nucleosides
prepared as per the teachings of U.S. Patent 5,459,255 in
its "wing" segments, 2'-OH nucleosides in its "gap" and
phosphorothioate linkages through out is prepared.

ii. C-5 modified pyrimidine containing oligoribonucleotide,
15 e.g., [Mod-pyr]/PS·[2'-OH]/PS·[Mod-pyr]/PS oligoribonucleo-
tide

In the manner of Example 8, a chimeric compound
having 5-propynyl pyrimidine nucleosides prepared as per the
teachings of U.S. Patent 5,484,908 in its "wing" segments,
20 2'-OH nucleosides in its "gap" segment and phosphorothioate
linkages through out is prepared.

iii. N-2, C-6 modified purine containing
oligoribonucleotide, e.g., [Mod-purine]/PS·[2'-OH]/PS·[Mod-
purine]/PS oligoribonucleotide

25 In the manner of Example 8, a chimeric compound
having 6-hydroxy-2-fluoro purine nucleosides prepared as per
the teachings of U.S. Patent 5,459,255 in its "wing"
segments, 2'-OH nucleosides in its "gap" and
phosphorothioate linkages through out is prepared.

30 iv. 2'-O-alkyl, C-5 modified pyrimidine containing
oligoribonucleotide, e.g., [2'-O-Propyl-Mod-pyr]/PS·[2'-
OH]/PS·[2'-O-propyl-Mod-pyr]/PS oligoribonucleotide

In the manner of Example 8, a chimeric compound

having 2'-O-propyl-5-methyl cytidine nucleosides in its "wing" segments, 2'-OH nucleosides in its "gap" segment and phosphorothioate linkages through out is prepared.

v. 2'-O-alkyl, N-2,C-5 modified pyrimidine containing
5 oligoribonucleotide, e.g., [2'-O-propyl-Mod-pyr]/PS·[2'-
OH]/PS·[2'-O-propyl-Mod-pyr]/PS oligoribonucleotide

In the manner of Example 8, a chimeric compound having 2'-O-propyl-2-thio-5-methyl uridine nucleosides in its "wing" segments, 2'-OH nucleosides in its "gap" segment
10 and phosphorothioate linkages through out is prepared.

vi. 2'-O-aminoalkyl, N-2,C-5 modified pyrimidine containing
oligoribonucleotide, e.g., [2'-O-aminopropyl-Mod-
pyr]/PS·[2'-OH]/PS·[2'-O-aminopropyl-Mod-pyr]/PS oligoribo-
nucleotide

15 In the manner of Example 8, a chimeric compound having 2'-O-aminopropyl-2-thio-5-methyl uridine nucleosides in its "wing" segments, 2'-OH nucleosides in its "gap" segment and phosphorothioate linkages through out is prepared.

20 vii. 2'-O-fluoro, N-2, C-5 modified pyrimidine containing
oligoribonucleotide, e.g., [2'-O-fluoro-Mod-pyr]/PS·[2'-
OH]/PS·[2'-O-fluoro-Mod-pyr]/PS oligoribonucleotide

In the manner of Example 8, a chimeric compound having 2'-O-fluoro-2-thio-5-methyl uridine nucleosides in
25 its "wing" segments, 2'-OH nucleosides in its "gap" segment and phosphorothioate linkages through out is prepared.

EXAMPLE 17

Cell culture and Northern blot analysis of ras target

T24 cells were maintained as monolayers in McCoys
30 medium (GIBCO-BRL, Gaithersburg, MD) supplemented with 10% fetal bovine serum and 100 units/ml penicillin. After treatment with oligomeric compounds for 24 hrs the cells were trypsinized, centrifuged and total cellular RNA was

isolated according to standard protocols (see Ausubel et al., *Current Protocols in Molecular Biology*, 1988, Wiley and Sons, New York, NY). To quantify the relative abundance of *Ha-ras* mRNA, total RNA (10 ug) was transferred by northern blotting onto Bio-Rad Zeta probe membrane (Bio-Rad, Hercules, CA) and UV crosslinked (Stratalinker™, Stratagene, LaJolla, CA). Membrane bound RNA was hybridized to a ³²P labeled 0.9 kb *Ha-ras* cDNA probe (Oncogene Science, Pasadena, CA) and exposure to XAR film (Kodak, Rochester, N.Y.). The relative amount of *Ha-ras* signal was determined by normalizing the *Ha-ras* signal to that obtained when the same membrane was stripped and hybridized with a probe for human glyceraldehyde 3-phosphate dehydrogenase (G3PDH, Clontech, Palo Alto, CA). Signals from northern blots were quantified using phosphoimager and image quant software (Molecular Dynamics, Sunnyvale, CA).

EXAMPLE 18**Compound treatment of cells**

Cells growing in monolayer were washed once with warm PBS then Opti-MEM (GIBCO-BRL) medium containing Lipofectin (GIBCO-BRL) at a concentration of 5 ug/ml per 200nM of oligo with a maximum concentration of 15 ug/ml was added. Oligomeric compounds were added and incubated at 37°C for 4 hrs when the medium was replaced with full serum medium. After 24 hrs in the presence of the compound the cells were harvested and RNA prepared for further analysis.

EXAMPLE 19**RNase H Analysis**

RNase H analysis was performed using 17 base oligoribonucleotides corresponding to bases (+23 to +47) of activated (codon 12 mutation) *Ha-ras* mRNA. 5' End labeled RNA (20 nM) was incubated with a 100-fold molar excess of the various test oligoribonucleotides in a reaction containing 20 mM Tris-Cl, pH 7.5, 100 mM KCl, 10 mM MgCl₂, 1 mM dithiothreitol, and 4 units of RNase inhibitor (Pharmacia,

Newark, NJ) in a final volume of 100 μ l. The oligoribonucleotides were melted by heating to 95°C for 5 minutes then allowed to cool slowly to room temperature in 2 liters bath of water 90°C. Duplex formation was confirmed by 5 the shift in mobility between the single stranded end labeled sense RNA and the annealed duplex on non denaturing polyacrylamide gels. The resulting duplexes were tested as substrates for digestion by *E. coli* RNase H (USB, Cleveland, OH). 1 μ l of a 1×10^{-9} mg/ml solution of RNase H was added 10 to 10 μ l of the duplex reaction incubated at 37°C for 30 minutes, the reaction was terminated by the addition of denaturing loading buffer and reaction products were resolved on a 12 % polyacrylamide gel containing 7 M Urea and exposed to XAR film (Kodak).

15 **EXAMPLE 20**

Cell free *in vitro* nuclease assay

Duplexes used in the cell free T24 extract experiments were annealed as described above with the exception that after formation of the duplex, the reaction was treated with 20 1 μ l of a mixture RNase T and A (Ambion RPAII kit, Austin, TX) and incubated for 15 min at 37°C, and then gel purified from a nondenaturing 12% polyacrylamide gel. T24 cell nuclear and cytosolic fractions were isolated as described previously (Szyf, M., Bozovic, V., and Tanigawa, G., *J. 25 Biol. Chem.*, 1991, 266, 10027-10030). Annealed duplexes (10 μ l) were incubated with 3 μ g of the T24 cytosolic extract at 37°C. The reaction was terminated by phenol/chloroform extraction and ethanol precipitated with the addition of 10 μ g of tRNA as a carrier. Pellets were 30 resuspended in 10 μ l of denaturing loading dye, products were resolved on 12 % denaturing acrylamide gels as described above. 32 P-labeled 17-base RNA was hydrolysed by heating to 95°C for 10 mintes in the presence of 50 mM NaCO₃, pH=9.0 to generate a molecular weight ladder.

EXAMPLE 21**Determination of 5' and 3' termini**

Non-labeled duplex was treated with T24 extracts as done previously, half of this reaction was treated with calf 5 intestinal phosphatase (CIP, Stratagene) and half was left untreated. The phosphatase was inactivated by heating to 95° C and the reactions were extracted with phenol/chloroform and then precipitated in ethanol with glycogen as a carrier. The precipitates were then treated with T4 polynucleotide 10 kinase (Stratagene) and ^{32}P - γ -ATP (ICN, Irvine, CA). The samples were again extracted by phenol/chloroform and precipitated with ethanol, the products of the reaction were then resolved on a 12% acrylamide gel and visualized by exposure to XAR film. The 3'-terminus of the cleaved duplex 15 was evaluated by the reaction of duplex digestion products with T4 RNA ligase (Stratagene) and ^{32}P -pCp (ICN).

EXAMPLE 22**Chimeric 2'-methoxy oligoribonucleotides mediate digestion of target RNA in T24 cells**

20 Structure activity analyses of antisense oligonucleotides specific for codon 12 of the *Ha-ras* oncogene containing various 2'-sugar modifications were reported by Monia, et al., *J. Biol. Chem.*, 1992, 267, 19954-19962 and Monia et al., *J. Biol. Chem.*, 1993, 268, 14514-25 14522. In those reports, although the 2'-modified oligonucleotides hybridized with greater affinity to RNA than did unmodified 2'-deoxy oligos they were completely ineffective in inhibiting *Ha-ras* gene expression. The lack of activity observed with these 2'-modified oligos was 30 directly attributed to their inability to create duplexes that could serve as substrates for degradation by RNase H. Following a similar protocol, stretches of ribonucleotides were introduced into the center of 17 base 2'-methoxy oligoribonucleotides targeting *Ha-ras* mRNA to form 2'-35 methoxy-2'-hydroxy-2'-methoxy phosphorothioate oligoribonucleotide "gapped" chimeric compounds that have

varying ribonucleotide content in the central gap segment (see Figure 1 for a representation of these compounds as well as their base sequence). When hybridized to their cellular target the resultant duplex consists of two 5 stretches that are not targets for nucleolytic degradation (the 2'-methoxy "wings") and one 2'-hydroxyl oligoribonucleotide stretch that was found to be a target for a novel ribonuclease activity that recognizes RNA:RNA duplexes. T24 human bladder carcinoma cells were used that 10 contain an activating G-T transversion mutation in the *Ha-ras* gene at the codon 12 position. The "gapped" chimeric compounds specific for this mutation were transfected into T24 cells growing in culture. After incubation with the compounds for 24 hrs, cells were harvested, total cytosolic 15 RNA isolated and Northern blot analysis for *Ha-ras* mRNA levels performed. Fully modified 2'-methoxy oligonucleotides did not support nucleolytic cleavage of target mRNA and therefore did not lead to a reduction in steady state levels of *Ha-ras* mRNA even at the highest 20 concentration tested (Figures 2A and 2B). An RNA gapmer oligonucleotide with only 3 ribonucleotides in the gap was also incapable of inducing nucleolytic cleavage of the target RNA (Figures 2C and 2D). However, T24 cells treated with RNA gapmer oligonucleotides containing 5, 7 and 9 25 ribonucleotides in the gap as well as a full phosphorothioate oligoribonucleotide molecule all displayed dose dependent reductions in *Ha-ras* steady state mRNA levels (Figures 3B-3D). T24 cells treated with a control 9 RNA gapmer oligonucleotide that contained four mismatched bases 30 in its sequence did not show dose dependent reduction in *Ha-ras* mRNA suggesting that hybridization to the target RNA is essential for activity (Figure 3E). The RNA gapmer compounds showed dose dependent inhibition of *Ha-ras* steady state mRNA levels.

35 The ability of the RNA gapmer compounds to reduce *Ha-ras* mRNA was dependent on the size of the RNA gap and thus the size of the RNA:RNA duplex formed *in vivo*. Treatment of

cells with the 3 base RNA gapmer compounds resulted in no cleavage of the target whereas the 5, 7 and 9 base RNA gapmer compounds resulted in reduction in *Ha-ras* mRNA (Figure 4). The fact that the RNA gapmer oligonucleotide 5 containing 3 ribonucleotides in the gap was unable to induce reduction in target mRNA suggests that the activity involved requires a minimal RNA:RNA duplex region of at least four ribonucleotides for binding and cleavage of the target. Interestingly, chimeric DNA gapmer oligonucleotides that 10 contain deoxynucleotides in the gap instead of ribonucleotides show the same minimal gap size requirements to form substrates for RNase H mediated degradation of the target mRNA (Crooke et al., *Annu. Rev. Pharmacol.*, 1996, 36, 107), suggesting that RNase H and the double stranded RNase 15 activity described here may share some properties, although their substrates are clearly different.

A control 9 RNA gapmer compound that contains four mismatched bases in its sequence resulted in essentially no reduction in *Ha-ras* mRNA as expected as is shown in Figure 20 3E. A full phosphorothioate oligoribonucleotide molecule had approximately the same activity as the 5 RNA gapmer oligo (Figure 3D). This might have been due to the relative decrease in stability of the full oligoribonucleotide *in vivo* resulting from inactivation by single stranded 25 ribonucleases, as 2'-methoxy phosphorothioate oligodeoxynucleotides are considerably more stable than phosphorothioate oligoribonucleotides. Crooke et al., *J. Pharmacol Exp. Ther.*, 1996, 277, 923-937. Treatment of T24 cells with the various oligonucleotides and various 30 concentrations up to 800nM was done in triplicate and quantification of *Ha-ras* mRNA levels indicate that at 600nM the 5 gapmer reduces *Ha-ras* mRNA by 51%, the 7 gapmer by 49%, the 9 gapmer by 77% and the full ribonucleotide by 38% when compared to non treated controls. This suggests that 35 RNA gapmer oligoribonucleotides protected by 2'-methoxy wings would be more potent molecules. As shown in this example, an endoribonuclease activity in T24 human bladder

carcinoma cells recognizes the internal RNA:oligoribonucleotide portion of a chimeric duplex and reduced the target mRNA levels.

EXAMPLE 23

5 An activity present in T24 cellular extracts induces cleavage of gapmer oligoribonucleotide:RNA duplex within the internal RNA:RNA portion *in vitro*

To further characterize the double-stranded RNA cleavage activity in T24 cells, T24 cellular extracts were 10 prepared and tested for the ability to cleave the 9 gap oligoribonucleotide:RNA duplex *in vitro*. The 9 gap compound:³²P-end labeled RNA duplex was incubated with 3 µg of cytosolic extract at 37°C for varying time periods as shown in Figure 4, followed by phenol chloroform extraction 15 ethanol precipitation and separation of the products on a denaturing gel. That this duplex was a substrate for digestion by an activity present in T24 extracts is shown by the loss of full length end labeled RNA and the appearance of lower molecular weight digestion products indicated by 20 arrows in Figure 4. In addition, the activity responsible for the cleavage of the duplex has specificity for the RNA:RNA portion of the duplex molecule, as indicated by the sizes of the cleavage products it produces (see the physical map of the ³²P-end labeled RNA, far right in Figure 4. RNase 25 H cleavage of a 9 deoxynucleotide gap oligonucleotide:RNA duplex and cleavage of the 9 ribonucleotide gap oligoribonucleotide:RNA duplex by T24 cellular extracts appears to result in similar digestion products. This is seen by comparing the gels of Figures 4 and 5. Both activities 30 displayed preferred cleavage sites near the 3' end of the target RNA in their respective duplexes which suggests that they may share binding as well as mechanistic properties. Cellular extracts prepared from human umbilical vein epithelial cells (HUVEC), human lung carcinoma (A549) and 35 Hela cell lines all contained an activity able to induce cleavage of the 9 RNA gapmer:RNA target duplex *in vitro*.

EXAMPLE 24**Cleavage of target RNA in both cytoplasmic and nuclear fractions of cell products**

The cellular distribution of the double stranded RNase activity described herein was further evaluated. Nuclear extracts were prepared from T24 cells and tested for the ability to digest the 9 RNA gapmer oligonucleotide:RNA duplex. Nuclear extracts prepared from T24 cells were able to degrade the target duplex, and the activity was found to be present in the nuclear fraction at comparable levels to that in the cytoplasmic fractions.

An RNA gapmer oligonucleotide was synthesized that contained phosphorothioate linkages throughout the entire length of the molecule. Since this results in increased stability to single stranded nucleases, it was reasoned that it would inhibit cleavage of the antisense strand by the dsRNase as well. Therefore, to determine if the activity described above can cleave both strands in a RNA duplex molecule, a 9 RNA gapmer antisense oligonucleotide that contained phosphorothioate linkages in the wings between the 2' methoxy nucleotides but had phosphodiester linkages between the nine ribonucleotides in the gap was synthesized. A duplex composed of this ³²P-labeled 9 RNA gapmer phosphodiester/phosphorothioate oligonucleotide and its complementary oligoribonucleotide was tested as a substrate for double stranded RNase activity in T24 extracts. The activity was capable of cleaving the antisense strand of this duplex as well as the sense strand and the pattern of the digestion products indicated that cleavage was again restricted to the RNA:RNA phosphodiester portion of the duplex.

EXAMPLE 25**An RNA Gapmer oligonucleotide:RNA duplex is not a substrate for RNase H**

To exclude the possibility that the cleavage shown in Example 23 might be due to RNase H, the ability of *E. coli*

RNase H to cleave a 17 base pair duplex of the 9 gapmer oligoribonucleotide and its complementary 5' ^{32}P -labeled RNA *in vitro* was tested. Figure 5 shows the expected shift in electrophoretic mobility when duplexes were formed and 5 analyzed on a native gel next to the single stranded ^{32}P -end labeled RNA. As can be seen in Figure 5 in the far right panel, the 9 Gapmer oligoribonucleotide:RNA duplex was not a substrate for RNase H cleavage as no lower molecular weight bands appeared when it was treated with RNase H. However, 10 as expected a full deoxy oligonucleotide:RNA duplex was cleaved by RNase H under the same conditions, as is evident by the appearance of lower molecular species in the enzyme treated lane (Figure 5, left panel). A duplex composed of a 15 9 gapmer DNA oligonucleotide and its complementary RNA was a substrate for RNase H cleavage. The fact that the RNase H cleavage sites in this particular duplex were localized to the DNA:RNA portions of the duplex further demonstrates that the RNA gapmer oligoribonucleotide:RNA duplex is not a substrate for RNase H digestion.

20 It is interesting to note that RNase H cleavage of the 9 DNA gapmer oligonucleotide:RNA duplex (Figure 5, left panel) and cleavage of the 9 RNA gapmer oligonucleotide:RNA duplex by T24 cellular extracts resulted in similar 25 digestion products (see Figure 4). Both RNase H and the activity in T24 cells displayed the same preferred cleavage sites on their respective duplexes. Moreover, at this site, both the oligonucleotides were roughly comparable in potency. Cleavage was restricted to the 3' end of the target RNA in the region opposite either the DNA or RNA gap 30 of the respective antisense molecule.

While not wishing to be bound by any particular theory, the immediately preceding result suggests that RNase H and the dsRNase of the invention may share binding as well as mechanistic properties. However, analysis of DNA and RNA 35 gapmer oligonucleotides targeting four sites on c-Raf mRNA revealed that RNase H and the dsRNase activity described here clearly have different substrate specificities. "RNA-

like" gapmer oligonucleotides targeted to the c-Raf mRNA were not able to induce reduction in mRNA whereas RNase H active oligodeoxynucleotides targeted to the same site were able to reduce target mRNA levels. To determine if the lack 5 of cleavage induced by the four c-Raf "RNA gapmers" in T24 cells was due to possible sequence specificity or cleavage, the four c-Raf "RNA-like gapmers," the ras "RNA-like gapmer" and the corresponding "DNA-like gapmers" were prehybridized to ³²P-labeled target oligoribonucleotides and incubated with 10 T24 homogenates. The ras "RNA-like gapmer" supported cleavage of the ras target RNA almost as efficiently as the "DNA gapmer." However, only one of the "RNA-like gapmers" targeted to c-Raf segments (SEQ ID NO:8) supported any cleavage and the rate of cleavage for the "RNA-like gapmer" 15 was much slower than the comparable "DNA-like gapmer." Thus, in contrast to RNase H, the dsRNase displays considerable sequence specificity.

EXAMPLE 26

20 **Nuclease activity generates 5'-phosphate and 3'-hydroxyl termini**

To determine the nature of the 5' termini left by nuclease cleavage of the duplex *in vitro*, non-labeled duplex was incubated with T24 cellular extracts as previously described then reacted with T4 polynucleotide kinase and 25 [³²P- γ -ATP] with or without prior treatment with calf intestinal phosphatase. Phosphatase treatment of the duplex products was seen to be essential for the incorporation of ³²P label during the reaction with polynucleotide kinase, indicating the presence of a phosphate group at the 5' 30 termini. The 3' termini were evaluated by the reaction of duplex digestion products with T4 RNA ligase and ³²P-pCp. T4 RNA ligase requires a free 3'-hydroxyl terminus for the ligation of ³²P-pCp. The ability of the duplex digestion products to incorporate ³²P-pCp by T4 RNA ligase indicates 35 the presence of 3'-hydroxyl groups.

EXAMPLE 27**Purification and characterization of double-stranded ribonucleases from mammalian tissues**

In order to determine if mammalian cells, other than 5 cultured cell lines, contain double-strand RNase activity, and to provide a source from which such ribonucleases might be purified, the following efforts were undertaken to identify and purify dsRNases from rat liver homogenates.

EXAMPLE 27-a**10 Substrates and assays for dsRNases**

In preliminary experiments, double-strand RNase activity was observed in rat liver homogenates, but the homogenates also displayed high levels of single-strand RNases that complicated analysis of the dsRNase activities 15 because of cleavage of the oligoribonucleotide overhangs after cleavage by the dsRNases. To solve this problem, two additional substrates and a non-denaturing gel assay were used. The "sense" strand was an oligoribonucleotide having phosphodiester linkages in an eight-base gap with flanks 20 having either (a) residues with phosphorothioate linkages or (b) 2'-methoxynucleosides with phosphorothioate linkages. The "antisense" strand in both substrates contained 2'-methoxy phosphorothioate wings on either side of an eight-base ribonucleotide gap having either phosphodiester or 25 phosphorothioate linkages (Table 1). Such dsRNase substrates were more stable to exonuclease digestion than an oligoribonucleotide and substrates with both phosphorothioate linkages and 2'-methoxy nucleosides was extremely stable. These features are important because of 30 the abundance of single-strand RNases relative to the double-strand RNase activity in the rat liver and supported the use of non-denaturing assays.

TABLE 1
Artificial Substrates for Mamalian dsRNases*

Ha-ras TARGETED SENSE/ANTISENSE OLIGONUCLEOTIDES	
5	SEQ ID NO:1 5'-GGG CGC CGU CGG UGU GG-3' SEQ ID NO:2 3'-CCC GCG GCA GCC ACA CC-5'
C-raf TARGETED SENSE/ANTISENSE OLIGONUCLEOTIDES	
10	SEQ ID NO:3 5'-CCG AAU GUG ACC GCC UCC CG-5' SEQ ID NO:4 3'-GGC UUA CAC UGG CGG AGG GC-3' SEQ ID NO:5 5'-UCA AUG GAG CAC AUA CAG GG-3' SEQ ID NO:6 3'-AGU UAC CUC GUG UAU GUC CC-5' SEQ ID NO:7 5'-AAU GCA UGU CAC AGG CGG GA-3' SEQ ID NO:8 3'-UUA CGU ACA GUG UCC GCC CU-5'

*Emboldened residues indicate 2'-methoxynucleotide residues in the "antisense" strands.

15 Both rat liver cytosolic and nuclear extracts induced cleavage of the duplex substrate. Both extracts resulted in more rapidly migrating bands on native gel electrophoretic analyses. The cytosolic extract appeared to be more active than the nuclear extract. A double-strand RNase, RNase V1
 20 (Pharmacia, Piscataway, NJ) cleaved the substrate; T24 extracts also cleaved the substrate. Neither bacterial nor single-strand RNase cleaved the substrate, with the exception of RNase A, which at very high concentrations resulted in some cleavage. It is unclear whether that
 25 cleavage was due to a contaminating double-strand RNase or if RNase A can, under some conditions, cleave double-strand substrates.

EXAMPLE 27-b

30 **Purification of dsRNases from rat liver cytosolic and nuclear extracts**

In order to purify the mammalian dsRNase identified herein, 0.5 kg of rat liver was homogenized in Buffer X [10

mM Hepes (ph 7.5), 25 mM KCl, 0.15 mM spermine, 0.5 mM spermidine, 1 mM EDTA, 2 M sucrose, 10% glycerol; all reagents from Sigma Chemical Co., St. Louis, MO] and centrifuged in a Beckman J2-21M centrifuge (Beckman, 5 Fullerton, CA) at 10,000 rpm for 1.5 hours. The supernatant was precipitated with 40% ammonium sulfate (Sigma). All the dsRNase activity was recovered in the 40% ammonium sulfate precipitate. The pellet was resuspended in Buffer A [20 mM Hepes (ph 6.5), 5 mM EDTA, 1 mM DTT, 0.25 mM 10 phenylmethylsulfonyl fluoride (PMSF), 0.1 M KCl, 5% glycerol, 0.1% NP40, 0.1% Triton X-100; all reagents from Sigma] and dialyzed to remove ammonium sulfate. Approximately 40 g of cytosolic extract were obtained from 0.5 kg liver.

15 A crude nuclear pellet, prepared as in the previous Examples, was resuspended and homogenized in Buffer Y [20 mM Hepes (ph 7.5), 0.42 M NaCl, 1.5 mM MgCl₂, 0.2 mM EDTA, 0.5 mM DTT, 0.5 mM PMSF, 25% glycerol]. The homogenate was centrifuged in a J2-21M centrifuge (Beckman) at 10,000 rpm 20 for 1.5 hrs. The supernatant was precipitated with 70% ammonium sulfate. The pellet was resuspended in Buffer A and dialyzed. All the dsRNase activity was recovered in the 70% ammonium sulfate precipitate. Approximately 5 g Of nuclear extract were obtained from 0.5 kg liver.

25 Ion exchange chromatography was then performed in order to further purify the dsRNases of the invention. Nuclear and cytosolic extracts in Buffer A were loaded onto Hi-Trap columns (Pharmacia, Piscataway, NJ) for FPLC. The extracts were eluted with a linear gradient of NaCl and samples were 30 collected. The UV absorption at 257 η M of the samples was determined. Samples were centrifuged at 8,000 g for 10 minutes, resuspended in Buffer A, concentrated in Ultrafree-15 centrifugal filter devices (Millipore, Bedford, MA) and analyzed for activity. The dsRNase activity eluted in 35 fractions corresponding 300-450 mM NaCl. In contrast, the dsRNase activity in the nuclear extract eluted at 700-800 mM NaCl.

Fractions from the ion exchange chromatography were concentrated and subjected to size exclusion chromatography. Active samples from the ion exchange chromatography were pooled, applied to a TSK G-3000 column (TosoHaas, 5 Montgomeryville, PA) and run with Buffer A containing 100 mM NaCl. Samples (200 to 400 μ l) were collected and their UV absorption at 257 η M was determined. Samples were concentrated using Ultrafree-15 centrifugal filter devices (Millipore) and then analyzed for activity.

10 Figure 6 shows a polyacrylamide gel electrophoretic analysis of the concentrated active fractions after the ion-exchange chromatography, and the fractions from the size exclusion chromatography. The fraction with greatest dsRNase activity (lane 4, Figure 6) had a molecular weight range of 15 about 50 to about 80 kilodaltons, and a band at approximately 50 kilodaltons appeared to be enhanced on 12 % polyacrylamide gel electrophoresis (PAGE) performed using precast gels (Novex, San Diego, CA).

20 Table 2 provides a summary of the purification and recovery of dsRNase activities from nuclear and cytosolic liver extracts.

TABLE 2
Summary of Purification of dsRNases from Rat Liver
Homogenates

5	Fraction	Protein (mg)	Total	Specific	Purifi-	Recovery (%)
			Activity (units*)	Activity (unit/mg)	cation Factor	
10	Cytosolic extract	30,000	1,020,00 0	34	1	100
10	Ion Exchange (Pool)	991	459,000	463	14	56
	Gel Filtration	18.4	100,980	5,600	165	22

15 One unit is defined as the amount of sample required to digest 10 fMol dsRNA duplex in 15 minutes at 37°C under the conditions described herein.

20 Purification of the dsRNase activities from liver nucleii and cytosol suggests that at least two dsRNases with differing properties are capable of cleaving double-strand RNA. The nuclear dsRNase eluted at higher NaCl concentrations from the ion exchange column than the cytosolic dsRNase. However, both require Mg⁺⁺ and cleave at several sites within the oligoribonucleotide gap. Both require a duplex substrate and 25 can cleave oligoribonucleotides in a duplex that is made up of oligoribonucleotide "sense" and a 2' methoxy phosphorothioate chimeric "antisense" strand when the duplex has phosphorothioate or phosphorothioate-2' methoxy nucleoside wings.

30 Having (1) established a reproducible and activity-specific assay for, (2) determined several sources of and (3) achieved an adequate degree of purification of the dsRNases of the invention via the methods described above, the dsRNases are further purified by a variety of means. In all instances, the 35 use of organic solvents is avoided as the dsRNases of the invention are unstable in acetonitrile or methanol (see below),

and the assays described herein are used to evaluate the presence or absence of the desired dsRNase in a sample. Further purification steps may include, but are not limited to, the following means.

5 Several types of heparin columns have been used to purify a variety of ribonucleases. For example, Sepharose columns have been utilized in the purification of a sequence-specific ribonuclease from *Rana catesbeiana* (bullfrog) oocytes (Liao, *Nucl. Acids Res.*, 1992, 20, 1371), a ribonuclease from *Xenopus laevis* oocytes (Nitta et al., *Biol. Pharm. Bull. (Jpn.)*, 1993, 16, 353), several ribonucleases from the thermophilic archaebacterium *Sulfolobus Solfataricus* (Fusi et al., *Eur. J. Biochem.*, 1993, 211, 305), and a ribonuclease from human spleen (Yasuda et al., *Eur. J. Biochem.*, 1990, 191, 523).

10 Hydrophobic interaction chromatography is a powerful protein purification means which depends on strong salting-out salts to increase the hydrophobic interactions between the desired protein and a ligand therefor (Narhi et al., *Anal. Biochem.*, 1989, 182, 266). Hydrophobic interaction columns (HICs) have been used to purify ribonuclease A from undesired contaminants (Wu et al., *Methods in Enzymology*, 1996, 270, 27; Wetlaufer et al., *J. Chromatography*, 1986, 359, 55).

15 The dsRNases of the invention may also be further purified by hydroxyapatite chromatography (Kennedy, *Methods in Enzymology*, 1990, 182, 339). Endo- and exo-ribonuclease have been purified from *Trypanosoma brucei* using hydroxyapatite chromatography (Gbenle, *Exp. Parasitol.*, 1990, 71, 432; Gbenle, *Mol. Biochem. Parasitol.*, 1985, 15, 37).

20 RNA affinity columns may also be used to further purify the dsRNases of the invention. In particular, a commercially available double-stranded RNA affinity column (Pharmacia, Piscataway, NJ) may be used. Alternatively, a column is prepared in which the matrix thereof comprises one or more of the dsRNase substrates of the invention (for details, see the following Example). Due to the relative sequence specificity of the dsRNase of the present invention, the latter type of affinity column may be preferable. In order to prevent

degradation of the matrix of either type of double-stranded affinity matrix, samples comprising the dsRNases of the invention are treated in such a manner so as to limit the degradative capacity of the dsRNase without significantly 5 altering its ability to bind to the double-stranded RNA substrate of the matrix. For example, the degradative activity of the dsRNase of the invention is inhibited in solutions lacking available Mg⁺⁺ due to, for example, the addition of appropriate chelating agents such as EDTA, or by addition of 10 NaCl to a sample containing such dsRNases to a final concentration of at least 300 mM (see the following subsection).

Those skilled in the art will recognize that the above means, as well as others not herein described, will need to be 15 optimized for optimal efficiency in purifying the dsRNases of the invention. For example, the selection of one or more of the above means as a further purification step, and of the order in which such means are applied, will effect the degree of purity and specific activity of the dsRNase so treated. 20 However, such optimization is believed to be within the skill of the art given that the assays described herein can be readily utilized by a skilled artisan to determine the effect of further purification steps on the activity of the desired dsRNase. Other techniques known in the art, such as SDS-PAGE, 25 can be used to determine the purity of samples subjected to the above purification means.

EXAMPLE 27-c

Characterization of purified mammalian dsRNases

The effects of various conditions on the dsRNase activity 30 were evaluated using the active fractions after ion exchange chromatography. The dsRNase activity was demonstrable in Tris or phosphate buffers from about pH 7 to about pH 10. The dsRNase activity was not stable in solution in acetonitrile or methanol. Furthermore, the activity was inhibited by NaCl; 35 dsRNase activity was inhibited by 30% at 10 mM NaCl, >60% at 100 mM NaCl and 100% at 300 mM NaCl. Heating for five minutes at 60°C, 80°C or 100°C, inactivated the dsRNase. Optimum

activity was seen in the temperature range of about 37°C to about 42°C. At 25°C, the dsRNase activity was approximately 50% of that observed at 37°C. The dsRNase activity was inhibited at 10, 20 and 50 mM EDTA, but not at 5 mM, in 5 agreement with its requirement for Mg⁺⁺, and was stable to multiple freeze/thaws.

EXAMPLE 28**Further characterization of the dsRNase cleavage site using purified rat dsRNase**

10 The purified dsRNases were used to characterize the site of cleavage in more detail. Because it was necessary to minimize any single-strand cleavage from occurring after endonuclease cleavage and during handling, particularly after denaturing of the duplex. Consequently, the most 15 stable duplex substrate, i.e., one in which both strands of the duplex contained flanking regions comprised of 2' methoxy nucleosides and phosphorothioate linkages was used.

EXAMPLE 28-a**³²P labeling of oligonucleotides**

20 The sense oligonucleotide was 5'-end labeled with ³²P using [γ ³²P]ATP, T4 polynucleotide kinase, and standard procedures (Ausubel et al., 1989). The labeled oligonucleotide was purified by electrophoresis on 12% denaturing PAGE (Sambrook et al., 1989). The specific 25 activity of the labeled oligonucleotide was approximately 5000 cpm/fmol.

EXAMPLE 28-b**Double-strand RNA digestion assay**

Oligonucleotide duplexes were prepared in 30uL reaction 30 buffer [20 mM tris-HCl (pH 7.5), 20 mM KCl, 10 mM MgCl₂, 0.1 mM DTT] containing 10 nM antisense oligonucleotide and 10⁵ cpm ³²P labeled sense oligonucleotide. Reactions were heated at 90° C for 5 min and incubated at 37° C for 2 h. The oligonucleotide duplexes were incubated in either unpurified 35 and semipurified cellular extracts at a total protein concentration of 75 ug unpurified cytosolic extract, 60 ug

unpurified nuclear extract, 5 ug ion exchange purified cytosolic fraction, 5 ug ion exchange purified nuclear fraction, or 0.5 ug ion exchange and gel filtration purified nuclear fraction. Digestion reactions were incubated at 37° 5 C for 0-240 min. Following incubation, 10 uL of each reaction was removed and quenched by addition of denaturing gel loading buffer [5 uL 8 M urea, 0.25% xylene cyanole FF, 0.25% bromphenol blue]. The reactions were heated at 95° C for 5 min and resolved in a 12% denaturing polyacrylamide 10 gel. The remaining aliquot was quenched in 2 uL native gel loading buffer [glycerol, 0.25% xylene cyanole FF. The reactions were resolved at 10° C in a 12% native polyacrylamide gel containing 44 mM Tris-borate and 1 mM MgCl₂. Gels were analyzed using a Molecular Dynamics 15 Phosphorimager.

Figure 7 displays the native gel results. Lane 1 shows the position at which the untreated ³²P-labeled sense strand migrated in the native gel, and lane 2 shows "sense" strand RNA treated with 0.02 units RNase V1. In the remaining 20 lanes, the results of treatment of dsRNase substrates with 0.02 (lane 3) and 0.002 (lane 4) units of RNase V1, unpurified nuclear extract for 0 minutes (lane 5) or 240 minutes (lane 6), unpurified nuclear extract for 240 minutes without Mg⁺⁺ (lane 7), unpurified cytosolic extract 25 for 240 minutes (lane 8), ion exchange purified cytosolic extract for 240 minutes in the presence (lane 9) or absence (lane 10) of Mg⁺⁺, and ion exchange/gel filtration purified cytosolic extract for 240 minutes in the presence (lane 9) or absence (lane 10) of Mg⁺⁺ are shown.

30 Figure 8 shows the results of analysis of products of digestion of dsRNase substrates by denaturing polyacrylamide gel electrophoresis. Lane 1 shows "sense" strand RNA treated with 5 x 10⁻³ units of RNase A, and lane 2 shows "sense" strand RNA treated with 0.02 units RNase V1. The 35 remaining lanes show dsRNase products treated with 0.02 (lane 3) and 0.002 (lane 4) units of RNase V1, with unpurified nuclear extract for 0 minutes (lane 5) or 240

minutes (lane 6), with unpurified cytosolic extract for 240 minutes (lane 7), with ion exchange purified cytosolic extract for 240 minutes (lane 8), and with ion exchange/gel filtration purified cytosolic extract for 240 minutes (lane 9). Lane 10 is an RNA base hydrolysis ladder included for sizing purpose. RNase V1 digestion of the single-strand substrate resulted in little degradation (lane 2). RNase V1 digestion of the duplex resulted in degradates reflecting cleavage at several sites within the gap (lanes 3 and 4). In lanes 4-9, the band at the top of the gel demonstrates that even after denaturation, some of the duplex remained annealed, reflecting the very high affinity of duplexes comprised to 2'-methoxy nucleosides. Lanes 6-9 show that both the nuclear and cytosolic ribonucleases cleaved the triplex substrate at several sites with the oligoribonucleotide gap and that the sites of degradation were different from those of RNase V1. The position of the degradates in lanes 6-9 is consistent with them being the 2' methoxy phosphorothioate flanking regions (wings).

20 **EXAMPLE 29**

RNA affinity columns and methods of purifying ribonucleases

Techniques for preparing nucleic acid affinity columns are known in the art (see, e.g., Kadonaga, *Methods in Enzymology*, 1991, 208, 10). Such affinity columns comprise a matrix comprising a nucleic acid substrate for a desired compound that binds the substrate either nonspecifically or in a sequence-specific manner. Initially utilized in the purification of DNA-binding proteins, RNA affinity columns have also been employed to purify RNA-binding proteins and ribonucleases (see, e.g., Prokipcak et al., *J. Biol. Chem.*, 1994, 269, 9261; Dake et al., *J. Biol. Chem.*, 1988, 263, 7691). A matrix comprising one or more dsRNase substrates of the invention has the advantage of providing a dsRNA substrate that is resistant to the action of single-stranded ribonuclease which are prevalent in many tissues and cells. Such a matrix also comprises a suitable solid support and a

linker that provides a bridge between the solid support and the dsRNase substrate(s).

Suitable solid supports include, but are not limited to, graft polymers (U.S. Patent No. 4,908,405 to Bayer and 5 Rapp); polyacrylamide (Fahy *et al.*, *Nucl. Acids Res.*, 1993, 21, 1819); polyacrylmorpholide, polystyrene and derivatized polystyrene resins (Syvanen *et al.*, *Nucl. Acids Res.*, 1988, 16, 11327; U.S. Patent Nos. 4,373,071 and 4,401,796 to Itakura), including amino methyl styrene resins (U.S. Patent 10 No. 4,507,433 to Miller and Ts'0); copolymers of N-vinylpyrrolidone and vinylacetate (Selinger *et al.*, *Tetrahedron Letts.*, 1973, 31, 2911; Selinger *et al.*, *Die Makromolekulare Chemie*, 1975, 176, 609; and Selinger, *Die Makromolekulare Chemie*, 1975, 176, 1611); TEFLONTM (Lohrmann 15 *et al.*, *DNA*, 1984, 3, 122; Duncan *et al.*, *Anal. Biochem.*, 1988, 169, 104); controlled pore glass (Chow *et al.*, *Anal. Biochem.*, 1988, 175, 63); polysaccharide supports such as agarose (Kadonaga, *Methods Enzymol.*, 1991, 208, 10; Arndt-Jovin *et al.*, *Eur. J. Biochem.*, 1975, 54, 411; Wu *et al.*, 20 *Science*, 1987, 238, 1247; Blank *et al.*, *Nucleic Acids Res.*, 1988, 16, 10283) or cellulose (Goldkorn *et al.*, *Nucl. Acids Res.*, 1986, 14, 9171; Alberts *et al.*, *Meth. Enzymol.*, 1971, 21, 198) or derivatives thereof, e.g., DEAE-cellulose (Schott, *J. Chromatogr.*, 1975, 115, 461) or phosphocellulose 25 (Siddell, *Eur. J. Biochem.*, 1978, 92, 621; Bunemann *et al.*, *Nucl. Acids Res.*, 1982, 10, 7163; Noyes *et al.*, *Cell*, 1975, 5, 301; Bunemann *et al.*, *Nucl. Acids Res.*, 1982, 10, 7181); dextran sulfate (Gingeras *et al.*, *Nucl. Acids Res.*, 1987, 15, 5373); polypropylene (Matson *et al.*, *Anal. Biochem.*, 30 1994, 217, 306); agarose beads (Kadonaga *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 1986, 83, 5889); latex particles (Kawaguchi *et al.*, *Nucleic Acids Res.*, 1989, 17, 6229); nylon beads (Van Ness *et al.*, *Nucl. Acids Res.*, 1991, 19, 3345); paramagnetic beads (Gabrielson *et al.*, *Nucl. Acids 35 Res.*, 1989, 17, 6253; Lund, *et al.*, *Nucl. Acids Res.*, 1988, 16, 10861; Day *et al.*, *Biochem. J.*, 1991, 278, 735); silica gels (Yashima *et al.*, *J. Chromatogr.*, 1992, 603, 111);

derivatized forms of silica gels, polytetrafluoroethylene, cellulose or metallic oxides (U.S. Patent No. 4,812,512 to Buendia); and art-recognized equivalents of any of the preceding solid supports; microtiter plates (Drmanac et al., 5 *Science*, 1993, 260, 1649); crosslinked copolymers of N-vinylpyrrolidone, other N-vinyl-lactam monomers and an ethylenically unsaturated monomer having at least one amine or amine-displacable functionality as disclosed in U.S. Patent No. 5,391,667. In one set of preferred embodiments, 10 polystyrene or long chain alkyl CPG (controlled pore glass) beads are employed. In another set of preferred embodiments, microscopic glass slides are employed (Fodor et al., *Science*, 1991, 251, 767; Maskos et al., *Nucleic Acids Research*, 1992, 20, 1679; Guo et al., 1994, 22, 5456; Pease 15 et al., *Proc. Natl. Acad. Sci. U.S.A.*, 1994, 91, 5022).

With regard to the linker, a variety of chemical linking groups or chains may be employed in the matrices of the invention. Any chemical group or chain capable of forming a chemical linkage between the solid support and the 20 dsRNase substrate may be employed. A suitable linker has the preferred characteristic of non-reactivity with compounds introduced during the various steps of oligonucleotide synthesis. It will be appreciated by those skilled in the art that the chemical composition of the 25 solid support and the dsRNase substrate will influence the choice of the linker. Many suitable linkers will comprise a primary amine group at either or both termini, as many chemical reactions are known in the art for linking primary amine groups to a variety of other chemical groups; however, 30 other terminal reactive moieties are known and may be used in the invention. Suitable linkers include, but are not limited to, linkers having a terminal thiol group for introducing a disulfide linkages to the solid support (Day et al., *Biochem. J.*, 1991, 278, 735; Zuckermann et al., 35 *Nucl. Acids Res.*, 15, 5305); linkers having a terminal bromoacetyl group for introducing a thiol-bromoacetyl linkage to the solid support (Fahy et al., *Nucl. Acids Res.*,

1993, 21, 1819); linkers having a terminal amino group which can be reacted with an activated 5' phosphate of an oligonucleotide (Takeda et al., *Tetrahedron Letts.*, 1983, 24, 245; Smith et al., *Nucl. Acids Res.*, 1985, 13, 2399; 5 Zarytova et al., *Anal. Biochem.*, 1990, 188, 214); poly(ethyleneimine) (Van Ness et al., *Nucl. Acids Res.*, 1991, 19, 3345); acyl chains (Akashi et al., *Chem. Lett.*, 1988, 1093; Yashima et al., *J. Chromatogr.*, 1992, 603, 111); polyvinyl alcohol (Schott, *J. Chromatogr.*, 1975, 115, 461); 10 alkyl chains (Goss et al., *J. Chromatogr.*, 1990, 508, 279); alkylamine chains (Pon et al., *BioTechniques*, 1988, 6, 768); biotin-avidin or biotin-streptavidin linkages (Kasher et al., *Mol. Cell. Biol.*, 1986, 6, 3117; Chodosh et al., *Mol. Cell. Biol.*, 1986, 6, 4723; Fishell et al., *Methods Enzymol.*, 1990, 184, 328); and art-recognized equivalents of 15 any of the preceding linkers. In a preferred embodiment of the invention, an *n*-aminoalkyl chain is the linker. Methods of determining an appropriate (i.e., providing the optimal degree and specificity of hybridization between the sensor 20 array and the target oligonucleotide) linker length are known in the art (see, e.g., Day et al., *Biochem. J.*, 1991, 278, 735).

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Stanley T. Crooke
- 5 (ii) TITLE OF INVENTION: Oligonucleotides And
Ribonucleases For Cleaving RNA
- (iii) NUMBER OF SEQUENCES: 8
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
10 & Norris LLP
 - (B) STREET: One Liberty Place - 46th Floor
 - (C) CITY: Philadelphia
 - (D) STATE: PA
 - (E) COUNTRY: U.S.A.
 - (F) ZIP: 19103
- 15 (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: WordPerfect 6.1
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- 25 (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Joseph Lucci
 - (B) REGISTRATION NUMBER: 33,307
 - (C) REFERENCE/DOCKET NUMBER: ISIS-2484
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 215-568-3100
 - (B) TELEFAX: 215-568-3439

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 17 bases
 - 35 (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
GGGCGCCGUC GGUGUCC

17

5 (2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

10 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
CCACACCGA CGGCGCCC

17

(2) INFORMATION FOR SEQ ID NO:3:

15 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CCGAAUGUGA CCGCCUCCG

20

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

25

- (A) LENGTH: 20 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

30 CGGGAGGCAG UCACAUUCGG

20

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
UCAAUGGAGC ACAUACAGGG

20

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

10 (A) LENGTH: 20 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

15 CCCUGUAUGU GCUCCAUUGA

20

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

20 (A) LENGTH: 20 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

AAUGCAUGUC ACAGGGCGGGA

25 20

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

30 (A) LENGTH: 20 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

UCCCGCCUGU GAC AUGCAUU

20

CLAIMS

What is claimed is:

1. A synthetic oligomeric compound which is specifically hybridizable with a preselected RNA target and 5 comprises;

a first segment having at least one ribofuranosyl nucleoside subunit which is modified to improve the binding affinity of said compound to the preselected RNA target when compared to the binding affinity of an unmodified 10 oligoribonucleotide to the RNA target; and

a second segment comprising at least four consecutive ribofuranosyl nucleoside subunits having 2'-hydroxyl moieties thereon;

said nucleoside subunits of said oligomeric compound 15 being connected by internucleoside linkages which are modified to stabilize said linkages from degradation as compared to phosphodiester linkages.

2. The oligomeric compound of claim 1 further comprising a third segment comprising at least one 20 ribofuranosyl nucleoside subunit which is modified to improve the binding affinity of said compound to the preselected RNA target when compared to the binding affinity of an unmodified oligoribonucleotide to the RNA target.

3. The oligomeric compound of claim 1 which, when 25 hybridized with said RNA target, is capable of activating a double-stranded RNase enzyme to effect cleavage of said RNA target.

4. The oligomeric compound of claim 2 wherein said second segment is positioned between said first and said 30 third segments.

5. The oligomeric compound of claim 2 wherein each of

said first and third segments comprise at least three subunits.

6. The oligomeric compound of claim 2 wherein said second segment comprises from four to twelve nucleoside 5 subunits.

7. The oligomeric compound of claim 6 wherein said second segment comprises from five to nine nucleoside subunits.

8. The oligomeric compound of claim 2 wherein said 10 second segment has at least five subunits and said first and third segments each have at least three subunits.

9. The oligomeric compound of claim 8 wherein said second segment has at least seven nucleoside subunits.

10. A synthetic oligomeric compound which is 15 specifically hybridizable with a preselected RNA target and comprises;

a first segment having at least one ribofuranosyl nucleoside subunit that is modified to improve at least one of: pharmacokinetic binding, absorption, distribution or 20 clearance properties of the compound; affinity or specificity of said compound to said target RNA; or modification of the charge of said compound as compared to unmodified compound; and

a second segment comprising at least four consecutive 25 ribofuranosyl nucleoside subunits having 2'-hydroxyl moieties thereon;

30 said nucleoside subunits of said oligomeric compound being connected by internucleoside linkages which are modified to stabilize said linkages from degradation as compared to phosphodiester linkages.

11. The oligomeric compound of claim 10 further comprising a third segment comprising at least one ribofuranosyl nucleoside subunit that is modified to improve at least one of: pharmacokinetic binding, absorption, 5 distribution or clearance properties of the compound; affinity or specificity of said compound to said target RNA; or modification of the charge of said compound as compared to unmodified compound.

12. The oligomeric compound of claim 10 which, when 10 hybridized with said RNA target, is capable of activating a double-stranded RNase enzyme to effect cleavage of said RNA target.

13. The oligomeric compound of claim 11 wherein said second segment is positioned between said first and said 15 third segments.

14. The oligomeric compound of claim 11 wherein each of said first and third segments comprise at least three subunits.

15. The oligomeric compound of claim 11 wherein said 20 second segment comprises from four to twelve nucleoside subunits.

16. The oligomeric compound of claim 15 wherein said second segment comprises from five to nine nucleoside subunits.

25 17. The oligomeric compound of claim 11 wherein said second segment has at least five subunits and said first and third segments each have at least three subunits.

18. The oligomeric compound of claim 17 wherein said second segment has at least seven nucleoside subunits.

19. A synthetic oligomeric compound which is specifically hybridizable with a preselected RNA target comprising;

5 a first segment having at least one 2'-O-C₁₋₂₀ alkyl, 2'-O-substituted C₁₋₂₀ alkyl or 2'-fluoro modified ribofuranosyl nucleoside subunit where the substitution on said alkyl is amino, hydroxy or C₁₋₁₀ alkyl ether modification;

10 a second segment comprising at least four consecutive ribofuranosyl nucleoside subunits having 2'-hydroxyl moieties thereon; and

said nucleoside subunits of said oligomeric compound being connected by internucleoside linkages that are stable to degradation as compared to phosphodiester bonds.

20. The oligomeric compound of claim 19 further comprising a third segment comprising at least one 2'-O-C₁₋₂₀ alkyl, 2'-O-substituted C₁₋₂₀ alkyl or 2'-fluoro modified ribofuranosyl nucleoside subunit where the substitution on said alkyl is amino, hydroxy or C₁₋₁₀ alkyl ether.

21. The oligomeric compound of claim 20 wherein said 20 second segment is positioned between said first and said third segments.

22. The oligomeric compound of claim 20 wherein each of said first and third segments comprise at least three subunits.

25 23. The oligomeric compound of claim 20 wherein said second segment comprises from four to twelve nucleoside subunits.

24. The oligomeric compound of claim 20 wherein said 30 second segment comprises from five to nine nucleoside subunits.

25. The oligomeric compound of claim 20 wherein said second segment has at least five subunits and said first and third segments each have at least three subunits.

26. The oligomeric compound of claim 20 wherein said 5 second segment has at least seven nucleoside subunits.

27. The oligomeric compound of claim 19 which, when hybridized with said RNA target, is capable of activating a double stranded RNase enzyme to effect cleavage of said RNA target.

10 28. The oligomeric compound of claim 22 wherein each of said ribofuranosyl nucleoside subunits of said first and said third segments is modified to include a 2'-O-C₁₋₂₀ alkyl, 2'-O-substituted C₁₋₂₀ alkyl or 2'-fluoro and wherein the substitution on said alkyl is amino, hydroxy or C₁₋₁₀ alkyl
15 ether.

29. The oligomeric compound of claim 19 wherein at least two of said nucleoside subunits are connected by a phosphorothioate, 3'-deoxy-3'-thio-phosphorothioate, 5'-deoxy-5'-thio-phosphorothioate, phosphorodithioate, 20 phosphoroselenate, 3'-deoxy phosphinate, 5'-deoxy phosphinate, borano phosphate, 3'-deoxy-3'-amino phosphoramidate, 5'-deoxy-5'-amino phosphoramidate, hydrogen phosphonate, borano phosphate ester, phosphoramidate, alkyl phosphonate, aryl phosphonate or phosphotriester linkage.

25 30. The oligomeric compound of claim 19 wherein each of the nucleoside subunits of said first segment are connected by phosphorothioate, 3'-deoxy-3'-thio-phosphorothioate, 5'-deoxy-5'-thio-phosphorothioate, phosphorodithioate, phosphoroselenate, 3'-deoxy phosphinate, 30 5'-deoxy phosphinate, borano phosphate, 3'-deoxy-3'-amino phosphoramidate, 5'-deoxy-5'-amino phosphoramidate, hydrogen phosphonate, borano phosphate ester, phosphoramidate, alkyl

phosphonate, aryl phosphonate or phosphotriester linkages.

31. The oligomeric compound of claim 19 wherein each of said nucleoside subunits of said first segment are connected by phosphorothioate linkages.

5 32. The oligomeric compound of claim 19 wherein each of said nucleoside subunits of said second segment are connected by phosphorothioate linkages.

10 33. The oligomeric compound of claim 20 wherein each of said nucleoside subunits of said third segment are connected by phosphorothioate, 3'-deoxy-3'-thio-phosphorothioate, 5'-deoxy-5'-thio-phosphorothioate, phosphorodithioate, phosphoroselenate, 3'-deoxy phosphinate, 5'-deoxy phosphinate, borano phosphate, 3'-deoxy-3'-amino phosphoramidate, 5'-deoxy-5'-amino phosphoramidate, hydrogen 15 phosphonate, borano phosphate ester, phosphoramidate, alkyl phosphonate, aryl phosphonate or phosphotriester linkages.

34. The oligomeric compound of claim 20 wherein each of said nucleoside subunits of said third segment are connected by phosphorothioate linkages.

20 35. The oligomeric compound of claim 20 wherein each of said nucleoside subunits of said first, said second and said third subunits are connected by phosphorothioate linkages.

25 36. The oligomeric compound of claim 19 wherein each of the nucleoside subunits of said first segment are connected by carbonate, carbamate, silyl, sulfur, sulfonate, sulfonamide, formacetal, thioformacetal, oxime, methyleneimino, methylenemethylimino, methylenehydrazo, methylenedimethylhydrazo, methyleneoxymethylimino or 30 methylenecarbonylamino linkages.

37. The oligomeric compound of claim 20 wherein each of the nucleoside subunits of said third segment are connected by carbonate, carbamate, silyl, sulfur, sulfonate, sulfonamide, formacetal, thioformacetal, oxime, 5 methyleneimino, methylenemethylimino, methylenehydrazo, methylenedimethylhydrazo, methyleneoxymethylimino or methylenecarbonylamino linkages.

38. A synthetic oligomeric compound which is specifically hybridizable with a preselected RNA comprising 10 at least twelve ribofuranosyl nucleosides in a sequence; said nucleoside subunits being joined by internucleoside bonds which are more stable to degradation as compared to phosphodiester bonds;

the compound having two wing portions interspaced by a 15 gap portion;

the wing portions each comprising at least one modified nucleoside subunit, which modified nucleoside subunit is modified to improve at least one of: pharmacokinetic binding, absorption, distribution or clearance properties of 20 the compound; affinity or specificity of said compound to said target RNA; or modification of the charge of said compound as compared to unmodified compound;

the gap portion having at least four consecutive ribonucleoside subunits.

25 39. The oligomeric compound of claim 38 wherein said gap portion has at least five consecutive ribonucleoside subunits.

40. A synthetic oligomeric compound comprising, in sequence;

30 a first segment having a plurality of 2'-O-alkyl nucleoside subunits;

a second segment having at least four consecutive 2'-hydroxyl ribonucleoside subunits; and

a third segment having a plurality of 2'-O-alkyl

nucleoside subunits; and

the nucleoside subunits of the oligomer being joined by phosphorothioate internucleoside linkages.

41. The oligomeric compound of claim 40 wherein said 5 second segment has at least five consecutive 2'-hydroxyl ribonucleotide subunits.

42. The oligomeric compound of claim 40 wherein said oligomer is specifically hybridizable with a preselected RNA.

10 43. A method for specifically cleaving a preselected RNA comprising contacting said RNA with an oligomeric compound comprising at least twelve ribofuranosyl nucleosides subunits in a sequence which is specifically hybridizable with said preselected RNA;

15 said nucleoside subunits being joined by internucleoside bonds which are more stable to degradation as compared to phosphodiester bonds;

the compound having at least one segment comprising at least one modified nucleoside subunit, which modified 20 nucleoside subunit is modified to improve at least one of: pharmacokinetic binding, absorption, distribution or clearance properties of the compound; affinity or specificity of said compound to said target RNA; or modification of the charge of said compound as compared to 25 an unmodified compound;

said compound having a further segment having at least four consecutive 2'-hydroxyl ribonucleoside subunits.

44. The method of claim 43 wherein said further 30 segment has at least five consecutive ribonucleoside subunits.

45. A method for treating an organism having a disease characterized by the undesired production of a protein

comprising contacting the organism with an oligomeric compound of the invention having a sequence of nucleoside subunits capable of specifically hybridizing with a complementary strand of ribonucleic acid with at least one 5 of the nucleoside subunits being modified to improve at least one of: pharmacokinetic binding, absorption, distribution or clearance properties of the compound; affinity or specificity of said compound to said target RNA; or modification of the charge of said compound as compared 10 to unmodified compound; a plurality of the nucleoside subunits being located in a consecutive sequence and having 2'-hydroxyl-pentofuranosyl sugar moieties.

46. A compositions including a pharmaceutically effective amount of an oligomeric compound in a pharmaceutically acceptable diluent or carrier, said oligomeric compound comprising a sequence of nucleoside subunits capable of specifically hybridizing with a complementary strand of RNA wherein a plurality of the nucleoside subunits of the oligomeric compound are modified to improve at least 15 one of: pharmacokinetic binding, absorption, distribution or clearance properties of the compound; affinity or specificity of said compound to said target RNA; or modification of the charge of said compound as compared to an unmodified compound; wherein a further plurality of the 20 nucleoside subunits have 2'-hydroxyl-pentofuranosyl sugar moieties.

47. A method for *in vitro* modification of a sequence-specific target RNA comprising contacting a test solution containing a dsRNase enzyme and said target RNA with an 30 oligomeric compound having a sequence of nucleoside subunits capable of specifically hybridizing to said target RNA where at least one of the nucleoside subunits is modified to improve the affinity or specificity of said compound to said target RNA; and where a plurality of the nucleoside subunits 35 have 2'-hydroxyl-pentofuranosyl sugar moieties.

48. A method of concurrently enhancing hybridization and dsRNase enzyme activation in an organism comprising contacting the organism with an oligomeric compound having a sequence of nucleoside subunits capable of specifically 5 hybridizing to a complementary strand of target RNA, where at least one of the nucleoside subunits is modified to improve at least one of: pharmacokinetic binding, absorption, distribution or clearance properties of the compound; affinity or specificity of said compound to said 10 target RNA; or modification of the charge of said compound as compared to unmodified compound; wherein a plurality of the nucleoside subunits have 2'-hydroxy-pentofuranosyl sugar moieties.

49. A synthetic oligomeric compound which is 15 specifically hybridizable with a preselected RNA target comprising;
a first segment including at least one surrogate nucleoside subunit;
a second segment comprising at least four ribofuranosyl 20 nucleoside subunits located in a consecutive sequence and having 2'-hydroxyl moieties thereon; and
said nucleoside subunits of said oligomeric compound being connected by internucleoside linkages that are stable to degradation as compared to phosphodiester bonds.

25 50. The oligomeric compound of claim 49 wherein said surrogate nucleoside subunit is a peptide nucleic acid subunit.

51. The oligomeric compound of claim 49 wherein said 30 surrogate nucleoside subunit is a morpholino nucleoside subunit.

52. The oligomeric compound of claim of 49 wherein said surrogate nucleoside is a cyclobutyl nucleoside.

53. The oligomeric compound of claim 49 wherein said surrogate nucleoside is a pyrrolidine nucleoside.

54. A synthetic oligomeric compound which is specifically hybridizable with a preselected RNA target comprising;

a first segment including at least two nucleoside subunits;

said nucleoside subunits of said first segment being connected by non-phosphorus internucleoside linkages;

10 a second segment comprising at least four consecutive ribofuranosyl nucleoside subunits having 2'-hydroxyl moieties thereon; and

15 said nucleoside subunits of said second segment being connected by internucleoside linkages that are stable to degradation as compared to phosphodiester bonds.

55. The oligomeric compound of claim 54 wherein said non-phosphorous linkages are carbonate, carbamate, silyl, sulfur, sulfonate, sulfonamide, formacetal, thioformacetal, oxime, methyleneimino, methylenemethylimino, methylene-20 hydrazo, methylenedimethylhydrazo or methyleneoxymethylimino, methylenecarbonylamino internucleoside linkages.

56. The oligomeric compound of claim 54 wherein said non-phosphorus internucleoside linkages are formacetal, thioformacetal, methylenemethylimino, methylenedimethylhydrazo, methyleneoxymethylimino or methylenecarbonylamino internucleoside linkages.

57. The oligomeric compound of claim 54 said nucleoside subunits of said second segment being connected by phosphoro-thioate internucleoside linkages.

58. A synthetic oligomeric compound which is specifically hybridizable with a preselected RNA target

comprising;

a first segment including at least three nucleoside subunits;

5 said nucleoside subunits of said first segment being connected by alternating phosphorus, non-phosphorus internucleoside linkages;

a second segment comprising at least four consecutive ribofuranosyl nucleoside subunits having 2'-hydroxyl moieties thereon; and

10 said nucleoside subunits of said second segment being connected by internucleoside linkages that are more stable to degradation as compared to phosphodiester bonds.

59. The oligomeric compound of claim 58 wherein said non-phosphorous linkages are carbonate, carbamate, silyl,

15 sulfur, sulfonate, sulfonamide, formacetal, thioformacetal, oxime, methyleneimino, methylenemethylimino, methylene-hydrazo, methylenedimethylhydrazo or methyleneoxymethylhydrazo or methyleneoxymethylimino, methylenecarbonylamino internucleoside linkages.

20

60. The oligomeric compound of claim 58 wherein said non-phosphorus internucleoside linkages are formacetal, thioformacetal, methylenemethylimino, methylenedimethylhydrazo, methyleneoxymethylhydrazo or methyleneoxymethylimino or methylenecarbonylamino internucleoside linkages.

61. The oligomeric compound of claim 58 wherein said nucleoside subunits of said second segment are connected by phosphorothioate internucleoside linkages.

62. A synthetic oligomeric compound which is 30 specifically hybridizable with a preselected RNA target comprising;

a first segment including at least two nucleoside subunits;

said nucleoside subunits of said first segment being

connected by 3'-deoxy-3'-thio-phosphorothioate, 5'-deoxy-5'-thio-phosphorothioate, phosphorodithioate, phosphoroselenate, 3'-deoxy phosphinate, 5'-deoxy phosphinate, borano phosphate, 3'-deoxy-3'-amino phosphoramidate, 5'-deoxy-5'-amino phosphoramidate, hydrogen phosphonate, borano phosphate ester, phosphoramidate, alkyl phosphonate, aryl phosphonate or phosphotriester phosphate linkages; and

10 a second segment comprising at least four consecutive ribofuranosyl nucleoside subunits having 2'-hydroxyl moieties thereon; and

15 said nucleoside subunits of said second segment being connected by internucleoside linkages that are more stable to degradation as compared to phosphodiester bonds.

15 63. The oligomeric compound of claim 62 including a third segment of at least two nucleoside subunits, said nucleoside subunits of said third segment connected by 3'-deoxy-3'-thio-phosphorothioate, 5'-deoxy-5'-thio-phosphorothioate, phosphorodithioate, phosphoroselenate, 3'-deoxy phosphinate, 5'-deoxy phosphinate, borano phosphate, 3'-deoxy-3'-amino phosphoramidate, 5'-deoxy-5'-amino phosphoramidate, hydrogen phosphonate, borano phosphate ester, phosphoramidate, alkyl phosphonate, aryl phosphonate or phosphotriester phosphate linkages.

25 64. The oligomeric compound of claim 62 wherein said nucleoside subunits of said first and third segments are connected by phosphorodithioate, phosphoroselenate, 3'-deoxy phosphinate, 3'-deoxy-3'-amino phosphoramidate, phosphoramidate, alkyl phosphonate, aryl phosphonate or phosphotriester phosphate linkages.

30 65. A synthetic oligomeric compound which is specifically hybridizable with a preselected RNA target and comprises;

a first segment having at least one ribofuranosyl

nucleoside subunit that is not a DNA or RNA major building block nucleoside;

a second segment comprising at least four consecutive ribofuranosyl nucleoside subunits having 2'-hydroxyl

5 moieties thereon;

said nucleoside subunits of said oligomeric compound being connected by internucleoside linkages which are modified to stabilize said linkages from degradation as compared to phosphodiester linkages.

10 66. The compound of claim 65 wherein said first segment nucleoside subunit is selected from nucleosides having xanthine, hypoxanthine, 2-aminoadenine, 6-alkyl derivatives of adenine and guanine, 2-alkyl derivatives of adenine and guanine, 7-alkyl derivatives of adenine and
15 guanine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 2 thio uracil and cytosine, 8-halo, amino, thiol, thioalkyl, hydroxyl adenine and guanine, and 5-trifluoromethyl uracil and cytosine, as their
20 heterocyclic base.

67. A synthetic oligomeric compound which is specifically hybridizable with a preselected RNA target and comprises;

a first segment having at least one ribofuranosyl
25 nucleoside subunit excluding the nucleoside group consisting of adenosine, 2'-deoxyadenosine, guanosine, 2'-deoxyguanosine, cytidine, 2'-deoxycytidine, uridine and 2'-deoxythymidine;

a second segment comprising at least four consecutive
30 ribofuranosyl nucleoside subunits having 2'-hydroxyl moieties thereon;

said nucleoside subunits of said oligomeric compound being connected by internucleoside linkages which are modified to stabilize said linkages from degradation as
35 compared to phosphodiester linkages.

68. A mammalian ribonuclease having the activity of catalyzing the degradation of a double stranded substrate wherein one of said strands of said substrate is a mRNA and the other of said strands of said substrate comprises a 5 compound having in sequence a first segment comprising a plurality of 2' modified nucleoside subunits and a second segment comprising at least four consecutive ribofuranosyl nucleoside subunits having 2'-hydroxyl moieties thereon.

69. A mammalian ribonuclease of claim 68 wherein said 10 subunits of said compound are joined by phosphorothioate internucleoside linkages or phosphodiester internucleoside linkages.

70. A mammalian ribonuclease of claim 68 wherein said subunits of said first segment of said compound are joined 15 by phosphorothioate internucleoside linkages.

71. A mammalian ribonuclease of claim 70 wherein said subunits of said second segment of said compound are joined by phosphodiester internucleoside linkages.

72. A mammalian ribonuclease of claim 70 wherein said 20 subunits of said second segment of said compound are joined by phosphorothioate internucleoside linkages.

73. A mammalian ribonuclease of claim 68 wherein said subunits of said first segment of said compound are 2'-O-alkyl nucleoside subunits.

74. A mammalian ribonuclease of claim 68, wherein:
(A) said activity is inhibited by NaCl;
(B) said activity requires Mg⁺⁺; and
(D) said mammalian ribonuclease has an apparent molecular weight, as determined by SDS-PAGE, of 30 about 50 to about 80 kilodaltons.

75. A mammalian ribonuclease of claim 68, wherein said ribonuclease is isolated from nucleii.

76. A mammalian ribonuclease of claim 68, wherein said ribonuclease is isolated from cytosol.

5 77. The mammalian protein of claim 68, wherein said ribonuclease is isolatable from human cells or tissues.

78. A double-stranded RNA substrate comprising a duplex of a first oligonucleotide and a second oligonucleotide, wherein

10 (A) said first and said second oligonucleotide each have a central portion having at least four consecutive ribofuranosyl residues having phosphodiester linkages, wherein said central portions are base-paired with each other in said duplex;

15 (B) at least one of said first and said second oligonucleotides have portions flanking said central portions having chemical modifications which make them resistant to single-stranded nucleases.

20

79. A double-stranded RNA substrate comprising a duplex of a first oligonucleotide and a second oligonucleotide, wherein

25 (A) said first and said second oligonucleotide each have a central portion having at least four consecutive ribofuranosyl residues having phosphodiester linkages, wherein said central portions are base-paired with each other in said duplex;

30 (B) at least one of said first and said second oligonucleotides have portions flanking said central portions having chemical modifications which make them resistant to single-stranded

nucleases and increase their affinity for the
other oligonucleotide of the duplex.

80. A double-stranded RNA substrate of claim 78,
wherein said chemical modifications are phosphorothioate
5 linkages or 2'-methoxy modifications.

81. An affinity matrix comprising the dsRNA substrate
of claim 78.

82. A method of purifying a ribonuclease or non-
degradative RNA-binding protein comprising contacting a
10 sample containing said ribonuclease or non-degradative RNA-
binding protein with the affinity matrix of claim 81.

83. A synthetic oligomeric compound comprising, in
sequence;

a first segment having a plurality of 2'-O-alkyl
15 nucleoside subunits being joined by phosphorothioate
internucleoside linkages; and

a second segment having at least four consecutive 2'-
hydroxyl ribonucleoside subunits being joined by
phosphorothioate internucleoside linkages or by
20 phosphodiester internucleoside linkages.

84. A compound of claim 83 further comprising a third
segment having a plurality of 2'-O-alkyl nucleoside subunits
being joined by phosphorothioate internucleoside linkages,
said second segment being positioned in said oligomeric
25 between said first and said third segments.

85. A compound of claim 83 wherein said second segment
has phosphodiester internucleoside linkages.

86. A compound of claim 83 wherein said second segment
has phosphorothioate internucleoside linkages.

87. A synthetic oligomeric compound comprising, in sequence;

a first segment having a plurality of 2'-O-alkyl nucleoside subunits being joined by phosphorothioate internucleoside linkages;

a second segment having at least four consecutive 2'-hydroxyl ribonucleoside subunits joined by phosphorothioate internucleoside linkages or by phosphodiester internucleoside linkages, and

10 a third segment having a plurality of 2'-O-alkyl nucleoside subunits being joined by phosphorothioate internucleoside linkages.

88. A compound of claim 87 wherein said second segment has phosphorothioate internucleoside linkages.

15 89. Use of said ribonuclease of claim 68 for treating an organism having a disease characterized by the undesired production of a protein encoded by said mRNA.

20 90. Use of said ribonuclease of claim 68 for identifying one of said mRNA or a protein encoded by said mRNA.

91. Use of said ribonuclease of claim 68 for diagnosing an aberrant state in an organism associated with a protein encoded by said mRNA.

25 92. A mammalian ribonuclease having the activity of catalyzing the degradation of a double stranded substrate wherein one of said strands of said substrate is a mRNA and the other of said strands comprises a compound of claim 1.

30 93. A double-stranded RNA substrate of claim 78, wherein one of said oligonucleotides has the nucleotide sequence of SEQ ID NO:8.

ABSTRACT

Oligomeric compounds including oligoribonucleotides and oligoribonucleosides are provided that have subsequences of 2'-pentoribofuranosyl nucleosides that activate dsRNase.

5 The oligoribonucleotides and oligoribonucleosides can include substituent groups for increasing binding affinity to complementary nucleic acid strand as well as substituent groups for increasing nuclease resistance. The oligomeric compounds are useful for diagnostics and other research

10 purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics. Also included in the invention are mammalian ribonucleases, i.e., enzymes that degrade RNA, and

15 substrates for such ribonucleases. Such a ribonuclease is referred to herein as a dsRNase, wherein "ds" indicates the RNase's specificity for certain double-stranded RNA substrates. The artificial substrates for the dsRNases described herein are useful in preparing affinity matrices



20 for purifying mammalian ribonuclease as well as non-degradative RNA-binding proteins.

卷之三

FIGURE 1

**H-RAS TARGETED
ANTISENSE OLIGOS:**

FULL 2' methoxy	C C A C A C C G A C G G C G C C C
3 BASE RNA GAP	□ □ □ □ □ □ □ □ □ □ □ □ □ □ □
5 BASE RNA GAP	□ □ □ □ □ □ □ □ □ □ □ □ □ □ □
7 BASE RNA GAP	□ □ □ □ □ □ □ □ □ □ □ □ □ □ □
9 BASE RNA GAP	□ □ □ □ □ □ □ □ □ □ □ □ □ □ □
FULL RNA	● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●



3 GAP RNA FIG. 2D






FIG. 2C



5 GAP RNA

FIG. 3A





7 GAP RNA

FIG. 3B





9 GAP RNA

FIG. 3C



Full RNA

FIG. 3D



Mismatch

FIG. 3E





FIG. 4





FIG. 5

DUPLEX SENSE + GAP DNA, SENSE DNA, SENSE + GAP RNA,






FIGURE 6




FIGURE 7

1 2 3 4 5 6 7 8 9 10




FIGURE 8

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and

I verily believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA** the specification of which:

() is attached hereto.

(X) was filed on June 6, 1997 as Application Serial No. 08/870,608 and was amended on August 26, 1997.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to be material to the patentability of this application in accordance with 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of any application on which priority is claimed:

Country	Number	Date Filed	Priority Claimed
_____	_____	_____	_____
_____	_____	_____	_____
_____	_____	_____	_____

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to be material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.	Filing Date	Status (patented, pending)
<u>08/659,440</u>	<u>June 6, 1996</u>	<u>Pending</u>


I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: **John W. Caldwell and Paul K. Legaard**, Registration Nos. 28,937 and 38,534 of the firm of **WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS**, One Liberty Place - 46th Floor, Philadelphia, Pennsylvania 19103, and **Herb Boswell and Laurel Bernstein**, Registration Nos. 27,311 and 37,280, of **ISIS Pharmaceuticals**, 2292 Faraday Avenue, Carlsbad, California 92008.

Address all telephone calls and correspondence to:

Paul K. Legaard
WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone No. 215-568-3100.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the

United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1	Full Name: Stanley T. Crooke	Inventor's Signature:  Date: 11/11/87
	Residence: Carlsbad, California 92009	Citizenship: United States
	Post Office Address: 3211 Piragua Street, Carlsbad, California 92009	
2	Full Name:	Inventor's Signature:
	Residence:	Citizenship:
	Post Office Address:	
3	Full Name:	Inventor's Signature:
	Residence:	Citizenship:
	Post Office Address:	
4	Full Name:	Inventor's Signature:
	Residence:	Citizenship:
	Post Office Address:	
5	Full Name:	Inventor's Signature:
	Residence:	Citizenship:
	Post Office Address:	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

Stanley T. CrookeSerial No.: **Not Yet Assigned**Group No.: **Not Yet Assigned**Filed: **Herewith**Examiner: **Not Yet Assigned**For: **OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA**Assistant Commissioner for Patents
Washington, DC 20231

Sir:

ASSOCIATE POWER OF ATTORNEYThe undersigned, **Paul K. Legaard**, Registration No.**38,534**, of the firm WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS LLP, One Liberty Place - 46th Floor, Philadelphia, Pennsylvania 19103, Attorney and/or Agent for Applicant(s), hereby appoints the following:

Robert B. Washburn	Registration No. 16,574
Richard E. Kurtz	Registration No. 19,263
John J. Mackiewicz	Registration No. 19,709
Norman L. Norris	Registration No. 24,196
Albert W. Preston, Jr.	Registration No. 25,366
Dale M. Heist	Registration No. 28,425
John W. Caldwell	Registration No. 28,937
Gary H. Levin	Registration No. 28,734
Steven J. Rocci	Registration No. 30,489
Dianne B. Elderkin	Registration No. 28,598
Francis A. Paintin	Registration No. 19,386
John P. Donohue, Jr.	Registration No. 29,916
Henrik D. Parker	Registration No. 31,863
Suzanne E. Miller	Registration No. 32,279
Lynn B. Morreale	Registration No. 32,842
Mark DeLuca	Registration No. 33,229
Joseph Lucci	Registration No. 33,307
Michael P. Dunnam	Registration No. 32,611
Michael D. Stein	Registration No. 34,734

Albert J. Marcellino	Registration No. 34,664
David R. Bailey	Registration No. 35,057
Barbara L. Mullin	Registration No. 38,250
Lynn A. Malinoski	Registration No. 38,788
Doreen Yatko Trujillo	Registration No. 35,719
Michael P. Straher	Registration No. 38,325
Kevin M. Flannery	Registration No. 35,871
David A. Cherry	Registration No. 35,099
Anthony J. Rossi	Registration No. 24,053
Terence P. Strobaugh	Registration No. 25,460
Michael J. Swope	Registration No. 38,041
Michael J. Bonella	Registration No. 41,628
Harold H. Fullmer	Registration No. 42,560
William R. Richter	Registration No. 43,879
John E. McGlynn	Registration No. 42,863
Kimberly R. Hild	Registration No. 39,224
Lawrence A. Aaronson	Registration No. 38,369
Jonathan M. Waldman	Registration No. 40,861
Chad Ziegler	Registration No. 44,273
Gwilym John Owen Attwell	Registration No. P45,449
David N. Farsiou	Registration No. 44,104
Maureen Gibbons	Registration No. 44,121
Steven H. Meyer	Registration No. 37,189
Paul B. Milcetic	Registration No. P46,261
Joseph R. Condo	Registration No. 42,431
Michael K. Jones	Registration No. 41,100
Frank T. Carroll	Registration No. 42,392
Hans J. Crosby	Registration No. 44,634
Rena Patel	Registration No. 41,412
Mark J. Rosen	Registration No. 39,822
Mitchell R. Brustein	Registration No. 38,394
Peter M. Ullman	Registration No. 43,963
Thomas E. Watson	Registration No. 43,243
Gregory L. Hillyer	Registration No. 44,154
Maria M. Kourtakis	Registration No. 41,126
Richard B. LeBlanc	Registration No. 39,495
S. Maurice Valla	Registration No. 43,966
Vincent J. Roccia	Registration No. 43,887
Robin S. Quartin	Registration No. 45,028


and

Herb Boswell	Registration No. 27,311
Laurel Bernstein	Registration No. 37,280
Edward D. Robinson	Registration No. 43,049
Robert S. Andrews	Registration No. 44,508

of **ISIS PHARMACEUTICALS**, 2292 Faraday Avenue, Carlsbad,
California 92008; his associates, with full power to prosecute

the above-identified application and to transact all business in the Patent Office connected therewith and requests that correspondence continue to be directed to the firm of WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS LLP at the above address.

Date: January 7, 2000


Paul K. Legaard
Paul K. Legaard
Registration No. 38,534

WOODCOCK WASHBURN KURTZ
MACKIEWICZ & NORRIS LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
(215) 568-3100

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Stanley T. Crooke

(ii) TITLE OF INVENTION: Oligonucleotides And Ribonucleases For Cleaving
RNA

(iii) NUMBER OF SEQUENCES: 8

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & Norris LLP
(B) STREET: One Liberty Place - 46th Floor
(C) CITY: Philadelphia
(D) STATE: PA
(E) COUNTRY: U.S.A.
(F) ZIP: 19103

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: WordPerfect 8.0

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: 08/870,608
(B) FILING DATE: 06-JUN-1997
(C) CLASSIFICATION: N/A

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Joseph Lucci
(B) REGISTRATION NUMBER: 33,307
(C) REFERENCE/DOCKET NUMBER: ISIS-2484

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 215-568-3100
(B) TELEFAX: 215-568-3439

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GGCGCGCGUC GGUGUCC 17

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
CCACACCGAC GGCGCCC 17

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
CCGAAUGUGA CCGCCUCCCG 20

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
CGGGAGGCAG UCACAUUCGG 20

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
UCAAUGGAGC ACAUACAGGG 20

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
CCCUGUAUGU GCUCCAUUGA 20

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
AAUGCAUGUC ACAGGGGGGA 20

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
UCCCGCCUGU GACAUGCAUU 20